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„When you make the finding yourself, . . . even if you're the last person on earth to 
see the light, you'll never forget it. “ 
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1. PATHOGENESIS OF ATHEROSCLEROSIS 
Atherosclerosis is the most common cause of coronary heart disease and stroke in 
industrialized countries. It is characterized by the progressive accumulation of lipids 
(atheroma) and connective tissue (sclerosis) in the inner layer of the arterial wall leading 
to plaque formation and plaque rupture in combination with the formation of a blood clot 
which leads to a major blockage of blood flow. Atherosclerotic lesions occur principally in 
large and medium-sized arteries and can lead to vascular ischemic diseases in heart or 
brain, resulting in infarction. Atherosclerotic lesions can not only be found in adults but are 
already present in infants and young children as fatty streaks 136.  
Arteries are built up by several layers of specialized cells, the endothelium, that lines the 
blood vessel wall immediately adjacent to the lumen through which the blood flows. 
Beneath the endothelium are several concentric layers of extracellular matrix and cells 
that make up the artery wall: the intima is composed largely of amorphous collagens, 
proteoglycans, and elastic fibers. The media, a well-organized layer of smooth muscle 
cells whose contraction controls the diameter of the vessel lumen and thus influences 
blood pressure; and the adventitia, a layer of connective tissue and cells that form the 
interface between the vessel and the adjacent tissue (Figure 1-A). 
1.1. RESPONSE TO INJURY HYPOTHESIS 
This hypothesis, first introduced by Russell Ross in the early 90ies explains the molecular 
processes which lead to atherosclerotic lesions 155. 
The impaired function of the vesicular epithelium, caused by several factors such as 
diabetes, smoking, increased blood pressure, hypercholesterolaemia and low HDL-levels, 
lead to increased deposition of LDL in the intima. Macrophages in the artery wall 
endocytose and degrade LDL. The cells become filled with cholesteryl esters in lipid 
droplets and turn to foam cells. Macrophage foam cells accumulate in the arterial wall and 
initially form early fatty streaks (Figure 1-B). 
The next stage in atherosclerosis is marked by the continued accumulation of 
macrophage foam cells, T-cells, proliferation of smooth muscle cells, and migration of 
these cells from the media into the intima. Smooth muscle cells secrete additional 
extracellular matrix and the early fatty streak grows as the disease progresses, forming an 
early atherosclerotic plaque (Figure 1-C).  As the atherosclerotic plaque grows into the 
lumen of the artery, it may disrupt and block the blood flow by spontaneous clot formation. 
In some cases, the plaque alone can fully occlude the artery 156 (Figure 1-D). 
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Macrophages not only produce reactive oxygen species, proteases and cytokines they 
also provide scavenging functions mediated through pattern recognition receptors (PRRs) 
such as scavenger receptor CD36, SR-BI and SR-A. Those PRRs are rate-limiting in 
atherosclerosis because they internalize oxidized LDL (OxLDL) which activates 
macrophages, affects gene expression of  e.g. PPAR-γ, CD36 and ABCA1 and leads to 
the formation of foam cells 184. 
 
Figure 1: Major stages in the onset and progression of atherosclerosis in the artery 
wall. (a) The anatomy of a normal artery wall. (b) Accumulation of foam cells produces a 
fatty streak in the vessel wall that is only visible microscopically. (c) Continued generation 
of foam cells and migration of smooth muscle cells from the media into the intima is 
followed by cell death, producing an advanced atherosclerotic plaque. (d) As an 
atherosclerotic plaque grows into the lumen of the artery, it disrupts and reduces the flow 
of blood or can fully occlude the artery. [Adapted from Ross 2] 
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Toll like receptors (TLRs) are expressed in atherosclerotic lesions and may also 
participate in inflammatory signaling 56 and a TLR4 polymorphism is associated with 
reduced atherosclerosis in humans 101. CD14, a non-transmembrane receptor for 
lipopolysaccharide, initiates inflammatory response through interaction with TLRs 169. 
The immune response between macrophages and T-lymphocytes leads to proliferation of 
each of these cell types through IL-2 and colony stimulating factors (CSF’s). Cells within 
the center of the plaque die, producing a necrotic core containing large amounts of 
cholesteryl esters and unesterified cholesterol. 
 
1.2. RESPONSE TO RETENTION HYPOTHESIS 
Schwenke and Carew 171,172 showed in vivo that accumulation of atherogenic lipoproteins 
within the arterial wall is concentrated to sites where atheromas develop later on. This 
indicates that retention and not enhanced lipoprotein influx due to endothelial permeability, 
is the pathological key event in atherosclerosis. Subsequent studies in several animal 
models have demonstrated either increased 140 or decreased 173 rates of lipoprotein entry 
into atherosclerosis-susceptible sites, suggesting a nonessential role for alterations in 
endothelial permeability. All studies agree, however, that prelesional susceptible arterial 
sites show enhanced retention of apoB-rich, atherogenic lipoproteins 58. Furthermore, at 
sufficiently high plasma lipoprotein concentrations, lesions develop even at sites of low 
shear stress, such as non–branch points, or within the pulmonary arteries 93. Although 
stress-induced endothelial changes contribute to atherogenesis, the most directly relevant 
functional changes at prelesional sites that are susceptible to atherogenesis are turbulent 
blood flow, altered proteoglycan structure 28 and increased lipoprotein retention 203. 
The second process that has been proposed to be central to atherogenesis is lipoprotein 
oxidation 180,201. Current evidence indicates that pathophysiologically important oxidation 
can occur only after the retention of LDL. Following its retention by proteoglycans, LDL 
undergoes several modifications with important biological consequences. Proteoglycan-
bound LDL in vitro forms aggregates 90 and vesicular structures 186 that resemble material 
seen in vivo. LDL-proteoglycan complexes show increased susceptibility to oxidation 
under typical serum-free, albumin-free pro-oxidative experimental conditions 89. Minimally 
oxidized LDL induces endothelial and smooth muscle cells to express monocyte 
chemotactic activity 45. 
The response to retention hypothesis predicts that these vessel wall factors include 
molecules involved in lipoprotein retention, like proteoglycans, lipoprotein lipase, SMase, 
apoE, apoB, and apo(a). 
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2. METABOLISM OF APOB CONTAINING LIPOPROTEINS 
In order to make use of dietary lipids, they must first be absorbed from the small intestine 
in the body. Since these molecules are oils, they are essentially insoluble in the aqueous 
environment of the intestine. The solubilization (or emulsification) of dietary lipids is 
therefore accomplished by means of bile salts, which are synthesized from cholesterol in 
the liver and then stored in the gall bladder; they are secreted following the ingestion of 
fat.  
Dietary triacylglycerols and cholesterol are solubilized in lipid-protein complexes called 
lipoproteins. These complexes contain triacylglycerol lipid droplets and cholesteryl esters 
surrounded by the polar phospholipids and proteins identified as apolipoproteins. 
Lipoproteins differ in their content of proteins and lipids and are classified based on their 
density: 
• Chylomicron: the largest in size and lowest in density due to high lipid/protein ratio. 
• VLDL: very low density lipoprotein; 2nd highest in triacylglycerols as % of weight.  
• IDL: intermediate density lipoprotein  
• LDL: low density lipoprotein, highest in cholesteryl esters as % of weight and leads to 
lipid deposit in the peripheral tissue. 
2.1. CHYLOMICRONS 
In the intestine, cholesterol is present in the free, unesterified form. After its absorption, 
cholesterol - along with TG, PL, and apoproteins - is reassembled into a large micelle 
called chylomicron which undergoes the exogenous pathway to be transported from the 
intestine to the liver. There, cholesterol is esterified to fatty acid by an enzyme called Acyl 
coenzyme A:cholesterol acyltransferase (ACAT), in the plasma this is done by lecithin-
cholesterol acyltransferase (LCAT).  
Afterwards, cholesterol is either transported via the endogenous pathway from the liver to 
be stored in peripheral tissues, or it undergoes the reverse cholesterol pathway which 
transports it from peripheral tissues towards the liver, where it is excreted via the bile. 
Chylomicrons are synthesized in the intestinal tract and transport dietary fats, cholesterol 
and fat-soluble nutrients (vitamins etc.) Triglycerides are hydrolyzed by lipoprotein lipase 
(LPL) which is activated by ApoC-II. This hydrolysis reduces the surface area of 
chylomicrons and fatty acids are released. The remnant particles, rich in cholesteryl esters 
and ApoE, are taken up by receptors on hepatocytes and removed from the circulation. 
Chylomicrons are normally not detectable in the postprandial state. 
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2.2. VERY LOW DENSITY LIPOPROTEIN (VLDL) 
VLDL contains ApoB100 and phospholipids and is involved in the transport of triglycerides 
from the liver to peripheral tissues. The cholesterol in VLDL is either synthesized in the 
liver or is derived via chylomicron remnants. After secretion VLDL acquires ApoCII and 
ApoE from HDL. The size of VLDL is determined by the availability of triglycerides, large 
VLDL particles result from excess triglycerides such as in insulin resistance. Small VLDL 
particles result from limited triglyceride availability, those particles, rich in cholesterol, are 
secreted during weight loss. 
The triglycerides and fatty acids in the VLDL are hydrolyzed by LPL in the peripheral 
tissues and VLDL shrinks in size, becoming IDL which is taken up by a receptor mediated 
pathway in the liver. 
2.3. LOW DENSITY LIPOPROTEIN (LDL) 
LDL mainly contains cholesteryl esters and ApoB100 and is formed from the catabolism of 
VLDL and IDL. The main factor controlling the clearance of LDL from the plasma is the 
availability and activity of the LDL-receptor (LDLR) 6,67. After internalization, LDL is either 
degraded by the lysosome (Figure 2) or directly re-secreted by the liver via 
retroendocytosis 71. Macrophages take up LDL by scavenger receptors, which is not 
feedback-regulated thus leading to extensive LDL-uptake and diverting macrophages to 
foam cells. This occurs at normal LDL concentrations and is enhanced when LDL is 
elevated or modified by enzymes or oxidants. Another internalization pathway is via the 
LDL-receptor which is feedback-regulated. 
2.4. LDL-RECEPTOR 
The level of plasma LDL is regulated by the LDL receptor, a cell surface glycoprotein that 
removes VLDL, IDL and LDL from plasma by receptor-mediated endocytosis. These LDL 
receptors are found on all cells with predominance on hepatocytes and steroid hormone-
producing cells. Defects in the gene encoding the LDL receptor lead to familial 
hypercholesterolemia (FH) a disease associated with elevated plasma LDL levels and 
coronary atherosclerosis. In the liver, the number of LDL-receptors is regulated by the 
cholesterol content of the hepatocyte. When the cholesterol content of hepatocytes is 
raised by ingestion of diets high in saturated fat and cholesterol, LDL receptors are 
reduced and plasma LDL levels rise. Conversely, lowering the cholesterol content of 
hepatocytes stimulates LDL receptor production and lowers plasma LDL levels 25,82. 
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The LDL receptor gene is located on the short arm of chromosome 19 119. It 
consists of 18 exons and 17 introns that span 45 kilobases (kb) 182. The amino-
terminus of the protein contains the LDL-binding elements that recognize 
ApoB:100, the major apolipoprotein in LDL. LDL-receptor mediated cholesterol 
uptake downregulates intracellular cholesterol synthesis by inhibition of 3-hydroxy-
3-methylglutaryl-coenzyme A (HMGCoA) reductase and also the LDL-receptor 
expression to limit cholesterol uptake. Concomitantly, cholesterol released from 
the LDL degradation pathway is esterified by acyl coenzyme A:cholesterol 
acyltransferase (ACAT) and stored in lipid droplets. 
 
2.5. NIEMANN-PICK DISEASE TYPE C, A CHOLESTEROL TRAFFIC DISORDER 
After leaving the endosome, cholesterol trafficking critically depends on lipid trafficking 
effector proteins. Two genes are involved in this post-endosomal traffic, namely: NPC1 
and NPC2, mutations in these genes cause the autosomal recessive neurovascular lipid 
storage disorder Niemann-Pick type C disease (NPC) 23,122,149. One of the most striking 
abnormalities in affected cells is the accumulation of LDL-derived free cholesterol in late 
endosomes, lysosomes and the Golgi apparatus 18,148. In contrast to TD, plasma 
Figure 2: LDL uptake and metabolism. After uptake of LDL by the feedback-
regulated LDL-receptor it is degraded in the lysosome [Adapted from Alberts 
2003] 
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lipoprotein levels are only slightly affected with a 20-30% reduction in HDL-cholesterol 37 
and the patients do not develop vascular disease. In fibroblasts from individuals with NPC, 
LDL-derived cholesterol accumulates in lysosomes and the transport to the ER and the 
plasma membrane is delayed compared with normal cells. Normal feedback regulation of 
cholesterol homeostasis by oxysterols and de novo synthesized cholesterol suggests that 
the regulatory machinery in NPC cells is intact but that the transport of LDL-cholesterol to 
regulatory sites is compromised 121.  
The first gene mutated in NPC, NPC1, was identified by Carstea et al. 29 and it was shown 
that transport of the NPC1 protein to the cholesterol-laden lysosomal compartment is 
essential for expression of its biologic activity 198. NPC1 is an eukaryotic member of the 
resistance-nodulation-division (RND) permease family. Its detailed biologic role is still 
unclear, however, a recent study demonstrated that it functions as a transmembrane 
efflux pump which exports accumulated acriflavine from the endosomal / lysosomal 
system 46, Figure 3 shows the NPC gene mutation and it’s effect. 
 
 
Recently, the cholesterol binding molecule HE1 144, originally identified as a major 
secretory protein of the human epididymis 103 was reported as the second gene (NPC2) 
causing Niemann-Pick disease 137.   
3. MODIFIED LOW DENSITY LIPOPROTEINS 
LDL has a density ranging from 1,019 -1,063 g/ml and an average diameter of 22 nm. It is 
composed mainly from cholesterol esters, free cholesterol, phospholipids and 
triglycerides. The main protein component is ApoB-100 69.  
NPC1-/-NPC1+/+ 
Figure 3: Disturbed vesicular trafficking leads to  lipid accumulation in 
endosomal compartments. 1. In the normal state, lipids are endocytosed and then 
trafficked through the TGN towards the cell surface where it is exocytosed. 2. in the 
case of NPC-/- the lipids are shunted towards the lysosome and degraded there. 
Thus, leaving NPC patients without a cholesterol pool [Figure adapted from Alberts, 
2003]. 
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Native LDL has been shown not to induce foam cell formation 81 but depends on 
atherogenic modification of LDL 132. Native LDL is taken up by endocytosis via the LDLR 
which is feedback regulated whereas modified LDLs are assimilated by scavenger 
receptors not underlying this feedback mechanism, leading to an uncontrolled 
accumulation of cholesterol in the cells and subsequent foam cell formation 47.  
While oxidation of lipoproteins 208 is the most studied modification, recently other types of 
modifications like enzymatic modification 15 and acetylation 68 attracted increasing interest 
as potentially important in atherosclerosis.  
3.1. ENZYMATICALLY MODIFIED LOW DENSITY LIPOPROTEIN (E-LDL) 
Bhakdi et al. postulated that extracellular, enzymatic modification of LDL in atherosclerotic 
lesions contributes mainly to the initiation of atherosclerosis. Combined treatment with 
trypsin, cholesterol esterase, and neuraminidase transforms LDL, but not HDL or VLDL, to 
particles with properties similar to those of lipid extracted from atherosclerotic lesions. The 
mechanism proposed is that the proteolytic nicking of Apo-B by trypsin renders cholesterol 
esters accessible to the action of cholesterolesterase. E-LDL is rapidly taken up by human 
macrophages to an extent exceeding the uptake of acetylated LDL (Ac-LDL) or oxidatively 
modified LDL (Ox-LDL) 16. In-vitro E-LDL, similar to aggregated LDL found in lesions, fuse 
to a particle size of 200 nm in diameter. Moreover, E-LDL is much more potent in 
transforming macrophages into foam cells than Ox-LDL 100. Upon the enzymes that can 
modify E-LDL and are detected in the intima of arteries are: tryptase, plasmin, 
metalloproteases, lysosomal acid lipase (LAL), phospholipase A2 and cholinesterase 77.  
3.2. OXIDIZED LOW DENSITY LIPOPROTEIN (OX-LDL) 
LDL oxidation involves oxidative modification of apolipoprotein B-100 (ApoB-100) in 
addition to lipid peroxidation. Many reactive radical species can initiate lipid peroxidation. 
These reactions involve lipoxygenases, superoxide anions, hydroxyl radicals, peroxinitrite, 
heme proteins, ceruloplasmin and myeloperoxidase 202.  
Oxidation of LDL is believed to occur mainly in the extracellular matrix of the arterial 
intima. Ox-LDL accumulates in macrophages and in foam cells in atherosclerotic lesions. 
Ox-LDL exerts both proliferation and apoptosis in vascular cells, depending on its 
concentration and the exposure time. Low Ox-LDL concentrations (<10 µg/mL) induced 
proliferation, while higher concentrations (50-300 µg/mL) induced apoptotic cell death 62. It 
is specifically taken up by macrophages via scavenger receptors (SR) and induces the 
production of M-CSF which markedly and selectively increases the synthesis of type I and 
type II class-A macrophage scavenger receptors, again leading to an increase in Ox-LDL 
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uptake. Figure 6 shows the internalization steps of minimally oxidized LDL through clathrin 
dependent endocytosis. 
4. CHOLESTEROL INFLUX PATHWAYS  
Accumulation of cholesterol in artery walls characterizes the onset of atherosclerosis. This 
accumulation is subject to a tight homeostasis and follows several intake models. This 
homeostasis depends on the cellular uptake of LDL and the ongoing retention of LDL in 
the vessel wall. This retention underlies the physical and chemical characteristics of the 
involved lipoproteins. LDL is a 22 nm particle covered mainly with the hydrophobic 
apolipoprotein apoB100 whereas HDL is only 5-12 nm in size and is partially covered with 
the amphiphilic apolipoproteins: apoAI, apoAII, apoE and apoA. The smaller size and the 
relative lack of affinity to the vessel wall allow HDL to transit through the vessel wall 
without retention, leading to depletion of the atherogenic LDL. Several pathways have 
been suggested for cholesterol entry into the cell. Studies indicate that the endothelium 
actively takes up lipoproteins and transports them into the subendothelial space. The type 
of entry differs according to the type of LDL. 
While Ox-LDL enters mainly via the scavenger receptors, aggregated LDL is taken up by 
phagocytosis and is rapidly degraded in lysosomes. Several receptors have been shown 
to be implicated in the cholesterol accumulation in macrophages (Table 1). 
4.1. CLATHRIN-DEPENDENT ENDOCYTOSIS 
Uptake of LDL via clathrin-coated vesicles is typically a pathway for receptor mediated 
Table 1: Receptors implicated in cholesterol accumulation. The table shows the 
receptors expressed in macrophages and their lipoprotein ligands. 
I. Introduction                                                                                                                     11 
uptake of lipoproteins. Cells have receptors for LDL, β-VLDL and modified forms of LDL 
such as Ox-LDL. Apo-B containing lipoproteins taken up into coated vesicles are delivered 
to lysosomes 109, where they are degraded to amino acids, unesterified cholesterol and 
fatty acids, this pathway is actin-independent and leads to LDL uptake via peripheral 
surface-connected tubules. 
Three major steps are involved in this type of endocytosis: 
• Clathrin-pit formation: clathrin coat assembly is initiated by the binding of coat 
components to a docking site at the plasma membrane. First, transmembrane receptors 
bind to the heterotetrameric adaptor protein complex (AP-2), this complex binds to 
clathrin which polymerizes into a grid, pulling the plasma membrane inside152 (Figure 4).  
 
This action requires local changes in phospholipids composition leading to changes in 
the membrane curvature. Once the inward bending of the membrane is complete, the 
vesicle is separated from the membrane. To date, four ubiquitously expressed AP 
complexes have been identified in human and mouse: AP-1, AP-2, AP-3 and AP-4. In 
1986, Goldstein et al. demonstrated that the LDL-R from a hypercholesterolemia patient 
revealed a mutation which led to an impaired internalization of the receptor. This led to 
Figure 4: Clathrin coated-pit endocytosis. The assembly of clathrin molecules on the 
pit leads to invagination of the pit. Clathrin coated pits move in the plane of the 
membrane, but are also tethered to cytoskeletal elements, like actin. After the pit has 
fissioned from the membrane by the influence of dynamin, clathrin is recycled [Adapted 
from Takei 187
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Figure 5: Clathrin-dependent 
internalization of mildly oxidized LDL.
(1) The LDL receptors bind to apoB 
embedded in the phospholipid layer of 
LDL particles. Interaction between the 
LDL receptor and the AP2 complex 
incorporates the receptor-ligand complex 
forming endocytic vesicles. (2) Clathrin-
coated pits are pinched off by the same 
mechanism used to form clathrin/AP1 
vesicles on the TGN. (3) After the vesicle 
coat is shed, the uncoated endocytic 
vesicle (early endosome) fuses with the 
late endosome. (4) The acidic pH causes 
a conformational change in the LDL 
receptor leading to release of the bound 
LDL particle. The late endosome fuses 
with the lysosome, and the proteins and 
lipids of the free LDL particle are broken 
down by enzymes in the lysosome. (5) 
The LDL receptor recycles to the cell 
surface where it can bind another LDL 
particle. Brown and Goldstein 22 [Adapted 
from Alberts 2003]. 
the discovery of an endocytosis signal which involves tyrosine- and leucine-based 
motifs135. The leucine motif further provides a signal for lysosomal sorting. 
• Early endosome fusion: After the pit is internalized and converted into a clathrin coated 
vesicle, the clathrin coat is removed. Two proteins involved in this step are: Rab5 and 
early endosomal antigen-1 (EEA-1). In addition to endosome fusion, Rab5 mediates the 
movement of the endosome along the cytoskeleton.  
At this stage, Phosphatidylinositol-3-phosphate (PI3P), a product of PI3-Kinase, is 
enriched in early endosomes and contributes to endosome fusion. Furthermore, soluble 
N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) are required 
for endosome fusion (e.g. syntaxins, synaptotagmin).  
• Late endosome formation:  Until now it is unclear whether transport vehicles move cargo 
between early endosomes (EE) and late endosomes (LE), or whether EE mature into 
LE. However, LE tend to be more acidic (pH 5,5 in comparison to 6,5 in EE) and 
spherical in shape. 
 It seems that ubiquitination is an essential step for many proteins to move from the EE to 
LE. As example, the clathrin-dependent internalization of Ox-LDL is shown in figure 5. 
4.2. CLATHRIN-INDEPENDENT ENDOCYTOSIS 
A variety of pathways do not utilize clathrin but are responsible for uptake of large 
particles, these include: 
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• Phagocytosis 
• Caveolin-dependent endocytosis 
• Pinocytosis 
• Novel pathways 
4.2.1. PHAGOCYTOSIS 
Phagocytosis is an actin-dependent process by which large particles are taken up by 
macrophages. This type of endocytosis is triggered by binding of the particle to the cell-
surface receptors capable of transducing a phagocytic stimulus. This results in localized 
exocytosis at the site of particle attachment and subsequent pseudopodia extension that 
wraps around and engulfs the bound particle into a cytoplasmic phagosome. 
Phagocytosis is usually restricted to macrophages and other phagocytes specialized in 
uptake and digestion of large particles. Macrophages take up aggregated LDL by 
phagocytosis which leads to rapid lysosomal degradation of the aggregated LDL, since 
this pathway is not feedback regulated by cholesterol. According of the kind of membrane 
folding, two types of phagocytosis can be observed (Figure 6). 
Type-I phagocytosis: This type of phagocytosis is mediated by Fcγ-receptors (CD64, 
CD32, and CD16); it occurs via the ‘zipper’ mechanism and uses the GTP-ases Cdc42 
and Rac. 
Type-II phagocytosis: This phagocytosis is complement receptor-mediated (CR3: 
CD11b; CD18) and particles ‘sink’ into the cell. This mechanism uses the GTPase Rho. 
4.2.2. PINOCYTOSIS AND MACROPINOCYTOSIS 
Pinocytosis is one of the pathways for cellular uptake and transport of lipoproteins, in this 
mechanism dissolved substances and particles of about 70 nm are being taken up non-
selectively, thus, all lipoproteins small enough to enter the pinocytic vesicles can be 
Figure 6. The two types of phagocytosis. To the left: type-II phagocytosis, to the 
right: type-I phagocytosis. Adapted from Castellano et.al 31. 
 
I. Introduction                                                                                                                     14 
transported in this manner. Chylomicrons for instance are too big (>75 nm) to enter the 
pinocytotic vesicles, explaining why they don’t enter the vessel wall and therefore are not 
associated with atherosclerosis. Pinocytotic vesicles accumulate bulk plasma fluid at the 
luminal side of the endothelium and then transport the fluid and its constituents to the 
abluminal side of the endothelium where the vesicle contents are released 123. 
Macropinocytosis refers to the formation of large and irregular actin-driven invaginations 
of the plasma membrane leading to primary endocytic vesicles (typically 0,5-2,5 µM in 
diameter) by the closure of lamellipodia. They frequently move inwards towards the centre 
of the cell, and persist for approximately 5–20 min 185.  
The membrane components of macropinosomes are likely to be recycled back to the 
plasma membrane over a similar time-scale, potentially passing via other organelles 
within the cell, and macropinosomes must recruit specific machinery in order to do this. 
Membrane recycling between the plasma membrane and endosomal compartments 
during macropinocytosis is most likely regulated by the small GTPase ARF6 and it’s 
related protein ADP-ribosylation factor-like 7 (ARL7).  
This pathway is distinguished from other pinocytic pathways by its susceptibility to agents, 
which depolymerize actin and tubulin. Macropinocytosis might account for some of the 
pinocytosis observed when clathrin dependent endocytosis is inhibited. Formation of the 
macropinosome generally involves the protein dynamin.  
4.2.3. CAVEOLIN-DEPENDENT ENDOCYTOSIS 
Caveolae are flask-shaped, non-coated plasma membrane invaginations present in many 
cell types, especially in endothelial cells. Biochemically, caveolae can be isolated as 
detergent-resistant membranes (DRMs) enriched in cholesterol and glycosphingolipids, a 
characteristic shared with lipid rafts and other membrane microdomains 114. Several 
membrane receptors, signaling molecules and membrane transporters localize to 
caveolae as well as molecules found within lipid rafts. The finding that caveolae contain 
one key element of the machinery involved in vesicle budding, the GTPase dynamin 15 
and dynamin 16, suggests that they also participate in membrane internalization. The fact 
that elements of the docking and fusion machinery, such as SNARE proteins, are 
enriched in caveolae strengthens this theory 168. 
Insight into the mechanism of caveolar internalization of cell-surface molecules has been 
obtained by visualizing the cargo that internalizes through caveolae. It is important to point 
out that, in contrast to classic clathrin-dependent endocytosis, the caveolar internalization 
pathway seems to bypass lysosomes. Internalized caveolae fuse with caveosomes, and 
the caveosomes deliver their contents into other subcellular (non-lysosomal) 
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compartments. The bypass of the acidic and harmful milieu might be a major advantage 
for the SV40 virus which uses caveolae to gain entry into the cell, where ultimately it is 
delivered to the ER 142.  
Owing to their cholesterol binding ability, caveolae are undoubtedly involved in cholesterol 
transport and homeostasis 59.  
Whether the presence of caveolin, which distinguishes caveolae from other lipid rafts, 
could play the role of a classical coat by providing the driving force necessary for 
membrane deformation remains a matter of debate. 
 
4.2.4. NOVEL UPTAKE MECHANISMS 
In addition to this established uptake pathways, newly defined mechanisms have been 
elucidated. They are summarized in the following sections:  
 
 
The existence of alternative cellular lipid transport routes along continuous tubular 
membrane complexes is also supported by the observations that macrophages can 
endocytose LDL via ”surface connected compartments”, plasma membrane invaginations 
that are directly connected to the cell surface 110. LDL liposomes enter the surface 
connected compartments in macrophages through a unique endocytic pathway which 
involves ApoE, this uptake did not occur through LDL-receptors, LDL-receptor-related 
proteins, or scavenger receptors. Aggregated LDL enters surface-connected membrane 
bound compartments (SSC) and is mostly stored rather than degraded 112.  
Another alternative tubular transport route for lipophilic substrates has been reported by 
Thieblemont involving the cellular uptake of bacterial lipopolysaccharides LPS-micelles via 
CD14 a GPI-anchored receptor. It could be demonstrated that LPS is imported into the 
Golgi of polymorphonuclear leukocytes and HeLa cells independently from the endosomal 
and lysosomal endocytotic pathway 189. Soluble CD14, the shedded form of the LPS-
receptor glycoprotein is found in plasma and acts as a shuttle for LPS and 
lysophospholipids and can mediate efflux from THP-1 cells 183. It has been shown that 
treatment of cells with LPS leads to an increase of ABCA1 expression through an LXR-
independent pathway. Nevertheless, induction of LPS led to reduced HDL levels. This is 
possibly due to reduction of ApoAI, ApoE, LCAT and CETP.  
In light of these independent observations, it can be postulated that (i) the cell surface and 
cell organelles, in addition to established lipid trafficking routes, are capable of interacting 
4.2.4.1 SURFACE CONNECTED COMPARTMENTS (SSC)
4.2.4.2 ENDOCYTOSIS THROUGH COMPARTMENTS INVOLVING CD14 
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with each other via continuous membrane systems and (ii) that these membrane 
structures provide a morphologic basis for alternative cellular lipid transport mechanisms. 
This implies that translocation processes of lipid substrates along tubular membrane 
compartments may be involved in important physiologic functions in cellular lipid transport. 
For example, it is conceivable that the known translocation of metabolites of the 
cholesterol biosynthesis pathway between the ER and peroxisomes occurs via continuous 
tubular membrane systems.  
4.2.4.3. DEEP TUBULAR INVAGINATIONS 
Deep tubular invaginations are hardly detectable in normal electron microscopy, but their 
existence is revealed by exposure of mucosal tissue to the non permeable surface marker 
Ruthenium Red. They appear as a part of the apical surface of the enterocyte. In some 
cases, they can be seen penetrating up to 0,5-1 µm into the cytoplasm, a distance 
sufficient to reach across the terminal web and obtain a close proximity to the subapical 
compartment (SAC).  
Caveolin-1, a frequently used marker for lipid rafts and caveolae, as well as the glycolipid 
GM1, distinctly localize to deep apical tubules. 
Annexin A2, another protein known to be associated with lipid rafts and proposed to be 
involved in membrane trafficking events, is also present in deep apical tubules. Annexin 
A2 is capable of interacting with actin and actin-binding proteins such as α-actinin, ezrin, 
and moesin, and thus to function as an interface between lipid raft membranes and the 
actin cytoskeleton 78. It is also a known substrate for protein kinases, including protein 
kinase C.  
CD13 is also present in deep tubular invaginations and is the target for ezetrol, a specific 
inhibitor of intestinal cholesterol absorption, which blocks endocytosis of cholesterol-rich 
membrane microdomains, thereby limiting intestinal cholesterol absorption 106. Deep 
tubular invaginations connect to the NPC1 and NPC1L pathway that direct exogenous 
cholesterol towards late endosomes. NPC1 and its homologue NPC1L may belong to a 
family of related proteins that have similar functions at different subcellular locations, 
perhaps at sequential steps of the same cholesterol transport pathway 92. 
This particular transcytotic trafficking route has been studied intensively for many years 
revealing details in the intracellular transport events leading from internalization into 
basolateral early endosomes, via a common endosome, to an apical recycling endosome 
before secretion from the apical surface. The apical recycling endosome, also referred to 
as the SAC, is crucial in sorting of both proteins and lipids in dynamic transit between the 
basolateral and apical plasma membrane domains. The SAC is the last known stage in 
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the basolateral-to-apical transcytotic pathway, and in the enterocyte, it is typically found in 
the apical cytoplasm just beneath the terminal web region. Deep apical tubules are the 
only part of the brush border surface directly accessible to membrane traffic from the SAC 
and are often seen in very close proximity to this endosomal compartment, lending 
support to the notion that elements of the SAC may fuse directly with the cell surface. 
Alternatively, the final stage of transport could be vesicle-mediated, but regardless of the 
mechanism, the function of deep apical tubules is that of a hub in the final exocytotic 
stage of transcytosis, a process that has previously been shown to occur through lipid raft 
containing compartments in enterocytes.  
Aggregated LDL enters the macrophage vacuolar labyrinth which remains connected to 
the macrophage surface by the surface invagination, where it remains before it is 
degraded by fusion with primary lysosomes. Plasmin-mediated LDL-degradation, reverts 
LDL aggregation allowing disaggregated LDL to efflux from the open surface-connected 
compartments back to the extracellular space.  
4.2.4.4. CONTINUOUS CELLULAR MEMBRANE SYSTEM 
Scow and Blanchette-Mackie 174 demonstrated the existence of continuous cellular 
membrane systems in brown and white fat cells, along which lipids such as fatty acids and 
monoacylglycerols are translocated via lateral movement as shown in figure 7. 
The external leaflet of the plasma membrane of the endothelial cell and that of the 
adipocyte form a continuum at the site of contact between the cells. The interfacial 
continuum would include the chylomicron surface film when the surface film is fused 
temporarily with the external leaflet of the endothelial plasma membrane. FA formed by 
lipoprotein lipase are expected to enter the continuum from the capillary lumen, move in 
the continuum to the ER of the adipocyte, leave the continuum after reesterification to 
triacylglycerol and then accumulate as lipid droplets between leaflets of the reticulum. FA 
formed by action of tissue lipase on intracellular triacylglycerol would reenter the 
continuum at the site of lipolysis in the ER, move along the continuum to mitochondria, 
and leave the continuum after activation of FA in the outer mitochondrial membrane for 
transfer to the inner mitochondrial membrane.  
In neuroendocrine PC12 cells, a tubular subplasmalemmal membrane system was 
identified that is continuously connected with the plasma membrane and from which 
synaptic-like microvesicles (SLMV) originate 160. 
I. Introduction                                                                                                                     18 
 
Recent experiments show that endophilin I, in conjunction with the GTPase dynamin, 
plays a critical role in the segregation of SLMV from the plasma membrane 161. Moreover, 
we were able to detect SLMV in steroidogenic cells (Orsó and Schmitz, unpublished data). 
5. METABOLISM OF APO-AI CONTAINING HIGH DENSITY LIPOPROTEIN (HDL) 
High-density lipoprotein (HDL) is an acceptor of free cholesterol and in concert with 
cholesteryl ester transfer protein (CETP), lipoprotein lipase (LPL), hepatic lipase (HL) and 
lecithin:cholesterol acyltransferase (LCAT) it mediates the transport of cholesterol from 
peripheral tissues to the liver for elimination from the body, a mechanism called “reverse 
cholesterol transport”.  
Lipid-poor apoA-I (preβ-HDL) is mainly synthesized in the liver, intestinal mucosa cells 
and nascent HDL acquires phospholipids, free cholesterol and apoE during maturation. 
Preβ-HDL is produced by interaction of apoA-I, the major apolipoprotein in HDL, with 
ABCA1. Free cholesterol transferred from the cell to HDL, is esterified by LCAT, which is 
activated by apoA-I. This increases the density of HDL particles which are thus converted 
from HDL3 to the denser HDL2. HDL2 exchanges cholesterol for triglycerides, a process 
mediated by CETP and PLTP. Cholesteryl esters are taken up by the liver for further 
Figure 7: Alternative lipid transport routes for transport of fatty acids (FA) 
from capillary lumen to adipocytes. 1. plasma membrane of endothelium, 2. 
membrane of transcellular channels in endothelium, 3. plasma membrane of 
adipocytes, 4. Membrane of surface-connected channels, 5. ER-membrane, 6. 
Outer mitochondrial membrane in adipocytes. [According to Blanchette-Mackie 
and Scow 19]. 
I. Introduction                                                                                                                     19 
excretion into the bile. HDLs are believed to be antiatherogenic by several mechanisms 
including reverse cholesterol transport (RCT), inhibition of cytokine induced expression of 
adhesion molecules by endothelial cells and protection of LDL from oxidation. In 
particular, participation of HDL in the RCT pathway is considered to be most important in 
preventing atherosclerosis development by delivering cholesterol synthesized or stored in 
peripheral tissues to the liver for ultimate excretion. 
5.1. CHOLESTEROL EFFLUX FROM MACROPHAGES  
Macrophages can excrete the cholesterol they accumulate through many processes. Most 
of these processes involve the use of lipid particles rich in phospholipids which remove 
cholesterol from the macrophage. HDLs are specialized lipoprotein cholesterol acceptors 
containing amphipathic apolipoproteins like apoAI that circulate in the blood and are 
present in atherosclerotic plaques 178. When incubated with macrophages they induce 
cholesterol efflux 167, by stimulating translocation of cholesterol from intracellular 
membranes to the plasma membrane 8. Then, HDL acquires excess plasma membrane 
cholesterol 145.  
ATP-binding cassette transporter A1 (ABCA1), a protein mutated in Tangier Disease, 
functions in the lipidation of the amphipathic apolipoproteins apoAI and apoAIV, a required 
step for these apolipoproteins to stimulate cholesterol efflux 166. 
Macrophages also can produce their own HDL particles that mediate macrophage 
cholesterol efflux through an autocrine/paracrine mechanism. This occurs when 
macrophages secrete apolipoprotein E (apoE) and PLTP which associate with 
macrophage phospholipids (possibly similar to exogenous amphipathic apolipoproteins) to 
form apoE-phospholipid discoidal complexes 111. Macrophage specific expression of 
human apoE reduces atherosclerosis in hypercholesterolemic apoE-null mice, supporting 
a possible function of macrophage-produced apoE within atherosclerotic plaques in 
promoting cholesterol efflux. In the presence of HDL the resecretion of apoE and 
cholesterol leads to the formation of apoE/cholesterol-enriched HDL particles. 
Furthermore, apoE recycling involves the internalization of HDL3-derived apoAI and its 
targeting to apoE/cholesterol-containing endosomes. Subsequently, HDL could interact 
with ATP-binding cassette transporter A1 (ABCA1) 165 and scavenger receptor class B 
type I (SR-BI) at the cell surface 205, leading to cholesterol efflux.  
Alternatively, macrophages can secrete CETP/apoCI containing lipoprotein particlesupon 
stimulation with apoAI. 
After cholesterol is incorporated into HDL, it is esterified by lecithin:cholesterol acyl 
transferase (LCAT), an  enzyme present in the plasma. Large HDL particles can transfer 
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their cholesteryl esters to other apoB-containing lipoproteins through cholesteryl ester–
transfer protein (CETP) or to cells (e.g. liver and steroidogenic cells) through SR-BI 
receptors. Selective uptake of cholesteryl esters from HDL can also be mediated by the 
SR-BI receptors. After HDL binds to SR-BI, cholesteryl esters in the core are selectively 
transferred to the cell membrane and then translocated into the cytosol. The remaining 
lipid-depleted HDL particle rapidly dissociates from the receptor and returns to the 
circulation 107.  
Studies conducted by Peng et. al, 147 showed that SR-BI is not strongly associated with 
detergent resistant membranes (DRM’s) also called “rafts”. This observation raises an 
important issue of lipids in these DRMs where SR-BI mediates HDL uptake of cholesterol 
thus mediating a bidirectional flux of free cholesterol between the membrane and HDL. It 
has been shown that liposomes rich in unesterified cholesterol (UC) are able to carry 
cholesterol during cholesterol excretion from macrophages. Similar liposome 
accumulation of cholesterol can be seen in patients with defective NPC1 protein. 
5.2. MULTIPLE PATHWAYS FOR CELLULAR CHOLESTEROL EFFLUX  
Three pathways are currently known by which cellular cholesterol is transported out of the 
cell and HDL is the acceptor of cellular lipids. 
5.2.1. PASSIVE DIFFUSION  
In this mechanism, also called diffusion-mediated cell cholesterol efflux, cholesterol 
diffuses to the HDL particle in a passive way. This pathway predominates in erythrocytes 
in the absence of vesicular transport in these cells 51. Free cholesterol molecules 
spontaneously desorb from the plasma membrane, diffuse through the aqueous phase 
and subsequently incorporate into HDL particles 128.  A variety of acceptors can mediate 
this diffusion, namely: LDL, globulins, phospholipid vesicles and cyclodextrins, (nicely 
reviewed in 157). During this reaction, cholesterol is mainly mobilized from the plasma 
membrane compartment rather than from intracellular compartments 79. 
Net cholesterol efflux is regulated by the gradient of free cholesterol contents between the 
acceptor and donor cell membrane compartments and by the acceptor’s ability for 
cholesterol adsorption and desorption. Consequently, the reaction is mostly bidirectional 
and is driven by the phospholipid content of lipoprotein acceptors, but does not involve 
any specific factor such as HDL binding to the cell or intracellular signaling pathways. 
However, HDL particles are excellent physiological acceptors involved in passive diffusion 
because of the ability of the HDL particle to esterify free cholesterol through the action of 
its associated enzyme lecithin:cholesterol acyltransferase (LCAT) 12. In conclusion, active 
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esterification of cholesterol within the HDL particle by LCAT plays a physiological role in 
passive diffusion of cell cholesterol from peripheral cells and cholesteryl ester transfer 
protein (CETP) and phospholipid transfer protein (PLTP) are key proteins involved in this 
intravascular lipoprotein metabolism. CETP enables the transfer of cholesteryl esters, 
generated by the LCAT reaction, from HDL to very low density lipoproteins (VLDL) and 
LDL. PLTP catalyzes the transfer of phospholipids between lipoproteins.  
5.2.2. SR-BI-FACILITATED DIFFUSION OF CHOLESTEROL TO HDL 
SR-BI is an ubiquitous multi-ligand receptor that interacts with a broad range of acceptors, 
including HDL2, LDL, oxidized LDL and acetylated LDL 1,  it yields a high level of 
expression in steroidogenic tissues and the liver, where it is implicated in the selective 
uptake of cholesteryl esters 66. 
Expression levels of SR-BI correlate with the efflux of free cholesterol (FC) from cultured 
cells as well as efflux to LDL and other nonlipoprotein acceptors such as phospholipid 
vesicles 157. Therefore, SR-BI mediates a bidirectional exchange of FC via a concentration 
gradient between the plasma membrane of the cell and a wide  variety of phospholipid-
containing acceptors, in a process defined as ‘facilitated aqueous diffusion’. 
The detailed mechanism by which SR-BI facilitates cellular cholesterol efflux remains 
unclear but it seems that distinct extracellular receptor domains besides the lipids and 
apolipoproteins in HDL may be involved in SR-BI binding to HDL. The interaction between 
SR-BI and the class A amphipathic α-helices was earlier reported by Williams and 
colleagues 200. These studies strongly suggest that SR-BI interacts with HDL via the 
amphipathic α-helical repeat units of apoA-I, which may therefore explain the interaction 
of SR-BI with a wide variety of apolipoproteins via a specific  secondary structure, the 
class A amphipathic α-helix, which is a common structural motif in the apolipoproteins of 
HDL. Nevertheless, HDL binding to SR-BI is not enough to ensure efficient FC efflux 128.  
SR-BI seems to function in a two-step process where HDL binding to SR-BI (step 1) is 
coupled to the flux of FC (step 2). Therefore, HDL binding to cell surface SR-BI may 
enhance FC efflux via SR-BI at low ligand  concentrations 190, but is independent of SR-BI 
in a more physiological situation, i.e. when the receptor is saturated. 
Peng and colleagues showed that SR-BI-facilitated cholesterol trafficking between cells 
and HDL occurs primarily in clusters of SR-BI on microvillar extensions of the plasma 
membrane, but independently of caveolae or raft domains 147. 
In conclusion, it is likely that the ability of SR-BI to stimulate cholesterol efflux may reflect 
the reorganization of membrane cholesterol domains that are distinct from rafts or 
caveolae. HDL-apolipoprotein composition, conformation and binding to SR-BI may 
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enhance this process. This would explain why HDL is the most physiological particle 
involved in SR-BI facilitated cholesterol efflux. In the liver, SR-BI rather mediates HDL2-
mediated selective uptake of cholestryl esters than cholesterol efflux 194. 
In addition, SR-BI mediates the selective uptake of cholesteryl esters from HDL2. This 
pathway is defined as a high-capacity system in which cells internalize cholesteryl esters 
rather than apolipoprotein components of the HDL-particle. This is in contrast to the LDL-
receptor pathway in which particles are internalized through clathrin coated vesicles for 
degradation and lipid recycling.  
SR-BI mediates a bidirectional exchange of lipids, mainly promoting transfer of cholesteryl 
esters and free cholesterol from HDL and LDL to the cell 179, and a cholesterol efflux from 
cell plasma membranes to lipoproteins and non-lipoprotein receptors 95. 
This function underlies a tight equilibrium between apolipoproteins and lipids and any 
modification of the lipoprotein particles that modulate this steady state will modify selective 
CE uptake, thus, an increasing TG/CE ratio will decrease CE uptake, in contrast to LPL- 
or HL-mediated HDL-TG hydrolysis which increases CE uptake 70. 
In addition, HDL can be endocytosed by two different pathways: one dependent on 
internalization via SR-BI, representing the selective transfer of lipoprotein cholesterol 
which could explain selective sorting of cholesterol to the bile canaliculus. The other 
endocytic route is independent of SR-BI, representing the HDL protein catabolic pathway, 
mediated by an as yet unknown receptor 177.  
HDL-mediated cholesterol efflux may involve a passive diffusion-mediated process in 
which HDL interacts with SR-BI. 
5.2.3. ABCA1-MEDIATED ACTIVE EFFLUX 
Lipid-free apoA-I is a physiological acceptor involved in phospholipid and cholesterol 
efflux from cells. A breakthrough in this area has been the discovery that apoA-I-mediated 
specific phospholipids and cholesterol efflux from the cell is critically dependent on the 
function of ABCA1, a member of the ABC transporter family of proteins. It was also shown 
in cross-linking experiments that the ABCA1 transporter may act as an apoA-I receptor 61. 
Chimini and colleagues however, assessed that binding of apoA-I may not involve a direct 
molecular interaction between ABCA1 and apoA-I 33. ABCA1 expression was directly 
correlated both with lipid efflux and with an increase in lipid-free apoA-I binding, but not 
with any increase in HDL binding 195. Helical lipid-free apolipoproteins of HDL, such as 
apoA-I, A-II and E are able to induce phospholipid and cholesterol release from cells to 
generate nascent HDL particles with physical and biochemical characteristics of pre-β-
HDL.  
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5.3. ATP-BINDING CASSETTE TRANSPORTER 
The ATP-binding cassette (ABC) superfamily is composed of about 50 functionally diverse 
transmembrane proteins 53. These proteins are fundamental to intracellular compartmental 
transport as well as transport through the plasma membrane. These proteins utilize 
energy derived from the hydrolysis of ATP to transport the substrate across the 
membrane against a concentration gradient. The typical ABC transporter consists of two 
transmembrane domains and two nucleotide-binding domains (NBDs) or ATP-binding 
cassettes (ABC) encoded by a single polypeptide. Each nucleotide-binding domain 
contains two sequence motifs, the Walker A and Walker B motifs, common motifs of 
nucleotide binding proteins. The distinctive feature of all ABC transporters is the C motif 
that has the consensus sequence "LeuSerGlyGlyGln“. ABC transporters are termed either 
„full-size“, standing for full functionality, like ABCA1 or „half-size“ like ABCG family which 
means they have to form homodimers or heterodimers in order to gain functionality.   
ABC transporters are gaining attention because mutations in these proteins cause various 
human inherited diseases. Among these are: familial HDL deficiency (ABCA1) 21, fatal 
surfactant deficiency in newborns (ABCA3) 176, different chorioretinal diseases (ABCR or 
ABCA4) 5, Progressive Familial Intrahepatic Cholestasis (PFIC) type II (ABCB11) and type 
III (MDR3 or ABCB4) 48, lamellar ichthyosis type 2 (ABCA12) 117, Dubin-Johnson 
syndrome (ABCC2) 105, Pseudoxanthoma Elasticum (MRP6 or ABCC6) 193, 
Adrenoleukodystrophy (ALDR or ABCD2) 133 and β-Sitosterolemia (ABCG5, ABCG8) 116.  
Recently, a novel missense mutation in ABCA1 was described in a patient with Scott 
syndrome, a mild bleeding disorder that also affects platelet aggregation, leading to 
altered protein trafficking and reduced phosphatidylserine translocation 4. A number of 
human ABC transporters is involved in bile acid, phospholipid and sterol transport 22,164, 
and the expression of these ABC proteins is controlled by lipids 115. 
The full-size transporters are mainly localized at the plasma membrane but can also be 
found intracellularly as a result of vesicular trafficking. On the other hand, most half size 
molecules are routed to intracellular membrane systems such as mitochondria, 
peroxisomes, the endoplasmic reticulum and the Golgi compartment. 
ABC transporters can be divided into two categories according to their mode of action: 
active transporters or pumps, such as members of the ABCB (MDR/TAP) subfamily which 
show a high movement of molecules across membranes against a chemical concentration 
gradient and transport facilitators, which show nucleotide binding and a subsequent 
conformational change but very low ATP hydrolysis such as ABCC7 (CFTR), ABCC8 
(SUR1), ABCC9 (SUR2) and ABCA1. 
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5.3.1. ABCA SUBFAMILY 
This subfamily is composed only of full-size transporters. The ABCA1-family contains 12 
proteins: (ABCA5, ABCA6, ABCA8, ABCA9, and ABCA10) which cluster on chromosome 
17q24 and (ABCA1, ABCA2, ABCA3, ABCA4, ABCA7, ABCA12, ABCA13) which are 
distributed over six different chromosomes. Interestingly, the transcription of at least 
seven ABCA members is regulated by and sensitive to lipids 96-99,104 indicating an 
important role of the whole ABCA subfamily in cellular lipid transport processes. 
ABCA1 mediates cellular phospholipid and cholesterol release via an indirect mechanism, 
possibly by ATP-sensitive regulation of a not yet characterized molecule and mutations of 
ABCA1 lead to HDL-Deficiency Syndromes such as Tangier Disease 21.  
5.3.2. ABCA1 AND FAMILIAL HDL-DEFICIENCY  
The cellular expression of ABCA1 is highly regulated both on transcriptional and 
posttranscriptional levels 196. The turnover of ABCA1 protein is rapid, with a half-life of less 
than one hour in murine macrophage-like cells and differentiated THP-1 cells 146. It was 
shown that calpain-mediated ABCA1 protein degradation is regulated by a PEST 
sequence in the cytoplasmic region of ABCA1. Interestingly, the interaction of ABCA1 with 
extracellular apoA-I inhibits calpain degradation of ABCA1 in a PEST-sequence 
dependent fashion and thereby increases ABCA1 protein level at the cell surface. It was 
observed that apoA-I promotes PEST sequence dephosphorylation. Furthermore, calpain-
Figure 8: Reverse cholesterol 
transport and role of ABCA1. 
Cholesterol esters are hydrolyzed into 
free cholesterol in peripheral tissues 
and are transported by ABCA1 to 
ApoA-I. In the circulation, a pre-β HDL 
particle is formed and through further 
modification by LCAT, this particle 
matures to HDL3 and HDL2. 
Cholesterol from these HDLs is 
internalized by the liver via the 
scavenger receptor SR-BI and then 
cholesterol is excreted via the bile. 
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mediated degradation of ABCA1 can be induced by the phosphorylation of a target 
protein 126.  
Mutations in the human ABCA1 gene lead to familial HDL-deficiency syndromes such as 
classical Tangier disease (TD) 24,165. These patients almost completely lack plasma HDL, 
due to an enhanced catabolism of HDL precursors; they reveal low serum cholesterol 
levels and a reduced efflux of cholesterol and phospholipids from cells.  
Not only HDL-plasma levels are affected in TD, also the composition is impaired, thus 
plasma HDL from TD patients is composed of small pre-β1-migrating HDL particles 
containing only apoAI and phospholipids but lack free cholesterol and apoAII 7. In TD 
patients, concentration of LDL-cholesterol is only 40% of healthy controls and the particles 
are often rich in triglycerides. This is caused by disturbance of the cholesteryl ester 
transfer pathways and phospholipid transfer, resulting in changes of LDL composition and 
size. TD patients suffer from accumulation of cholesteryl esters either in the cells of the 
reticulo-endothelial system (RES) leading to splenomegaly and enlargement of tonsils or 
lymph nodes, or in the vascular wall, leading to premature atherosclerosis (Figure 8 
shows the function of ABCA1 in RCT). 
5.4. TANGIER DISEASE 
Tangier disease, a rare and severe form of HDL deficiency characterized by a biochemical 
defect in cellular cholesterol efflux, is caused by mutations in the ATP-binding-cassette 
(ABC1) gene. This gene codes for the cholesterol-efflux regulatory protein (CERP). 
Complete loss of ABCA1 function leads to severely decreased cellular cholesterol efflux 
and cholesteryl ester accumulation in macrophages and other cells of the 
reticuloendothelial system. Clinically, TD patients often present with hepatosplenomegaly, 
peripheral neuropathy, enlarged yellow tonsils and fatty deposits in the rectal mucosa. 
Earlier studies suggested that certain carriers of ABCA1 defects bear a moderately 
increased risk for CAD 21. 
Because of its ability to reduce macrophage cholesterol content and to raise plasma HDL 
levels, ABCA1 has become a promising therapeutic target for preventing cardiovascular 
disease. 
5.5. ATP-SYNTHASE, A NEW CONCEPT IN THE DUAL REGULATION OF 
ENDOCYTOSIS AND APOAI-MEDIATED CHOLESTEROL EFFLUX 
Plasma HDL is involved in a complex interplay with several cellular partners in order to 
establish the reverse cholesterol transport. Among those partners are: ABCA1 and ApoAI  
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as contributors of HDL formation and others which are mostly involved in HDL catabolism 
like SR-BI and ATP synthase 128. 
Several binding sites for HDL or ApoAI have been identified in the liver plasma membrane 
and the internalization of HDL in the liver is accomplished via clathrin-coated vesicles, 
following engagement of the low-affinity binding sites 63.  
Moreover, recent data showed that remodeling of HDL induces different binding and 
internalization characteristics of the HDL particles and that the high-affinity HDL binding 
sites might trigger the internalization of apo HDL through the low-affinity binding sites 72.  
A newly purified and characterized ApoAI-high-affinity binding site in the plasma 
membrane was the β-chain of human ATP-synthase, a major protein complex of the 
mitochondrial inner membrane also present in the plasma membrane, involved in ATP 
synthesis 127. It has two major domains: F0 and F1, the latter containing five different 
subunits among which the β-chain interacts with ApoAI.  
Beisiegel and Mahley already reported in 1988 that both, the α- and β-chain of ATP 
synthase, are receptors for ApoE-enriched HDL in the plasma membrane 13. Furthermore, 
apoE recycling involves the internalization of HDL3-derived apoAI and its targeting to 
apoE/cholesterol-containing endosomes, indicating that apoAI regulates the resecretion of 
apoE 80. 
Recently, Martinez et. al demonstrated that by adding free ApoAI, ADP generation 
through hydrolysis activity of ATP synthase at the cell surface was strongly stimulated in 
HepG2 cells, a proof that the binding of ApoAI regulates the hydrolysis activity of ATP 
synthase 128. The synthesis of ATP requires an electrochemical proton gradient across the 
inner mitochondrial membrane. The collapse or absence (for instance when the F1 
complex is present alone) of the electrochemical proton gradient induces a switch in 
enzymatic activity from ATP synthesis to ATP hydrolysis. 
The same group showed that the F1-domain of ATPase contributes to HDL internalization. 
Thus, ApoAI binds to high-affinity binding sites i.e. the β-chain of ATP synthase, which is 
an upstream event in the HDL endocytosis pathway. 
A possible concept for this action is shown in figure 9, since the ATP synthase catalyzes 
the conversion of ADP to ATP and vice versa.  ATP synthase is regulated by ApoAI 
leading to enhanced conversion of ATP to ADP. The absence of apoAI would lead to 
enhanced synthesis of ATP resulting in enhanced sinking in phagocytosis since actin can 
bind ATP, polymerize and form F-actin which is essential for type I phagocytosis. Hence 
ApoAI could lead to increased influx. On the other hand, ApoAI binds to ABCA1 leading to 
enhanced efflux. 
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This influx / efflux rheostat model controls cellular lipid homeostasis in a balance; 
dysfunction of this equilibrium may lead to severe disturbances of cellular lipid traffic. This 
is obvious in TD patients where ABCA1 is inoperative and apoAI-dependent cholesterol is 
absent. Cholesterol influx however, is enhanced due to apoAI-dependent stimulation of 
ATP synthase B leading to cholesteryl ester formation and enhanced foam cell formation. 
6. VESICLE FORMATION IN THE GOLGI-DEPENDENT ABCA1 SECRETORY 
PATHWAY 
The group of Alan Tall 35 reported earlier that ABCA1 promotes the formation of 
phospholipid-apoAI-complexes which initially stimulate cholesterol efflux from certain 
regions in the plasma membrane that preferably utilize cholesteryl esters deposited by 
modified LDL in late endosomes and lysosomes rather than cholesterol deposited in other 
intracellular sites. This would explain the fact that de novo synthesized cholesterol and 
cholesterol entering via the HDL/SR-BI pathway can be metabolized normally, whereas 
LDL-derived cholesterol becomes sequestered in the late endosome compartment and 
can not be metabolized in Niemann-Pick C (NPC)-defective cells. However, other studies 
with ACAT inhibition such as Sandoz (S)-58035  also indicated that release of unesterified 
cholesterol from lipid droplets also stimulates apoAI/ABCA1 dependent cholesterol 
efflux 108. 
NPC1 and 2, a protein whose defect leads to selective impairment in cholesterol 
trafficking to the endoplasmic reticulum (ER) and excessive lysosomal storage of LDL 
cholesterol, controls this equilibrium of intracellular sterol trafficking and regulates 
cholesterol exit from late endosomes. Nevertheless, trafficking of ABCA1 to late 
Figure 9: Proposed model of a flux compensation of cholesterol/phospholipid 
traffic in macrophages. ApoAI either binds to ABCA1 leading to increased efflux, or 
to ATP synthase where it activates the β-chain, leading to increased influx. 
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Table 2: The Sec family in yeast and their homologs in human 
Human Yeast
Sec3-like Sec3p
Sec6-like1 Sec6
RAS-like protein Sec15
COP β,β',γ,α,δ,ε,ζ Sec26/27/21 (COP1)
ARF1 (ADP-ribosylation factor) Sar1 (Parts from COPII)
RAB5A Sec4
Syntaxin 1A binding protein Sec1
NSF Sec18
SNAP-α Sec17
SNAREs Sec22
endosomes/lysosomes is not required for the formation of phospholipid-apoAI-complexes. 
ABCA1 is present in late endosomes and Trans-Golgi network and traffics between these 
compartments and the cell surface 138. These data suggested that ABCA1 trafficking 
between late endosomes and the cell surface is involved in cholesterol efflux, a thesis 
supported by the recent finding of Chen et al 36 that ABCA1 colocalizes with LAMP2 in late 
endosomes. This transport requires transport vesicle formation which carries the 
lipoproteins from the Golgi to the cell surface.  
A multi-protein complex, called exocyst, is required for this internal exocytosis. The yeast 
exocyst complex consists of eight components: Sec3, Sec5, Sec6, Sec8, Sec10, Sec15, 
Exo70 and Exo84, yeast genes which are homologous to the human COP, ARF, Rab, 
NSF and SNAREs as shown in table 2. 
 
 
All of them localized to sites of active exocytosis, where they mediate the targeting and 
tethering of post-Golgi secretory vesicles for subsequent membrane fusion 85. Polarized 
exocytosis has three stages: first, post-Golgi secretory vesicles are transported along 
cytoskeletal elements, involving actin, towards specific regions of the plasma membrane. 
Second, the vesicles, mediated by the exocyst complex, are tethered and docked at 
specific domains of the plasma membrane. Finally, the lipid bilayers of the vesicle 
membrane and plasma membrane fuse in a reaction catalyzed by the interaction of 
integral membrane proteins called v-SNAREs and t-SNAREs. This action is regulated by 
small GTP-binding proteins, the Rab family. The exocyst proteins interact with the Rab 
GTPase and dock the secretory vesicles to the plasma membrane for secretion (Figure 
10). The function of the exocyst complex can be elucidated by the example of glucose 
transporter 4 (GLUT4). Insulin stimulation leads to translocation of GLUT4 from its 
intracellular tubulo-vesicular compartments to the plasma membrane via dynamic 
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trafficking, including sorting, budding, tethering, docking and fusion. This is done through 
a complex containing the adapter protein CbI, CbI-associated protein (CAP) and the Rho-
family GTP-binding protein TC10. This complex is phosphorylated and binds to flotillin 
which resides in membrane lipid rafts. TC10 has been shown to bind to Exo70, another 
component of the exocyst pathway and this interaction is necessary for the final steps in 
GLUT4 exocytosis. 
 
At the final stage of exocytosis, the lipid bilayers of the vesicle and plasma membrane 
fuse in a reaction catalyzed by SNF-attachment proteins (SNAPs) and SNAP-Receptors 
(SNAREs). The formation of a stable complex between these SNAREs brings the vesicle 
and the target membrane to close proximity eventually leading to fusion (Figure 10). 
Rabs are members of the Ras superfamily which ensure accuracy in docking and/or 
fusion of vesicles with their correct acceptor compartments. RAB proteins undergo 
regulated exchange of GTP for GDP, and slowly hydrolyze the bound GTP in a reaction 
regulating the timing and unidirectional nature of the fusion. The Rab5-effector EEA1 has 
Figure 10: A: Insulin-induced GLUT4 translocation from intracellular storage 
compartments to the plasma membrane requires two independent signaling 
pathways; one is dependent on the IRSPI 3-kinase pathway (signal 1) and the 
other is dependent on the CAP/Cbl/TC10 pathway (signal 2). These two 
distinct insulin-induced signal transduction pathways act together to elicit the 
translocation of GLUT4 protein mediating via membrane trafficking systems. 
IRS, insulin receptor; PKB, protein kinase B; FLT, flotillin; PKC, protein kinase 
C; APS, Adaptor protein containing PH and SH2 domains.  
B: Tethering and docking of GLUT4-containing vesicles at the plasma 
membrane are dependent on the interaction between TC10 and the exocyst 
protein complex. Following insulin stimulation the lipid-raft-resident TC10 
recruits Exo70 and its associated exocyst protein complex to the plasma 
membrane. This interaction is necessary for the final fusion step of GLUT4-
containing vesicles to the plasma membrane mediated by SNARE proteins 
(SNAP-23, syntaxin4, synip, Munc18c and VAMP2) 131. 
A B
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been shown to directly interact with syntaxin 13 demonstrating the role of Rabs in 
controlling membrane fusion and endosome docking 39. 
Cdc42, also involved in regulating the actin cytoskeletal architecture and filopodia 
formation, has been shown also to act as a trafficking regulator for Rabs thus playing a 
role in intracellular trafficking 32. Besides, the filopodia formation leads to an increase in 
cell surface giving a bigger area where cholesterol efflux can take place due to increased 
vesicle fusion.  
In addition, the Rho proteins interact with the exocyst and control the localization of the 
docking. Finally, small Ras-related regulatory GTPases called ADP-ribosylation factors 
(ARFs), control the stage of vesicle budding and eventually fusion 158. ARF-like proteins 
(ARLs) have similar functions like the Ras-family, Arl7 contributes to a vesicular transport 
step between the late endosome and ABCA1-accessible cholesterol pool at the plasma 
membrane and thereby participates in the RCT pathway which enables the cell to export 
cholesterol when the cellular level of cholesterol is rising and cholesterol secretion is 
necessary in order to protect the cell from the devastating effects resulting from 
cholesterol overloading. The fact that Arl7-mediated stimulation of cholesterol efflux is 
dependent on the presence of apoAI makes it likely that ARL7 acts in concert with ABCA1 
57 either by modulating apoAI and/or ABCA1 endocytic transport or altering the half life of 
ABCA1 (Figure 11). 
Figure 11: The core machinery of COPI recruitment to 
membranes,coat polymerization vesicular budding and uncoating. 
[Adapted from Alberts, 2003 and Nickel et al. 139] 
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A central role in this recruitment is played by the adapter related protein complex 3 (AP-3). 
In drosophila, mutations in the AP-3 complex as well as mutations in ABCG5 and ABCG8 
(both half-size ABC transporters which interact to form the functional full-size) lead to 
changes in the eye color, due to trafficking disturbances in lysosomes and related 
organelles 88.  
In mice, the „mocha” and „pearl” platelet storage pool deficiency (SPD) mutants also have 
defects in the Ap-3 complex 86,199. In addition, Huang et al 86 showed that mutations in 
syntaxin 13 binding protein (pallidin) lead to „pallid“ and „gunmetal“ phenotypes. The latter 
mutants are defective in a more downstream event of vesicle-trafficking: namely, vesicle-
docking and fusion. These mice suffer from hypo pigmentation, lung fibrosis, kidney 
lysosomal enzyme elevation and prolonged bleeding. AP-3 pathway constituents are: 
ARL7 57, Syntaxin 13 and ABCA1 10, Syntaxin 13-interacting protein (pallidin), Cdc42 83,163 
ABCG1/G2/G4 (which leads to mutations: white, brown and scarlet), HPS1-7:Hermansky-
Pudlak-Syndrome complex, P2-Purinergic receptors and GIRKs (G-protein coupled 
inward rectifying K-channels). 
In human, defects of the secretory lysosome lead to a number of genetic diseases like 
Hermansky-Pudlak syndrome (HPS) and Chediak-Higachi syndrome (CHS), autosomal 
recessive disorders which lead to storage defects resulting, among others, from defects in 
secretory lysosomes leading to pulmonary fibrosis and prolonged bleeding.  
Another family of proteins which regulate trafficking to lysosome-related organelles is the 
biogenesis of lysosome-related organelles complex-3 (BLOC 3); it includes the proteins 
HPS1 and HPS4 which lead to Hermansky-Pudlak syndrome (HPS) a genetic disorder 
characterized by albinism, bleeding, and lysosomal storage disorder resulting from defects 
of multiple cytoplasmic organelles: melanosomes, platelet-dense granules, and 
lysosomes, it is a parallel to the HPS disorder in mice which involves a syntaxin 13-
interacting protein called pallidin as well as other genes like muted, and cappuccino, all of 
which are members of the BLOC1 family. The BLOC family encodes the β3A-subunit of 
the adapter protein (AP) complex, AP3 125. 
Table 3 summarizes the defect genes, the affected compartments and the resulting 
mouse mutants. 
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6.1. COATED VESICLE ASSEMBLY 
All types of coated vesicles are formed by polymerization of cytosolic coat proteins on a 
donor (parent) membrane to form vesicle buds that eventually pinch off from the 
membrane to release a complete vesicle. Three types of coated vesicles have been 
characterized, each with a different type of protein coat and each formed by reversible 
polymerization of a distinct set of GTP-binding proteins (ARF or Sar1) belonging to the 
GTPase superfamily. Also, each of them transports cargo proteins from particular parent 
organelles to particular destination organelles: 
• COPII vesicles transport proteins from the rough ER to the Golgi. 
• COPI vesicles mainly transport proteins in the retrograde direction between Golgi 
cisternae and from the cis-Golgi back to the rough ER. 
• Clathrin vesicles transport proteins from the plasma membrane (cell surface) and 
the trans-Golgi network to late endosomes. 
After formation of vesicles by budding from a donor membrane, the coats depolymerize 
into their subunits, which are reused to form additional transport vesicles, this is 
summarized in (Figure 12). 
 
 
Human Disease Defective cells Defective gene Affected complex Mouse mutant
Hermansky-Pudlak-Syndrome Melanocytes and platelets HPS1 BLOC-3 "Pale ear"
Hermansky-Pudlak-Syndrome Immunocytes, melanocytes & platelets AP3B1 (HPS2) AP-3 "Pearl"
Hermansky-Pudlak-Syndrome Melanocytes and platelets HPS3 BLOC-2 "Cocoa"
Hermansky-Pudlak-Syndrome Melanocytes and platelets HPS4 BLOC-3 "Light ear"
Hermansky-Pudlak-Syndrome Melanocytes and platelets HPS5 BLOC-2 "Ruby-Eye2"
Hermansky-Pudlak-Syndrome Melanocytes and platelets HPS6 BLOC-2 "Ruby-Eye"
Hermansky-Pudlak-Syndrome Melanocytes and platelets DTNBP1 (HPS7) BLOC-1 "Sandy"
Hermansky-Pudlak-Syndrome Melanocytes and platelets AP3D1 AP-3 "Mocha"
Hermansky-Pudlak-Syndrome Immunocytes, melanocytes & platelets RABGGTA Transient with Rabs "Gunmetal"
Hermansky-Pudlak-Syndrome Melanocytes and platelets PLDN BLOC-1 "Pallid"
Hermansky-Pudlak-Syndrome Melanocytes and platelets MU BLOC-1 "Muted"
Hermansky-Pudlak-Syndrome Melanocytes and platelets CNO BLOC-1 "Cappuccino"
Hermansky-Pudlak-Syndrome Melanocytes and platelets VPS33A Unknown "Buff"
Chediak-Higashi-Syndrome Immunocytes and melanocytes LYST Unknown "Beige"
Elejalde-Syndrome (Griscelli 1) Melanocytes and neurons MYO V Rab27a/MyoV/Melanophilin "Dilute"
Griscelli-Syndrome 2 Immunocytes and melanocytes RAB27A Rab27a/MyoV/Melanophilin "Ashen"
Griscelli-Syndrome 3 Melanocytes MLPH Rab27a/MyoV/Melanophilin "Leaden"
Table 3: Mouse models of lipid trafficking disorders  
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The general scheme of vesicle budding shown in Figure 13 applies to all three known 
types of coated vesicles. 
Figure 12: Involvement of the three major types of coat proteins in 
vesicular traffic in the secretory and endocytic pathways.  
A. 1.COPII vesicles mediate anterograde transport from the rough ER to the 
cis-Golgi/cis-Golgi network. 2. COPI vesicles mediate retrograde transport 
within the Golgi and from the cis-Golgi/cis-Golgi network to the rough ER. 3. 
The coat proteins surrounding secretory vesicles are not yet characterized; 
these vesicles carry secreted proteins and plasma-membrane proteins from 
the trans-Golgi network to the cell surface. 4-5. Vesicles coated with clathrin 
bud from the trans-Golgi network and from the plasma membrane; after 
uncoating, these vesicles fuse with late endosomes. Adapted from Alberts 
2003, pg. 719  
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Figure 13: Budding and fusion. Overview of vesicle budding and fusion with a target 
membrane. (a) Budding is initiated by recruitment of a small GTP-binding protein to a 
patch of donor membrane. Complexes of coat proteins in the cytosol then bind to the 
cytosolic domain of membrane cargo proteins, some of which also act as receptors that 
bind soluble proteins in the lumen, thereby recruiting luminal cargo proteins into the 
budding vesicle. (b) After being released and shedding its coat, a vesicle fuses with its 
target membrane in a process that involves interaction of cognate T-SNARE proteins 
[Alberts, 2003]. 
B. Vesicle fusionA. Vesicle budding 
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Shortly after a vesicle buds off from the donor membrane, the vesicle coat disassembles 
to uncover a vesicle-specific membrane protein, a v-SNARE. Likewise, each type of target 
membrane in a cell contains t-SNARE membrane proteins. After Rab-mediated docking of 
a vesicle on its target (destination) membrane, the interaction of cognate SNAREs brings 
the two membranes close enough together that they can fuse. The SNARE-mediated 
vesicle fusion can be viewed in figure 14. 
 
Figure 14: Syntaxins and SNAREs in vesicle fusion. A v-SNARE, known as 
VAMP (vesicle-associated membrane protein), is incorporated into secretory 
vesicles as they bud from the trans-Golgi network. Syntaxins are t-SNAREs, 
integral membrane protein in the plasma membrane, and SNAP-25, which is 
attached to the plasma membrane by a hydrophobic lipid anchor in the middle of 
the protein. The cytosolic region in each of these three SNARE proteins contains 
a repeating sequence that allows four α−helices - one from VAMP, one from 
syntaxin, and two from SNAP-25 to coil around one another to form a four-helix 
bundle. As the four-helix bundles form, the vesicle and target membranes are 
drawn together by the embedded transmembrane domains of VAMP and
syntaxin, an effect induced by Ca++ ions.  
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6.2. SYNTAXINS AS CONSTITUENTS OF THE SNARE FAMILY 
Syntaxins are SNARE proteins required in vesicular docking and fusion. All mammalian 
syntaxins, except syntaxin 11, are transmembrane proteins. The structure is highly 
conserved and consists of a transmembrane domain, several hydrophobic regions forming 
coiled-coil domains and a characteristic and conserved SNARE domain. Roughly, 
syntaxins can be divided into two categories, the first with a transmembrane domain 
(TMD) revealing a long amino acid TMD is predominantly located at the PM, the second, 
with short amino acid TMD is distributed in cell organelles. Table 4 shows the intracellular 
distribution of syntaxins. 
 
 
It is this SNARE domain which mediates the interaction with the SNARE domain of other 
target membrane SNARE proteins to form a t-SNARE complex. The t-SNARE complex 
interacts with the vesicle SNARE domain forming the core fusion complex.  
Syntaxins have been shown to interact with several proteins, syntaxin 1a interacts with 
SNAP-25 34, RAB27a 191 and to Slo calcium-activated potassium channel 40, syntaxin 2 
interacts with RAB3A 102, syntaxin 3 interacts with Munc-18-2 153, syntaxin 4 interacts with 
actin 9, syntaxin 13 interacts with EEA1 129 and with ABCA1 10, only to mention a few.  
 
Table 4: Localization and known function of syntaxins.   
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6.3. THE RAB PATHWAY AND ITS INVOLVEMENT IN VESICULAR TRANSPORT 
The RAS superfamily of GTP (guanosine triphosphate) hydrolysis-coupled signal 
transduction relay proteins can be subclassified into RAS, RHO, RAB, and ARF families. 
Ras family GTPases regulate cell signaling events that lead to alterations in gene 
transcription; Rho family GTPases (Rho, Rac and Cdc42), function as regulators of the 
actin cytoskeleton and can also influence gene transcription; Rab (>60 members) and 
(ADP-ribosylation factor) ARF (Arf1–Arf6, Arl1–Arl7) family GTPases control the 
formation, fusion and movement of vesicular traffic between different membrane 
compartments of the cell. 
Multiple Rab GTPases, such as Rab1, Rab4, Rab5, Rab7 and Rab11, have been 
identified to regulate ER–Golgi transport as well as the endocytosis and trafficking of G-
protein coupled receptors between early, late and recycling endosomes and lysosomes 17 
The following figure 15 shows the distribution of Rabs throughout the cell.  
 
 
Figure 15: Distribution of Rabs 
throughout the cell and their 
influence on vesicular transport 
shuttling and fusion. 
NPC 
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Rabs can be separated into two groups according to the speed they handle trafficking 
with. Rapidly recycling Rabs are Rab4, Rab5, Rab7, whereas Rab11 regulates slow 
recycling endosomes.  
Zerial and co-workers 206 have proposed that endosomes are organized as a mosaic of 
different Rabs. The early endosome would comprise of Rab4 and Rab5, the intermediate 
endosome of Rab6, the recycling endosome Rab11 and the late endosomes of Rab7 and 
Rab9. Cargos coming from the TGN may be able to enter any of these endosomal 
domains, thus, providing these pathways with newly synthesized material.  
Due to mutations in either NPC1 or 2, cholesterol as well as other lipids and proteins 
accumulate in the different endosomal organelles 30. 
Consequently, cholesterol homeostatic responses in the endoplasmic reticulum fail, as 
manifested by defective cholesterol esterification and inappropriately high cholesterol 
synthesis 121. NPC1 is a membrane protein localized in Rab7-positive late endosomes 209. 
NPC2 is a cholesterol-binding soluble protein that is also targeted to Rab7-positive late 
endocytic organelles. The group of Elina Ikonen has recently reported that the clearance 
of lysosomal cholesterol deposits can also be inhibited by Rab-GDP dissociation inhibitor 
(Rab GDI) 84. This protein controls multiple vesicular transport pathways by sequestering 
GDP bound (inactive) forms of the small GTPases of the Rab family in the cytoplasm.  
In this concept, Rab11 serves as an important regulator of membrane trafficking 
depending upon cellular cholesterol balance and, in addition, modulates endosomal 
cholesterol levels independent of LDL uptake. 
7. GENE ARRAYS 
Gene array analysis and data validation with Taqman® was a major basis of this thesis. 
Therefore, this innovative technique will be introduced here in more detail.  
Gene expression analysis is essential for obtaining a comprehensive picture of cellular 
mRNA levels. Whole-genome analysis made it possible to investigate the abundance of 
nearly all mRNAs in a cellular tissue. 
Gene arrays consist of large numbers of DNA molecules spotted on a solid substrate such 
as a nylon membrane, a glass slide, or a silicon chip. Depending on the size of each DNA 
spot on the array, DNA arrays can be categorized as microarrays (each DNA spot has a 
diameter of <250 microns) and macroarrays (spot diameter of >300 microns). Different 
methods of manufacturing gene arrays have resulted in the generation of two array 
formats: oligonucleotide arrays and cDNA arrays. 
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In this thesis, we used oligonucleotide arrays from Affymetrix called “GeneChip® Human 
Genome U133A Arrays” to monitor the expression of approximately 14.500 human genes 
regulated by lipid loading and deloading. 
GeneChip® arrays are manufactured through a combination of photolithography and 
combinatorial chemistry using technologies adapted from the semiconductor industry. 
GeneChip manufacturing begins with a 5-inch square quartz wafer. Initially the quartz is 
washed to ensure uniform hydroxylation across its surface. In the next step, silane which 
reacts with the hydroxyl groups of the quartz is added, providing a light activated surface. 
Probe synthesis occurs in parallel, resulting in the addition of either an A, C, T, or G 
nucleotide to multiple growing chains. To define which oligonucleotide chains will receive 
a nucleotide in each step, photolithographic masks are placed over the coated wafer. 
When ultraviolet light is shone over the mask in the first step of synthesis, the exposed 
linkers become deprotected and are available for nucleotide coupling (Figure 15). 
Once the desired features have been activated, a solution containing a single type of 
deoxynucleotide with a removable protection group is flushed over the wafer's surface. 
The nucleotide attaches to the activated linkers, initiating the synthesis process. This 
process is repeated until the probes reach their full length, usually 25 nucleotides. 
 
 
Figure 15: Lithographic manufacture of Affymetrix GeneChip® Arrays. This technology is 
based on oligonucleotides coupled with light sensitive hydroxyl groups. Once the first layer is 
attached to the silane layer, the first line of nucleotides is deprotected and exposed to light 
revealing a group capable of binding new oligos (See text for details) [Affymetrix homepage]. 
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For each probe designed to be perfectly complementary to a target mRNA sequence, a 
partner probe is generated that is identical except for a single base mismatch in its center. 
These probe pairs, called the Perfect Match probe (PM) and the Mismatch probes (MM), 
allow the quantitation and subtraction of signals caused by non-specific cross-
hybridization. In general, 11 to 16 probes are selected among all possible 25-mers to 
represent each mRNA transcript. In addition to choosing the probes based on their 
predicted hybridization properties, candidate sequences are filtered for specificity. Their 
potential for cross-hybridizing with similar, but unrelated sequences is correlated. The 
gene expression data analysis was performed by Affymetrix GeneChip® Operating 
Software (GCOS) which automates the control of the fluidics stations and scanners. In 
addition, GCOS acquires data, manages sample and experimental information. 
Based on the expression algorithm, GCOS computes the detection call which defines 
whether a signal is absent, marginal present or present. This call is emphasized by a 
detection p-value and by a normalized signal which is background-subtracted and 
adjusted for noise. In addition, GCOS is capable of doing comparison analysis and 
calculating the difference call. Each transcript has five possible calls, Increase, Decrease, 
Marginal Increase, Marginal Decrease, No Change. 
Another important result obtained is the signal log ratio (SLR) which monitors the 
expression level of a transcript when two experiments are being compared. This value is 
logarithmic and a log2 ratio of 1 equals a fold change of 2. Using the SLR a fold change 
can be calculated using the following two formulas: 
 
FC= 2(SLR)   if SLR >=0;   
FC= -1*2(-SLR) if SLR<0 
 
8. THE YEAST TWO-HYBRID SYSTEM 
The yeast two-hybrid system can identify protein-protein interactions by using a number of 
different proteins as potential binding partners 60. 
The yeast two-hybrid technique uses two protein domains that have specific functions: a 
DNA-binding domain (BD), which binds to DNA, and an activation domain (AD), which 
activates transcription of the DNA. It is based on the principle that a protein with a DNA 
binding domain can activate transcription by binding to another protein containing an 
activation domain. 
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Figure 16: Screenshot of GCOS. This software controls the hardware composed of the fluidics 
station and the scanner, in addition to analyzing the results of hybridized arrays and calculating the 
expression profiles of the genes. 
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The aim of the thesis was to identify and further characterize novel genes in the ABCA1 
pathway and ABCA1 interactive proteins. Therefore, a Yeast-Two-Hybrid screening was 
performed with parts of ABCA1 as bait. Putative ABCA1 associated proteins were 
identified and association in complexes was confirmed by independent approaches. 
Functional studies were performed to elucidate the physiological consequences of these 
complexes. Another goal was to identify and characterize genes that are inversely 
regulated by atherogenic LDL and/or HDL using gene arrays. These experiments were 
performed with primary human monocytes differentiated in-vitro in the presence of M-CSF 
to macrophages. These investigations should contribute to the understanding of ABCA1 
and other macrophage-specific genes in the pathogenesis of atherosclerosis. 
 
III. Materials                                                                                                                         43 
 
 
 
 
 
 
 
 
 
 
III. MATERIALS 
III. Materials                                                                                                                         44 
1. CHEMICALS 
Agarose   Biozym, Hameln, Germany 
Ampicillin   Roche, Mannheim, Germany 
Bacto-Agar  Difco-Laboratories, Detroit, USA 
Bacto-Trypton  Difco-Laboratories, Detroit, USA 
Bacto-Yeast extracts Difco-Laboratories, Detroit, USA 
Blue-dyed Phagobeads (0,8 µm) Sigma, Deisenhofen, Germany  
BSA (Lipid-free)  Sigma, Deisenhofen, Germany 
DABCO (Triethylendiamin) Sigma, Deisenhofen, Germany 
EDTA (Di-sodium) Pharmacia Biotech, Freiburg, Germany 
Fluoromount-G Southern Biotech, Birmingham, USA 
Fluoesbrite microparticles Polysciences, Eppelheim, Germany 
H2O Nuclease-free  Promega, Madison, AL, USA 
Kanamycin Roche, Ingelheim, Germany 
L-glutamine  Gibco BRL, Berlin, Germany  
Lubrol WX  Serva, Heidelberg, Germany 
MEM (Non-essential Amino acid) Gibco BRL, Berlin, Germany 
Minimal SD Agar Base Clontech, Palo Alto, USA 
Nickel-Chelating Resin GenoTech Biosciences, Lohmar, Germany 
Penicillin/Streptomycin Gibco BRL, Berlin, Germany 
Polyvinyl alcohol Sigma, Deisenhofen, Germany  
Protease inhibitors  Calbiochem, Bad Soden, Germany 
Protein A-Dynabeads   Dynal, Hamburg, Germany 
Second strand buffer  Invitrogen, Glasgow, UK 
Triton X-100  Boehringer, Mannheim, Germany 
Urea Pharmacia Biotech, Freiburg, Germany 
 
2. STANDARDS AND KITS 
1 kb Ladder, DNA Gibco BRL, Berlin, Germany 
100 bp Ladder, DNA Pharmacia, Freiburg, Germany 
AMV-Reverse Transcriptase Promega, Madison USA 
BCA Protein Assay Kit Pierce, Rockford, IL, USA 
Cell Line Nucleofector Kit Amaxa GmbH, Cologne, Germany 
ECL™ Western Blotting Analysis System Amersham, Braunschweig, Germany 
GeneChip Sample Cleanup Module Affymetrix, Santa Clara, CA, USA 
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HighYield RNA Transcript Labeling Kit  Enzo Life, Farmingdale, NY, USA 
Limulus endotoxin assay Sigma, Deisenhofen, Germany 
Oligotex mRNA Kit    Qiagen, Hilden, Germany 
Oligolabeling Kit  Pharmacia, Freiburg, Germany 
Rainbow Coloured Molecular Marker Amersham, Braunschweig, Germany 
Reverse Transcription System Promega, Madison, AL, USA 
RNA 6000 Nano Chip Agilent, Palo Alto, CA, USA 
RNeasy Mini Kit Qiagen, Hilden, Germany 
SuperScript Choice System Invitrogen, Glasgow, UK 
T7-Oligo(dT) Promoter Kit Affymetrix, Santa Clara, CA, USA 
QIAEX II Gel Extraction Kit Qiagen, Hilden, Germany 
Qiashredder Qiagen, Hilden, Germany 
Qiaprep (Miniprep) Kit Qiagen, Hilden, Germany 
 
3. RADIOACTIVE MATERIALS 
[3H]Choline phospholipid Amersham, Braunschweig, Germany 
[14C]Cholesterol Amersham, Braunschweig, Germany 
 
4. ENZYMES  
Cholesterol Esterase Roche, Mannheim, Germany 
Klenow-Enzyme Pharmacia, Freiburg, Germany 
Long Template PCR System Roche, Mannheim, Germany 
RNase A  Fluka, Deisenhofen, Germany 
T4-DNA-Ligase Gibco BRL, Berlin, Germany 
T4-DNA-Polymerase Roche, Mannheim, Germany 
T4-Polynukleotidkinase Roche, Mannheim, Germany 
Taq-DNA-Polymerase Roche, Mannheim, Germany 
TaqMan PCR Mastermix ABI, Darmstadt, Germany 
Trypsin / EDTA Sigma, Deisenhofen, Germany 
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5. HUMAN PRIMARY CELLS AND CELL LINES 
5.1. MONOCYTES 
Leukocyte-enriched apheresates were obtained from healthy, normo-lipidemic donors 25–
45 years of age bearing either the apolipoprotein E3/E3 or the apolipoprotein E4/E4 
genotype after informed consent. Monocytes were isolated by counterflow elutriation and 
cells were cultured at 37°C in 5% CO2. 
5.2. FIBROBLASTS 
Human fibroblasts TD1, TD3, and TD5 were obtained from patients with documented 
mutations in their ABCA1 gene. Patient TD1 bears a homozygous K171X mutation, 
patients TD3 and TD5 display mutations that have been published previously 21. As 
control, human fibroblasts obtained from healthy individuals were used. The fibroblasts 
were incubated in DMEM medium supplemented with 1% MEM and 10% FCS at 37°C in 
5% CO2 atmosphere. 
5.3. HUMAN CELL LINES 
The following cell lines have been used: 
 
Cell line Description Reference 
Hep-G2 Hepatocellular carcinoma 2 
Meg-01 Chronic myeloid leukemia  143 
HL-60 Acute myeloid leukemia 43 
THP-1 Acute monocytic leukemia 192 
 
6. BACTERIA (E.COLI) 
One Shot® TOP10  F-, mcrA, Δ(mrr-hsdRMS-mcrBC), 
Φ80lacZΔM15, ΔlacX74, deoR, recA1, 
araD139, Δ(ara-leu)7697, galU, galK, 
rpsL(StrR), endA1, nupG, Invitrogen, 
Glasgow, UK 
7. PLASMIDS 
ABCA1 TD T. Langmann 
pAS2-1 Clontech, Palo Alto USA 
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pACT2 Clontech, Palo Alto USA 
pcDNA3.1.D/V5-His-TOPO Invitrogen, Glasgow, UK 
 
8. MEDIA AND BUFFERS 
Bacto-Agar Difco-Laboratories, Detroit USA 
Bacto-Trypton Difco-Laboratories, Detroit USA 
Bacto-Yeast extract Difco-Laboratories, Detroit USA 
DMEM with L-Glutamin Bio WHITTAKER, Walkersville USA 
DMEM with L-Glutamin, w/o Phosphate  Bio WHITTAKER, Walkersville USA 
Fetal Calf Serum (FCS)   Gibco BRL, Berlin, Germany 
-Leu DO Supplement Clontech, Palo Alto USA 
-Leu/-Trp DO Supplement Clontech, Palo Alto USA 
-Leu/-Trp/-His DO Supplement Clontech, Palo Alto USA 
Luria Broth Base Gibco BRL, Berlin, Germany 
Macrophage-SFM-Medium  Gibco BRL, Berlin, Germany 
PBS w/o Ca+2/Mg+2 Gibco BRL, Berlin, Germany 
RPMI 1640 Gibco BRL, Berlin, Germany 
YPD Medium Clontech, Palo Alto USA 
YPD Agar Medium Clontech, Palo Alto USA 
 
9. MICROARRAYS 
Human Genome U95Av2 Array  Affymetrix, Santa Clara, CA, USA 
Human Genome U133A                                 Affymetrix, Santa Clara, CA, USA 
Human Genome U133 Plus 2.0 Array            Affymetrix, Santa Clara, CA, USA 
10. TECHNICAL EQUIPMENTS 
2100 Bioanalyzer, Caliper Agilent, Palo Alto, CA, USA 
Autoclave Steam Sterilizer Type 24 Melag, Berlin, Germany 
Automatic Gamma Counter 1470 WIZARD Berthold, München, Germany 
Biofuge 15R Heraeus, Hanau, Germany 
Cell culture Incubator 6000 Heraeus, Hanau, Germany 
ELISA-reader  Tecan, Stuttgart, Germany 
FACScan BD, Heidelberg, Germany 
GeneQuant pro RNA/DNA Calculator Amersham, Braunschweig, Germany 
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GeneChip® Fluidics Station 450 Affymetrix, Santa Clara, CA, USA 
GeneChip® Scanner 3000 Affymetrix, Santa Clara, CA, USA 
Horizontal Shaker GFL-3016 GFL, Großburgwedel, Germany 
Hybridization Oven 640 Affymetrix, Santa Clara, CA, USA 
Incubator B 6120 Heraeus, Hanau, Germany 
Instant Camera MP4 Polaroid, Offenbach, Germany 
Kodak X-Omat 2000 processor Kodak, Rochester, NY, USA 
LaminAir Hood  Heraeus, Hanau, Germany 
Liquid Scintillation Counter Wallac 1410 Berthold, München, Germany 
Lumi Imager F1 Boehringer, Mannheim, Germany 
Megafuge 1.0 R Heraeus, Hanau, Germany 
Microscope (Visible) Leitz Laborlux S Leitz GmbH, Wetzlar, Germany 
Milli-Q UF Plus System Millipore, Bradford, VT, USA 
MiniSpin Plus Centrifuge Eppendorf, Hamburg, Germany 
Mini Transblot Cell BioRad, München, Germany 
Mini Protean-3 Electrophoresis Cell BioRad, München, Germany 
Mini-Sub Cell GT Electrophoresis  BioRad, München, Germany 
pH-Meter pH537 WTW, Weilheim, Germany 
Precision Balance Sartorius MD BA 200 Sartorius, Göttingen, Germany 
Power Supply PAC 300 BioRad, München, Germany 
Princeton MicroMax CCD-1317-K/1  Roper Scientific, Trenton, NJ, USA 
Shaking Incubator GFL-3032 GFL, Großburgwedel, Germany 
Shaking Water Bath Julabo SW-20C Julabo, Seelbach, Germany 
Spectrophotometer UV/VIS Lambda 2 Perkin Elmer, Überlingen, Germany 
Stirrer with Heating Surface IKAMAG Labor Center, Nürnberg, Germany 
SpeedVaq Alpha RVC Christ, Osterode, Germany 
Sysmex Micro-Cell Counter F-300 Digitana AG, Hamburg, Germany 
Thermocycler Gene Amp PCR System 9600 Perkin Elmer, Uberlingen, Germany 
Thermomixer Comfort Eppendorf, Hamburg, Germany 
Ultrasonic Disintegrator Soniprep 150 MSE, Watford Herts, United Kingdom 
Ultracentrifuge (fixed angle) J2-21 M/E Beckman, München, Germany 
Ultracentrifuge L-70  Beckman, München, Germany 
Ultracentrifuge Optima TLX Beckman, München, Germany 
Vortex-Mixer REAX 2000 Heidolph, Kelheim, Germany 
Zeiss Axiovert S-100 Spectral Microscope  Carl Zeiss, Goettingen, Germany 
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11. SILENCING RNA 
Syntaxin 13 (NM_177424) supplied by Ambion, Austin, TX, USA. 
Sense sequence: 5’-ggguaucugaaaaggaaaatt-3’ 
Antisense sequence: 5’- uuuuccuuuucagauaccctt-3’ 
Non-Silencing Control siRNA: Qiagen, Hilden, Germany. 
Sense sequence: 5’-UUCUCCGAACGUGUCACGUdTdT-3’ 
Antisense sequence: 5’-ACGUGACACGUUCGGAGAAdTdT-3’ 
Positive Silencing Control siRNA: Lamin A/C, Qiagen, Hilden, Germany. 
Sense sequence: 5’- CUGGACUUCCAGAAGAACAdTdT-3’ 
Antisense sequence: 5’- UGUUCUUCUGGAAGUCCAGdTdT-3’ 
Fluorescent Neg. Control siRNA Fluorescein, Qiagen, Hilden, Germany. 
Sense sequence: 5’-UUCUCCGAACGUGUCACGUdTdT-3’ 
Antisense sequence: 5’-ACGUGACACGUUCGGAGAAdTdT-3’ 
12. GENE BANKS  
Human Liver MATCHMAKER, cDNA Clontech, Palo Alto USA 
Marathon-Ready cDNA (Liver, Spleen) Clontech, Palo Alto USA 
13. FILMS AND MEMBRANES 
ECL Hyperfilm Amersham, Braunschweig, Germany 
Fluorotrans Membrane (PVDF) Pall Filtron GmbH, Dreieich, Germany 
Instant Picture Film Typ 667 Polaroid, Offenbach, Germany 
X-Ray Films Biomax Kodak, Rochester, NY, USA 
14. ANTIBODIES 
Antibody   Host    Company 
ABCA1 Rabbit Novus, Littleton, CO, USA 
β-Actin Mouse Sigma, Taufkirchen, Germany 
β2-Syntrophin Rabbit Pineda, Berlin, Germany 
Caspase 8 Rabbit Upstate Biotechnology, NY, USA 
Early endosome Antigen 1 Rabbit Abcam, Cambridge, United Kingdom 
FADD Rabbit Upstate Biotechnology, NY, USA 
Flotillin-1 Mouse BD Biosciences, San Diego, CA, USA 
MYC Mouse Invitrogen, Karlsruhe, Germany 
Syntaxin 1 Rabbit Calbiochem, Darmstadt, Germany 
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Syntaxin 2 Rabbit Calbiochem, Darmstadt, Germany 
Syntaxin 3 Rabbit Calbiochem, Darmstadt, Germany 
Syntaxin 4 Rabbit SySy, Goettingen, Germany 
Syntaxin 6 Rabbit BD Biosciences, San Diego, CA, USA 
Syntaxin 7 Rabbit SySy, Goettingen, Germany 
Syntaxin 8 Mouse BD Biosciences, San Diego, CA, USA 
Syntaxin 11 Mouse Transduction, Lexington, KY, USA 
Syntaxin 13 Mouse Imgenex, San Diego, CA, USA 
Syntaxin 13 Rabbit SySy, Goettingen, Germany 
Syntaxin 16 Rabbit SySy, Goettingen, Germany 
Rab9 Mouse Abcam, Cambridge, United Kingdom 
 
15. PREPARATION OF SOLUTIONS 
 
PBS-Tween 
10 l PBS 
100 ml 10% Tween 
 
 
Transfer-buffer (western blot) 
1 l Methanol 
30.3 g TRIS 
144 g Glycine 
Ad 10 l H2O 
 
5x SDS-Gel running buffer (western blot) 
75 g TRIS 
360 g Glycine 
250 ml 10% SDS 
 
5x sample loading buffer (Laemmli dye - western blot) 
5 ml Glycerol  
1 g SDS  
2.56 ml ß-Mercapto-Ethanol  
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2.13 ml 0.5M TrisHCl pH 6.8+ 0.4% SDS   
Bromo-Phenol Blue Traces 
 
Tris Base Sodium Chloride TBS-BG  (Fluorescent staining) 
100 ml   Tris/HCl pH 7.6   200 mM 
137 ml   NaCL                       1  M 
30   ml   KCl                     100 mM 
10   ml   MgCl2                 150 mM 
5    g      Glycine 
5    g      BSA check pH. fill up to 1 l and add: 
0.5  ml   Tween 20 
0.5  g      Na-Azid 
 
Mounting Medium (Fluorescent microscopy) 
12 g Glycerol (87% 13.8 g) 
12 ml H2O Mix and add 4.8 g Polyvinylalcohole (30-70.000). let stir overnight 
Add 24 ml 0.2 M Tris pH 8-8.5   30` at 50°C. Shake occasionally and add 1.15 g DABCO  
Centrifuge at 3000 g twice (5 min. RT). Remove supernatant and store in aliquots at -20°C 
for months or at 4°C for a week. 
 
5 x TBE-buffer (DNA) 
54 g Tris; 27.5 g Boric acid; 20 ml 0.5 M EDTA ( pH 8.0); ad 1 l H2O  
 
6 x Sample buffer  (DNA) 
0.25 % (w/v) Bromphenolblue; 0.25% (w/v) Xylencyanol; 15% (w/v) Ficoll 400 in H2O  
 
Ethidiumbromid stock solution (DNA – RNA) 
10 mg/ml Ethidiumbromide in H2O  
 
 
5 x Gel-running buffer (RNA) 
0.2 M MOPS. pH 7.0; 50 mM Na-Acetat; 5 mM EDTA 
 
10 x sample buffer (RNA)  
50% (v/v) Glycerol; 0.4% (w/v) Bromphenolblue; 0.4% (w/v) Xylencyanol; 1 mM EDTA in 
H2O  
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LB-Medium: 25 g Luria Broth Base; ad 1000 ml H2O; autoclave 
 
LB-Agar: LB-Medium with 1.5 % (w/v) Agar; autoclave  
 
LB-Agar-Amp: LB-Agar; autoclave; cool to 55°C; add 100 µg/ml Ampicillin  
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1. PRIMARY CELLS AND CELL LINES 
1.1. ELUTRIATION OF HUMAN MONOCYTES 
Suspensions enriched in human peripheral blood leukocytes were isolated by 
leukapheresis in a Spectra cell-separator (Gambro BCT), supplemented with the 
anticoagulant ADCA and diluted with an equal volume of PBS (w/o Ca2+, Mg2+). The 
diluted apheresate was subjected to counterflow centrifugation (J2-MC centrifuge with JE-
6B Rotor, Beckmann) using buffers and centrifuge adjustment as follows:  
Running buffer:  
PBS (w/o Ca2+, Mg2+) 
1.0 % (v/v) penicillin / streptomycin-solution 
0.5 % (w/v) BSA 
0.1 % (w/v) Glucose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The monocyte content of each fraction was determined using flow cytometry based on the 
different scatter properties of lymphocytes, granulocytes and monocytes. Fractions that 
were devoid of granulocytes with a monocyte content of at least 95% of leukocytes were 
pooled, washed with PBS (w/o Ca2+, Mg2+) and resuspended in culture medium. The 
concentration of the suspension was determined with a Sysmex micro-cell counter F-300. 
 
 
Rotation: 2040 rpm 
Rotor temperature: 15°C 
 Flow rate (ml/min) Volume of fraction (ml) 
Loading 7 - 
Pre-run 9 150 
Fractions 1 - 4 12 50 
Fractions 5 - 8 15 50 
Fractions 9 - 12 18 50 
Fractions 13 - 16 20 50 
Fractions 17 - 19 22 50 
Fractions 20 - 22 24 50 
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1.2. CULTIVATION AND DIFFERENTIATION OF HUMAN MONOCYTES 
10 million monocytes revealing a purity of >95% were seeded on cell culture dishes (10 
cm Ø) with a concentration of 1x106 monocytes/ml. The serum-free medium 
complemented with 50 ng/ml human M-CSF (R&D System) and monocytes were 
incubated for 4 days at 37°C / 5% CO2 (Heraeus Incubator) to induce phagocytic 
differentiation as described 181. Afterwards, the macrophages were lipid-loaded with either 
E-LDL (30 µg/ml) or Ox-LDL (100 µg/ml) for 48 h. Lipid Deloading was achieved by 
incubating the loaded foam cells with new SFM-medium supplemented with HDL3 (100 
µg/ml) for 24 h. 
1.3. CULTIVATION OF HUMAN TUMOR CELL LINES  
Pro-myelocytic HL-60 human leukemia cells were seeded at a concentration of 1x106 
cells/ml in non-adherent cell culture flasks (green cups, NUNC, Wiesbaden, Germany) in 
RPMI medium supplemented with 10% FCS and 1% MEM. The medium was changed 
once per week and cells were splitted at a 1:3 ratio. Cells were collected by centrifugation 
at 270 g and resuspended in 3-4 ml medium; counting was performed with Sysmex 
microcell counter F-300.  
Megakaryoblastic leukemia MEG-01 cells were seeded in non-adherent cell culture flasks 
in RPMI medium supplemented with 10% FCS and 1% MEM. Medium was changed twice 
weekly and splitting was performed after cells reached confluency at a ratio of 1:4. 
Human acute monocytic leukemia THP-1 cells were seeded in non-adherent cell culture 
flasks in RPMI medium supplemented with 10% FCS and 1% MEM. Medium was 
changed once weekly and splitting was performed after cells reached confluency at a ratio 
of 1:3. 
Differentiation and adhering was induced in all mentioned cell lines by 10 nM phorbol 
myristate acetate (PMA).   
1.4. TRANSFECTION OF CELL LINES 
For transfection, two different methods have been used according to the cell line 
transfected.  
1. Lipofectamine (Invitrogen): A liposome formulation which is suitable for the 
transfection of DNA into tissue culture cells. It interacts with DNA, forming a lipid-
DNA complex, the fusion of the latter with the cells results in efficient uptake of the 
DNA. The transfection was performed according to manufacturer’s instruction.  
2. Human Dermal Fibroblast Nucleofector Kit (Amaxa): A non-viral transfection 
method that permits high gene transfer efficiency for human fibroblasts, the DNA is 
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directly delivered into the nucleus during nucleofection. The cells are suspended in 
an appropriate electroporation buffer and put into an electroporation cuvette, DNA 
is added, the cuvette is connected to a power supply, and the cells are subjected 
to a high-voltage electrical pulse of defined magnitude and length. The 
electroporation was performed according to the optimized protocol from the 
supplier. 2 µg of DNA were transfected into 400’000 cells. 
 
2. LIPOPROTEINS 
2.1. ISOLATION OF LIPOPROTEINS 
Lipoproteins and lipoprotein-deficient serum were prepared from human plasma or serum 
by sequential preparative ultracentrifugation in KBr gradients followed by extensive 
dialysis and filter sterilization. All lipoprotein concentrations mentioned are protein 
concentrations determined by Lowry’s method 124. Lipoprotein fractions were stored at 4°C 
and used within two weeks from end of dialysis. 
2.2. ENZYMATIC AND OXIDATIVE MODIFICATION OF LDL 
Enzymatic degradation of LDL was performed by diluting LDL to 2 mg/ml protein in PBS 
(w/o Ca2+, Mg2+). Enzyme treatment was conducted with trypsin (6.6 mg/ml) and 
cholesterol esterase (40 mg/ml) for 24-36 h at 37°C until the solution was turbid. Mildly 
oxidative modification of LDL was performed by dialyzing purified LDL (1 mg of protein/ml) 
against 5 µM CuSO4 for 48 h. 
During LDL preparation and subsequent modification, general precautions were taken to 
avoid lipopolysaccharide (LPS) contamination. The latter was excluded by Limulus 
endotoxin assay (Sigma, Deisenhofen, Germany) 55. 
 
3. PROTEIN METHODS 
3.1. ISOLATION OF PROTEINS 
Cells were harvested, washed 3 times with PBS, collected by centrifugation for 7 min. at 
270 g. Afterwards, cells were resuspended in probe buffer (PBS, 1% Triton X-100, 
protease inhibitor) and homogenized by sonification on ice. The homogenate was left on 
ice for 30 min and centrifuged at 14000 rpm at 4°C for 30 min.  
3.2. PROTEIN CONCENTRATION DETERMINATION 
For protein quantification, the BCA protein assay kit (Pierce) was used. The method is 
based on the reduction of Cu2+-ions to Cu+-ions in alkaline environment (Biuret reaction). 
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The Cu+-ions form a complex with bicinchonic acid (BCA) a purpled colored complex with 
a peak absorption at 562 nm. The absorption is linear in a range of 20 - 2000 µg/ml and is 
proportional to the protein concentration.  
BCA reagent was freshly prepared by adding 4% CuSO4 to the protein solution at a ratio 
of 1:50. 25µl of the probe or the standard were added to a microtiter plate and mixed with 
200 µl of the prepared BCA solution. After incubation at 37°C for 30 min the extinction 
was measured in an ELISA-reader and the protein concentration was calculated. 
3.3. SDS-PAGE AND WESTERN BLOTTING 
Proteins are separated by SDS-PAGE (PolyAcrylamide Gel Electrophoresis) according to 
their size regardless of any other physical feature.  
For gel electrophoresis, pre-cast gradient gels (Bio-Rad) were used. Protein samples 
were diluted in 5x samples loading buffer (Laemmli dye) and incubated at 85°C for 10 min. 
The samples were loaded to the gel and separated by Bio-Rad apparatus at 25 mA per 
gel for 90 min at RT. 
After electrophoresis, the gel was transferred to a PVPF Fluotrans transfer membrane 
using a Mini Trans-Blot electrophoretic transfer cell (Bio-Rad). The transfer conditions 
were 4°C, 350 mA for 2 h. 
After blotting, the membrane was blocked using 5% non-fat dry milk in PBS-Tween (0,1%) 
at RT for 30 min. Afterwards, primary antibodies were applied at different dilutions (refer to 
antibodies) for 1 h. After washing 3 times with PBS-Tween 0,1%, the secondary 
peroxidase-conjugated antibody was diluted 1: 2000 -10000 and incubated at RT for 1 h. 
Signal detection was performed using ECL plus detection system according to 
manufacturer’s instruction. 
3.4. ISOLATION OF PHAGOSOMES WITH PHAGOBEADS 
Human macrophages were cultivated with SFM medium supplemented with M-CSF for 4 
d for phagocytic differentiation. Blue-dyed latex phagobeads (0,8 µm diameter, 10% 
aqueous suspension) were diluted at ratio 1:100 in SFM medium and incubated with 
10x106 macrophages. After a 1 h pulse (internalization), cells were washed with PBS and 
further incubated at 37°C for 2, 3, 6, 12 and 20 h (chase) before homogenization. Isolation 
of phagosomes was performed using a modification of a method described by Desjardins 
et al. 50. Cells were washed in cold PBS (3 x 5 ml) and scraped with a rubber Policeman at 
4°C. The cells were pelleted and washed in homogenization buffer (250 mM sucrose, 3 
mM imidazole, pH 7.4) at 4°C. They were then pelleted again, resuspended in 1 ml of 
homogenization buffer and homogenized in a homogenizer using ball bearings.  
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The homogenization was carried out until about 90% of cells were broken without major 
breakage of the nucleus, as monitored by light microscopy. Unbroken cells were pelleted 
in a 15 ml Falcon tube at 270 g for 5 min at 4°C and the supernatant, containing the 
phagosomes, was recovered. The phagosomes were then isolated by flotation on a 
sucrose step gradient (all sucrose solutions are wt/wt in 3 mM imidazole, pH 7.4) as 
follows: The supernatant from five subconfluent 10 cm dishes (about 1 ml) was brought to 
40% sucrose by adding the same volume of a 62% sucrose solution. This 40% sucrose 
supernatant was loaded on top of a 1ml cushion of 62 % sucrose. We then added 2 ml of 
35 % sucrose, 2 ml of 25 % sucrose, and 2 ml of 10% sucrose solutions. Centrifugation 
was done in swinging bucket rotor (SW40; Beckman Instruments, Palo Alto, CA) for 1 h at 
100,000 g at 4°C. The phagosomes band was collected from the interface of the 10 and 
25 % sucrose solutions and resuspended in 12 ml of cold PBS. The phagosomes were 
finally pelleted by a 15 min centrifugation at 40,000 g in an SW 40 rotor at 4°C. 
An important advantage of this flotation method is that the latex beads float the 
membranes enclosing them to a density on the gradient where no protein was detectable 
in the absence of beads. 
3.5. SUCROSE GRADIENT CENTRIFUGATION AND ISOLATION OF RAFTS 
After incubation and the removal of culture media, cells were scraped in PBS and 
subsequently centrifuged for 10 min at 700 g. The cell pellets (100 ± 30 mg of protein) 
were lysed for 30min on ice in 500 µl ice-cold TNE-lysis buffer containing 50 mM TRIS, 
150 mM NaCl, 5 mM EDTA, 200 mM aminoethylbenzensulfonylfluoride, 160 mM aprotinin, 
10 mM bestatin, 3 mM E64-protease inhibitor, 4 mM leupeptin, 2 mM pepstatin A and 
either 1% Triton X-100 or 1% Lubrol WX. The lysates were brought to 1,2 M sucrose by 
adding 300 µl of 2,4 M sucrose in TNE-buffer placed on the bottom of a SW55 TI tube 
(Beckmann) and overlaid with 1,2 ml of 0,9 M, 0,6 ml of 0,8 M, 1,2 ml of 0,7 M, 1,2 ml of 
0,1 M sucrose in TNE-buffer. Samples were ultracentrifuged at 335,000 g at 4°C for 16 h. 
After centrifugation, 600 µl fractions were collected from the top to the bottom and the 
pellet was resuspended in Triton X-100 at RT. Then the fractions were either subjected 
directly to further analysis or pooled to yield the following fractions: fractions 1-5 
representing the low-density fraction (LDF), fractions 6-8 representing the high-density 
fraction (HDF) and the pellet. In a subset of experiments, fractions 6 and 7 obtained after 
lysis in Lubrol WX were diluted 1:20 with TNE buffer and centrifuged at 100,000 g for 1 h.  
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3.6. CO-IMMUNOPRECIPITATION 
For co-immunoprecipitation, cells were lysed in 1% Triton X-100 in PBS with a protease 
inhibitor mixture for 30 min at 4°C followed by centrifugation at 15,000 x g for 10 min. The 
supernatant was incubated overnight with primary antibodies linked to magnetic protein-A 
beads. The beads were washed three times with the lysis buffer and were eluted by 
100 mM triethylamine, pH 11, supplemented with 10% dioxane. The eluates were 
analyzed by immunoblots. In addition, extracts were lysed in 50 mM Tris, 150 mM NaCl, 
1% Nonident P-40, and 0,5% Na deoxycholate in PBS with protease inhibitor (RIPA 
buffer) and then incubated with primary antibodies linked to magnetic beads for 1h, 
washed with RIPA buffer three times at RT, and further processed as described above. 
3.7. IMMUNOFLUORESCENT STAINING AND MICROSCOPY 
Cells were grown on slides or cover-slips, after removing the medium, the cells were 
washed with PBS 3 times for 5 min and fixed either with methanol (-20°C) or 
paraformaldehyde supplemented with glutaraldehyde. The slides were air dried and 
permeabilsed by covering the cells with PBS, 1% Triton X-100 for 5-30 min at RT 
according to cell type. Afterwards, the cells were blocked with TBS-BG (Tris Base Sodium 
Chloride) for at least 15 min. The primary antibody was diluted in PBS with 0,1% Triton X-
100 and 0,5% BSA, the dilutions ranged from 1:50 to 1:500. For double stains, the 
antibodies were simply combined (only Ab’s from different species), the incubation was 
performed for at least 1h at RT or over night at 4°C. After that the slides were washed 3 
times for 5 min in PBS and secondary antibody was added for 1 hour at RT in the dark. 
The antibody solution was prepared by diluting the secondary antibody 1:500 in PBS 
(0,1% detergent, 0,5% BSA and 0,5 µg/ml DAPI). 
Slides were washed 3 x 5 min in PBS, briefly dried and mounted by adding a drop of 
mounting medium right onto the cells and covered with a cover slip for at least 1h prior to 
microscoping. Non-confocal fluorescent images were collected on a Zeiss Axiovert S-100 
spectral microscope using a CCD camera from Princeton Instruments MicroMax 
RTE/CCD-1317-K/1 controlled by Metamorph software (Universal Imaging, Downingtown, 
PA, USA) with excitation and emission conditions chosen to clearly resolve Texas Red- 
and FITC-labeled secondary antibodies. The nuclear shape was determined from the 
DAPI staining. 
3.8. FLOW CYTOMETRY 
Flow cytometry of surface exposed antigens, 5x105 cells in 100 µl PBS, 0,5% BSA were 
incubated for 15 min on ice with saturating concentrations of the antibodies. Thereafter 
IV. Methods                                                                                                                         60 
two washing steps with PBS 0,5% BSA were performed. The cellular light-scatter signals 
and the fluorescence signals of 20 000 cells per sample were analyzed in list mode at a 
channel resolution of 1024 with forward scatter as the trigger parameter on an 
FACSCalibur flow cytometer (excitation: 488 nm (argon) / 635 nm (diode); emission filters: 
530/30 nm band pass (channel 1) / 585/47 nm band pass (channel 2) / 670 nm long pass 
(channel 3): 661/16 nm band pass (channel 4); The photomultiplier gains were calibrated 
with polychromatic fluorescent reference beads (Polysciences). Compensation was 
adjusted with fluorochrome-coated microbeads (Becton Dickinson, Heidelberg, Germany). 
Gating of cultivated fibroblasts was based on forward- and side-scatter dot plots. 
Antibodies used for detection were directly fluorochrome conjugated. Mean fluorescence 
values were corrected for background by subtraction of cellular auto fluorescence. For 
analysis of the list files the software CellQuest 2.0 (Becton Dickinson, Heidelberg, 
Germany) was used on a Macintosh G3. 
4. RADIOACTIVE LIPID EFFLUX 
Efflux of [3H]-choline phospholipids from cells was measured by the appearance of 
radioactive label in the medium after incubation with either apoA-I or HDL3. Lipids in the 
medium were extracted according to the method of Bligh and Dyer 20, and the radioactivity 
was measured by liquid scintillation counting. Lipid efflux was calculated by subtracting 
the radioactivity secreted in the supernatant from total radioactivity. Specific lipid efflux 
was determined as lipid efflux in the presence of apoA-I or HDL3 subtracted by the efflux 
in the absence of a nonspecific acceptor (BSA).  
5. CULTIVATION OF ESCHERICHIA COLI 
E. coli cultures were cultivated either on agar plates or in liquid medium over night at 37°C 
in an incubator. Cultures were obtained by inoculating a single colony or suspension of 
bacteria from a glycerol culture into LB-medium. Liquid cultures are incubated in a shaker 
at 37°C and 240 rpm over night. It is necessary to add an appropriate antibiotic 
(Ampicillin) to select a specific plasmid. 
E. coli cultures were permanently stored in glycerol, to achieve this 500 µl liquid culture 
was mixed with 500 µl sterile glycerol (30%) in  a Cryo-tube and were shock frozen in 
liquid nitrogen and stored at -80°C. 
6. NUCLEIC ACID METHODS 
6.1. RESTRICTION ENZYME DIGESTION OF DNA 
The restriction digest can either be performed analytically to analyze the DNA or 
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preparatively to prepare DNA for further cloning. The incubation is performed with buffers 
obtained from Roche (10x buffers: A, B, L, M, H) for 2 h at the according temperature in a 
thermo block. 
For the analytical approach, 1 µg DNA is digested with 10 units of restriction enzyme in 20 
µl total volume. For preparative digestions, 20 µg of DNA were digested with 30 units of 
enzyme at a total volume of 80 µl. 
6.2. DNA GEL ELECTROPHORESIS AND DNA EXTRACTION FROM AGAROSE GELS 
Different length DNA-molecules can be separated in agarose gels according to their 
mobility and the negative total charge of the DNA-double helix. 
The electrophoretic mobility of the DNA is inversely proportional to the logarithm of base 
pairs. Polyacrylamid gels are capable of separating DNA fragments up to 1 kb of size, 
whereas agarose gels separate fragments up to 20 kb. In order to achieve a maximum of 
separation capacity gels are cast in following concentrations: 
 
DNA fragment size < 1kb               1,5% - 4% gel 
DNA fragment size 1 – 10 kb         0,7% - 1% gel 
DNA fragment size > 10kb             0,5% gel 
 
The applied voltage varied between 80 – 100 V. To visualize the DNA in the gel, ethidium 
bromide was incorporated in the gel, and this mutagen substance binds to the DNA 
double helix, staining it with an orange colored fluorescent light when observed under UV 
(365nm). The gel was photographed with a MP-4 camera (Polaroid) or scanned with a 
Lumi-imager (Boehringer-Mannheim).  
DNA-fragments were extracted from agarose gels by selectively adsorbing them to a 
special matrix. This was accomplished using the „QIAEX II Gel Extraction Kit” (Qiagen). In 
this method, DNA is bound to a silica-matrix at a high salt concentration and then eluated 
in water at low salt concentrations. The agarose piece is diluted with 10 times of its 
volume with QX1 buffer and 10µl QIAEX II suspension is added and incubated at 50°C for 
10 min in a shaking thermo block. After centrifugation (18000 g, 2 min) the pellet was 
washed with PE-buffer, dried and the DNA was resuspended in 20 µl of sterile water.  
 
6.3. CLONING OF DNA FRAGMENTS 
Prior to transfection, the DNA fragment must be ligated to the plasmid, this is done by the 
T4-DNA-ligase enzyme in presence of ATP and Mg2+ ions. The optimal ratio between the 
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plasmid and the insert-DNA is 1:3.  
 Plasmid-DNA (200 ng/µl) 2,0 µl 
 Insert-DNA (200 ng/µl) 6,0 µl 
 5 × Ligase buffer 4,0 µl 
 T4-DNA-Ligase (5 U/µl) 1,0 µl 
 H2O (Millipore) 7,0 µl 
The ligation is performed over night at 14°C.  
Prior to transfection, the chemically competent E. coli were thawed on ice and the 
selection plates (LB +Amp) were pre-warmed to 37°C on the bottom shelf of an incubator. 
The ligation mixture was added to the cells and left on ice for 30 min followed by 30 sec at 
42°C. The cells were spread onto the pre-warmed plates, air dried for 5 min and cultured 
over night at 37°C. 
6.4. SMALL INTERFERENCE RNA (SIRNA) 
RNA interference is based on the observation that the presence of double stranded RNA 
in a cell eliminates the expression of a gene having the same sequence, whereas 
expression of other unrelated genes are left undisturbed.  
Double stranded RNA (dsRNA) is recognized and bound within the cell by the Dicer-RDE-
1 (RNAi deficient-1) protein complex. This protein complex cleaves long dsRNA into 19-22 
bp siRNA oligonucleotides. The antisense strand of the siRNA is used by an RNA-induced 
silencing complex (RISC) to guide mRNA cleavage, therefore promoting mRNA 
degradation. Knockdown of the syntaxin 13 expression was achieved by transfection of 
cells with siRNA. The siRNA was designed and supplied by Ambion (Austin, TX). A 
sequence of 19 nucleotides starting at position 421 of syntaxin 13 (NM_177424) was 
targeted; the sense sequence was 5’-ggguaucugaaaaggaaaatt- 3’, and the antisense 
sequence was 5’- uuuuccuuuucagauaccctt-3’. Transfection was done using RNAiFect 
reagents (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. As 
control a nonsilencing siRNA was used (Qiagen). The knockdown of syntaxin 13 
expression reached its maximum 3 d after transfection.  
6.5. RNA ISOLATION      
The method of choice is the Trizol method. Cells are washed with PBS and 1 ml Trizol is 
added for 10 x 106 cells. The RNA is now protected from degradation and can be stored at 
-80°C for several months. Before processing, the solution was pressed through a syringe 
for homogenization. A volume of 200 µl chloroform was added to 1 ml Trizol, vigorously 
shaken and, after incubation at RT for 3 min, centrifuged at 12,000g for 15 min at 4°C. 
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The upper aqueous phase with the RNA was collected and placed in a new cup. 500 µl 
isopropanol were added and left on ice for 15 min. After precipitation, the cup is 
centrifuged at 12,000 g for 30 min at 4°C. The pellet was washed twice with ethanol (75%) 
and the pellet was air-dried and afterwards resuspended in 100 µl of RNAse-free water.  
Note: Phenol, which also absorbs light at 260 nm, can greatly affect the quality and 
quantitation of total RNA sample, it further inhibits or reduces the efficiency of a RT-PCR 
reaction.  
6.6. QUALITY ASSESSMENT AND QUANTIFICATION OF RNA (AGILENT) 
After the RNA has been resuspended in water, it is left at -80°C over night for complete 
solubilization. 1µl was diluted at a ratio of 1:10 and measured at 260 nm. The 
concentration is calculated according to the following formula:  
                    
        C µg/ml = E260 . k / d       k= 40 for RNA, k = 20 for ss DNA, k = 50 for ds DNA 
                                                d = Path length of cuvette [cm]  
The quality was assessed by using the Agilent 2100 bioanalyzer in combination with the 
6000 Nano LabChip® according to manufacturer’s instructions. 
6.7. RNA GEL ELECTROPHORESIS 
Total RNA is separated in a formaldehyde-containing agarose gel after the secondary 
structure of RNA has been denaturated at 56°C; the formaldehyde keeps the RNA from 
renaturating.  
For a 100 ml gel, 1,2 g agarose were boiled in 63 ml of Millipore water. After cooling to 
60°C, 20 ml 5 x Gel Running Buffer (see material) and 17,8 ml formaldehyde were added.  
The RNA-probes were prepared as follows:  
                10 µg total-RNA             4,5 µl 
5 x Gel Running Buffer   2,0 µl 
Formamid                      10,0 µl 
Formaldehyde (37 % v/v)  3,5 µl 
After denaturation of RNA (15 min, 56°C), 2 µl 10 x RNA sample buffer were added and 
the sample was applied to the gel. Electrophoresis was performed in 1 x gel running buffer 
at 13 V over night. The gel was washed in Millipore water for 60 min and stained for 10 
min in 250 ml Millipore water + 10 µl ethidium bromide, washed again in water and 
photographed with a fluorescent ruler.   
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6.8. REVERSE TRANSCRIPTION PCR (RT-PCR) 
AMV reverse transcription system from Promega was used to synthesize single-stranded 
cDNA from total RNA.  
For 4µg of total RNA the following reaction mixture has been prepared: MgCl2 16 µl, RT-
buffer 8 µl, dNTP mix 8 µl, RNAsin 2 µl, AMV reverse transcriptase 3 µl, oligo dT 4 µl, in a 
total volume of 40 µl. 
The RNA is placed in a cup and incubated at 70°C for 10 min, then the mix is added and 
the cup is incubated at 42°C for 60 min. After heat-inactivation at 95°C, the reaction is 
cooled on ice for 5 min. 
6.9. REAL-TIME PCR  
In conventional PCR, quantification either requires multiple samples or several aliquots 
must be taken from a single sample at certain intervals. The accuracy of this method is 
limited because the amplification product has to be detected by ethidium bromide staining, 
a procedure which lacks sensitivity and specificity and is time consuming. These 
drawbacks can be eliminated by using a novel method which uses online-detection of 
fluorescence as a marker for the ongoing PCR. Two different methods are used in Real-
Time-PCR, both of which can be practiced either on the LightCycler system (Roche) or on 
the Taqman (ABI). 
  
6.9.1. GENE EXPRESSION MONITORING WITH SYBR-GREEN-I DYE (LIGHTCYCLER) 
The fluorescent dye SYBR-Green I binds to the minor groove of the DNA double helix. In 
solution, the unbound dye exhibits very little fluorescence, this is greatly enhanced upon 
DNA-binding.  
At the beginning of amplification, the reaction mixture contains the denatured DNA, the 
primers, and the dye and only a weak fluorescence is detectable (Figure 17 A). 
After annealing of the primers and beginning of the elongation step, SYBR-Green 
molecules bind to the dsDNA, resulting in increased light emittion upon excitation (Figure 
17 B). During elongation, more and more dye molecules bind to the newly synthesized 
DNA (Figure 17 C). By continuous monitoring of the reaction, an increase in fluorescence 
is determined in real-time. Upon denaturation of the DNA for the next heating cycle, the 
dye molecules are released and the fluorescence signal falls.  Fluorescence 
measurement at the end of the elongation step of every PCR cycle is performed to 
monitor the increasing amount of amplified DNA.  
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The advantages of this method are the easy way of conducting it, in addition to its low 
cost. The disadvantages lye in the relatively low specificity, since SYBR-Green will bind to 
any double stranded DNA regardless if it is the targeted DNA or not. 
 
 
 
 
 
 
 
 
 
 
The LightCycler experiments were performed with the hot-start DNA Master SYBR-
Green I kit provided by Roche Molecular Biochemicals (Mannheim, Germany). Specific 
primer pairs were used for PCR amplification.  
Each reaction (20 µl) contained 2 µl cDNA, 2.5 mM MgCl2, 1 pmol of each primer and 2 µl 
of Fast-Start Mix (containing buffer, dNTPs, SYBR-Green dye and Taq polymerase). The 
amplification program consisted of 1 cycle of 95°C with a 5 min hold ('hot start') followed 
by 45 cycles of 95°C with a 15 second hold, 60°C annealing temperature with a 5 second 
hold and 72°C with a 10-second hold. Amplification was followed by melting curve 
analysis to verify the correctness of the amplicon. A negative control without cDNA was 
run with every PCR to assess the specificity of the reaction. Analysis of data was 
performed using LightCycler software version 3.5. PCR efficiency was determined by 
analyzing a series of 2-fold dilutions of cDNA. Using the analysis mode of the LightCycler 
software, the slope of log concentrations of the cDNA dilutions was calculated. Efficiency 
was calculated as follows: Eff. = 10-1/slope. For quantification, we only used primer pairs 
showing amplification efficiency between 1.92 and 2.04. The measured efficiencies were 
used for calculation. GAPDH was analyzed in parallel as a housekeeping gene.  
6.9.2. GENE EXPRESSION MONITORING WITH HYDROLYSIS PROBES (TAQMAN) 
The hybridization probe format is used for DNA detection and quantification and provides 
a maximal specificity for product identification. In addition to the reaction components 
used for conventional PCR, a specially designed, sequence specific oligonucleotide is 
applied in this detection method. This oligonucleotide is called Taqman probe, it is labelled 
with two fluorescent dyes: one is the emitting fluorescent dye (FAM, VIC) and the other is 
A B C
Figure 17: Steps of real-time PCR in the Light Cycler. A. SYBR-Green dye does not bind to 
the denaturated single strand DNA. B. after elongation process, the double strand DNA begins 
to bind SYBR-Green. C. Increasing fluorescence is measured at the end of the elongation step 
every cycle. Roche applied science online site [Roche homepage]. 
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either a fluorescent (TAMRA) or a non-fluorescent quencher. As long as the two dyes are 
in close proximity, the light emitted from the first dye, is quenched by the other, but as 
elongation occurs, the probe is hydrolyzed and the two dyes are separated from each 
other allowing a fluorescence emission. The increasing amount of measured fluorescence 
is proportional to the increasing amount of DNA generated during the ongoing PCR 
process (Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. AFFYMETRIX® MICROARRAYS 
10 µg of total RNA were reverse transcribed by the Invitrogen Life Technologies 
SuperScript Choice system using T7-oligo-dT primer (50 µM) and the SuperScript II RT 
(400 U) for 75 min. After that a second strand cDNA is synthesized by T4 DNA 
polymerase (10 U).  
cDNA was synthesized by a Superscript II kit (Life Technologies) using T7-oligo(dT) 
primer. The cDNA is cleaned by the Gene Chip Sample Cleanup Module supplied by 
Affymetrix. The antisense cRNA strand is amplified and biotin-labeled by Enzo BioArray 
HighYield RNA Transcript Labeling Kit based on the manufacturer’s protocol. The Biotin-
labeled cRNA was purified, fragmented and quantified by measuring the 
A 
B
C D
Figure 18: Steps of real-time PCR in the Taqman. A. fluorescent reporter (R) dye and a 
quencher (Q) are attached to the 5' and 3' ends of a TaqMan probe. B. When the probe is intact, 
the reporter dye emission is quenched. C. During each extension cycle, the DNA polymerase 
cleaves the reporter dye from the probe. D. Once separated from the quencher, the reporter dye 
emits its characteristic fluorescence [Applied Bioscience homepage]. 
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spectrophotometric absorbance at 260 nm; the purity was determined by the use of the 
2100 Bioanalyzer (Agilent technologies). 
After addition of control oligonucleotide B2 (3 nM) and 20x Eukaryotic Hybridization 
Controls (bioB, bioC, bioD, cre) the cRNA was hybridized to Affymetrix H-U133A 
GeneChips (Santa Clara, CA) for 16 h at 45°C. The chips were stained with Streptavidin 
Phycoerythrin (SAPE), and washed in the Fluidics Station 450 with protocol EukGE-WS2 
which includes an antibody amplification step. The arrays were scanned on the Affymetrix 
array scanner and the gene expression data analysis was performed according to 
instructions and recommendations provided by Affymetrix using the Affymetrix statistical 
data analysis software, Affymetrix Microarray Suite (MAS, version 5.0), which controls the 
fluidics stations and scanners. In addition, MAS acquires data, manages sample and 
experimental information. 
For each gene, the gene expression of the treated cells and the control was compared. 
The comparison was based on a statistical analysis of probe sets consisting of 16 oligos 
recognizing different portions of the target gene. Based on the expression algorithm, MAS 
computes the detection call which defines whether a signal is absent, marginal or present. 
This call is emphasized by a detection p-value and by a normalized signal which is 
background-subtracted and adjusted for noise. In addition, MAS is capable of doing 
comparison analysis, calculating the difference call. Each transcript has five possible calls, 
Increase, Decrease, Marginal Increase, Marginal Decrease, No Change. The probe sets 
were excluded if the detection call for both target and reference was absent; or if the 
change call gave no change (NC) in comparison analysis or if the signal log ratio (SLR) 
between target and reference was between -1 and 1.  
The SLR monitors the expression level of a transcript between a baseline and an 
experiment array. This value is logarithmic and a log2 ratio of 1 equals a fold change of 2. 
Using the SLR a fold change can be calculated using the following formula: 
 
FC= 2 (SLR)        if SLR >=0 
FC= -1*2(-SLR)   if SLR<0 
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8. YEAST-TWO-HYBRID SYSTEM 
This part of work was done as described in 27,154, therefore, it will not be explained here in 
detail. Shortly, the last 144 C-terminal amino acids of ABCA1 were cloned into pAS2.1  
 
9. MASS SPECTROMETRY 
This part of work was done as cooperation with Dr. G. Liebisch as described in 118 
therefore, it will not be explained here in detail. Shortly, sera from 4 pallidin knock-out 
mice and 4 wild-type mice were collected and pooled in each category.  The sera were 
separated by fast protein liquid chromatography (FPLC) and subsequently lipoproteins 
were analyzed by electrospray ionization - tandem-mass spectrometry (ESI-MS/MS). 
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V. RESULTS 
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1. IDENTIFICATION OF ABCA1 INTERACTIVE PROTEINS BY YEAST-TWO-HYBRID 
SYSTEM 
Since ABCA1 plays a central role in the reverse cholesterol transport, we aimed to identify 
proteins which interact with ABCA1. These proteins may contribute to the stability and 
processing of ABCA1. The yeast-two-hybrid system was used to screen a human liver 
library. Since the C-terminal region of several ABC-transporters like CFTR are involved in 
protein-protein interactions, the C-terminal region of ABCA1 was used as bait. 
Therefore, we constructed a fusion construct of the Gal4 DNA-binding domain with the C-
terminus of human ABCA1 (bp 6292–6723) which resembles the 144 carboxy-terminal 
amino acids. The alignment of the ABCA1 C-terminus with ABCR shows the high 
conservation of several amino acids and a number of mutations and polymorphisms found 
in this region, further supporting the functional importance of these amino acids 
(Figure 19). 
This was used as bait with which we screened a human liver yeast-two-hybrid cDNA 
library, to identify proteins which may interact with ABCA1.  
 
 
 
 
Identified gene Unigene Number of 
clones 
Fas-associated death domain (FADD) Hs.86131 3 
β2-syntrophin (SNTB2) Hs.461117 3 
RET finger protein (RFP) Hs.440382 4 
PRP8 splicing factor Hs.181368 4 
Figure 19:  Model of ABCA1 protein and Yeast-Two-Hybrid approach. The coloured 
cylinders resemble the transmembrane domains, the two circles the walker motifs. The last 
144 amino acids were used as bait for a Yeast-Two-Hybrid approach to identify ABCA1 
interacting proteins in human liver library. 
Table 5: Proteins identified to interact with ABCA1. The name, the human unigene number 
(Hs.) and the number of clones identified are given. 
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2. CHARACTERIZATION OF THE ABCA1-FADD COMPLEX 
One of the positive clones identified to interact with the ABCA1 C terminus encoded the 
98 C-terminal amino acids of FADD (amino acid positions 111–208) as a Gal4 activation 
domain fusion protein. The identified ABCA1-interacting FADD fragment contains almost 
the complete death domain of FADD (amino acids 97–161).  
To further confirm the association of ABCA1 and FADD, pull-down assays were 
performed.  
His-tagged full-length human FADD bound to nickel-chelating resin (GenoTech 
Biosciences, Lohmar, Germany) was incubated with in-vitro translated ABCA1 C-terminus 
with an N-terminal Myc-tag. The ABCA1 C-terminus was pulled down by FADD-agarose 
and detected on the immunoblot using a Myc antibody, whereas FADD-agarose (Upstate 
Biotechnologies, NY, USA), with Myc-tagged aldehyde oxidase as control gave no signal 
on western blots (Figure 20 A).  
 
 
To verify the validity of ABCA1-FADD interaction in human cell lines, we repeated the pull-
down of ABCA1 with FADD-agarose from cell lysates of the human hepatoma cell line 
    
UDP-glucose pyrophosphorylase (UGP2) Hs.516217 4 
Succinate dehydrogenase (SDHB) 
(Iron-sulphur protein subunit) Hs.465924 2 
Aldehyde oxidase 1 (AOX1) Hs.406238 14 
Unknown  5 
Figure 20: Interaction of ABCA1 with FADD. (A) In-vitro translated ABCA1 C-terminus 
with an N-terminal Myc tag (left) and Myc-tagged aldehyde oxidase (right) as control was 
precipitated by FADD-agarose. The precipitates were analyzed on immunoblots using a Myc 
antibody. (B) FADD-agarose (-imidazole) and agarose where FADD has been eluted with 
100 mM imidazole (+imidazole) were incubated with cell lysates of the human hepatoma cell 
line HepG2, precipitates were analyzed on immunoblots using ABCA1 antibody. 
A 
B
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HepG2. As a control for this experiment we eluted FADD from the agarose by washing it 
with 100mM imidazole prior to loading it to the cell lysate and, as presumed, ABCA1 was 
not detected in the precipitate (Figure 20 B). 
To elucidate whether the amount of precipitated ABCA1 correlates with the amount of 
FADD used, the procedure was repeated in the megakaryoblastic leukaemia cell line 
Meg01 which reveals a high expression of ABCA1, but this time with increasing quantities 
of cell lysate (10, 20, and 30 µg). As result, increasing amounts of ABCA1 were pulled 
down by FADD agarose (Figure 21). 
 
 
 
 
 
 
 
 
 
 
 
All these experiments strongly supported our initial finding that ABCA1 interacts with 
FADD. Furthermore, caspase 8, a protein described to interact with FADD, was also 
detected in the FADD-agarose precipitates by immunoblotting in both Meg-01 and HepG2 
cells (Figure 22A).  Although caspase 8 is not associated with FADD in non-apoptotic 
cells, caspase 8 was precipitated by FADD-agarose. With this approach potentially 
Figure 21: Interaction of ABCA1 with FADD in Meg-01 cell line. FADD-agarose was incubated 
with 10, 20, and 30 µg of cell lysate prepared from the megakaryoblastic leukaemia cell line Meg-
01. The precipitates were analyzed on immunoblots with ABCA1 and caspase 8 antibodies. 
Figure 22: Co-immunoprecipitation of FADD with ABCA1 in cell lines. A. Immunoblot of ABCA1 
and caspase 8 precipitated from Meg-01 and HepG2 cell lysates using FADD-agarose. B. ABCA1 
antibody was covalently linked to magnetic beads and incubated with lysates from Meg-01 and 
HepG2. The precipitates were analyzed for ABCA1, FADD, and caspase 8 using the respective 
antibodies. 
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interacting proteins can be identified, but this alone does not prove that FADD and ABCA1 
are really associated in these cell lysates. Therefore, to investigate the presumptive 
endogenous association of ABCA1 with FADD, ABCA1 antiserum was covalently linked to 
magnetic beads. Upon incubation of the beads with cell lysates, the ABCA1 antibody was 
able to precipitate ABCA1 and endogenous FADD from lysates of the hepatoma cell line 
HepG2 and Meg-01 cells, caspase 8 was not co-immunoprecipitated (Figure 22 B).  
To verify this interaction in primary cells, human fibroblasts from two different healthy 
donors (F1 and F2) were lysed and ABCA1 and FADD but not caspase 8 were also 
precipitated from this lysates using ABCA1 antiserum (Figure 23). 
 
A control antiserum failed to immunoprecipitate ABCA1 and FADD from the lysate of F2 
(Figure 23). The supernatant of the lysate F2 after incubation with ABCA1 antibody was 5-
fold concentrated, and the immunoblot indicates that about 50% of ABCA1 and FADD and 
nearly 100% of caspase 8 remain in the supernatant. 
This indicates that caspase 8 does not interact with FADD associated with ABCA1 or that 
the amount of caspase 8 associated with ABCA1 and FADD is beyond the sensitivity of 
the western blot. 
Since ABCA1 in known to facilitate the transfer of phospholipids to apoA-I, whereas FADD 
is mainly described as an adaptor molecule in death receptor-induced apoptosis, the 
association of ABCA1 with FADD may imply a response of fibroblasts to lipid loading.  
Figure 23: Co-immunoprecipitation of FADD with ABCA1 in human 
fibroblasts. Lysates of fibroblasts were used for immunoprecipitation using ABCA1 
antibody (F1, IP-ABCA1; F2, IP-ABCA1). Immunoblots with the precipitates or the 
lysate were performed and probed with ABCA1, FADD, and caspase 8 antibodies. 
F1: Fibroblast 1; F2: Fibroblast 2; IP: Immunoprecipitation; IP-control: unrelated 
antibody. 
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Therefore we investigated the protein expression of FADD in fibroblast from controls 
incubated with E-LDL for 24 h, in serum-starved cells for 3 days and in cells incubated 
with HDL3 for 24 h to promote lipid efflux (Figure 24). 
FADD expression was not altered under these culture conditions indicating that FADD 
expression is not sensitive to lipid loading or deloading.  
 
 
To analyze whether inhibition of FADD may modulate ABCA1 function; a dominant 
negative form (FADD-DN) 87 was cloned into pcDNA3.1/NT-GFP and expressed with a N-
terminal GFP fusion in HepG2 cells. In addition, a GFP fusion with the 144-amino acid C 
terminus of ABCA1 was generated to analyze a possible inhibitory function of the ABCA1 
C terminus. Stable clones were selected, and expression of GFP was monitored by 
fluorescence microscopy and flow cytometry. Nearly 95% of the transfected HepG2 cells 
were GFP-positive with both methods.  
Immunoblot analysis with GFP antiserum revealed that the ABCA1 C-terminal construct 
was weakly expressed, whereas FADD-DN was expressed at a much higher level. In the 
transfected cells expression of ABCA1, FADD, and caspase 8 was investigated by 
immunoblots. Recombinant FADD-DN was much more abundant than native FADD, 
which was similarly expressed in the transfected cells (Figure 25 A).  
 
Figure 24: FADD is not sensitive to lipid-loading. FADD and actin immunoblot using 
whole cell lysates from human fibroblasts cultivated with 10% FCS for 4 d (10% FCS), and 
additionally 24 h in 10% FCS with 100 µg/ml HDL3 (10% FCS, HDL), or the same 
conditions with 0,25% FCS 
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The transfected cells were further analyzed for choline phospholipid efflux to apoA-I. Cells 
were labeled with [3H]-choline for 34 h and subsequently incubated in the presence of 
bovine serum albumin or bovine serum albumin plus apoA-I as an acceptor.  
After incubation, the media were removed and centrifuged at 800g to precipitate any 
detached cells. Cells were rinsed 3 times with PBS and lysed with 0,2% SDS. Lipids were 
extracted from supernatant media and cell lysates according to the method of Bligh and 
Dyer 3H-radioactivity was measured by liquid scintillation counting in total lipid extracts 
from cell lysates and in the incubation media. Lipid efflux in response to HDL3 is 
expressed as the percentage of “total radioactivity” that appeared in the medium after the 
chase period.  
The efflux of the GFP-transfected cells was set to 100%. Specific efflux in FADD-DN 
expressing cells was 46,2 ± 9.5% and 26,2 ± 7.4% in cells with recombinant ABCA1 C 
terminus. Four assays with triplicate determinations were performed. Specific efflux was 
calculated by subtraction of efflux without acceptor from apoA-I-mediated efflux. 
Reduction of efflux is significant for FADD-DN and ABCA-1 C terminus with p<0.001 
(Student’s t test). As result, expression of the ABCA1 C-terminus inhibited apoA-I-
inducible phospholipid efflux 4-fold and the expression of FADD-DN reduced efflux by 
50% thereby confirming that full length FADD has relevance for ABCA1 function (Figure 
25 B).   
FADD-DN protected HepG2 cells from TNF-α/CHX-induced apoptosis, whereas HepG2 
cells expressing GFP or the ABCA1 C-terminus revealed a similar response as detected 
by the release of histone-bound DNA fragments and trypan blue staining of dead cells.  
Figure 25: Expression of FADD-DN and ABCA1 in HepG2 cells and its effect on lipid 
efflux. A. HepG2 cells were stably transfected expressing ABCA1 C-terminus with an N-terminal 
GFP tag (lane 1), FADD-DN fused to GFP  (lane 2), or GFP alone as control (lane 3). B. specific 
choline phospholipid efflux from stably transfected HepG2 cells expressing GFP as control, 
FADD-DN fused to GFP, or ABCA1 C terminus with an N-terminal GFP tag. The efflux of the 
GFP-transfected cells was set to 100%.  
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3. CHARACTERIZATION OF THE ABCA1 - β2-SYNTROPHIN COMPLEX 
β2-syntrophin is a protein previously shown to interact with utrophin 151, it has a PSD95 
Disc large Zo1-domain and two functional pleckstrin-homology (PH) domains, which are 
often found in cytoskeletal or signalling proteins where they mediate protein-protein or 
protein-lipid interactions 175.  
Initially we searched for a cell line highly expressing ABCA1 by immunobloting cell lysates 
from fibroblasts, platelets and Meg-01 cell line (Figure 26) 
  
 
 
 
 
 
 
 
 
 
 
To verify the interaction of β2-syntrophin with ABCA1, we performed Co-
immunoprecipitation. ABCA1 antibodies were covalently linked to magnetic protein-A 
beads and incubated with Meg-01 cell lysates. The eluted protein was analyzed on 
immunoblots. β2-syntrophin was detected in ABCA1 immunoprecipitates whereas 
magnetic protein A beads coupled with a control antiserum did not bind the β2-syntrophin 
(Figure 27 A).  
Furthermore, the β2-syntrophin antiserum covalently linked to magnetic protein A beads 
precipitated ABCA1in Meg-01 lysates (Figure 27 A). 
These results confirmed the finding of the yeast two-hybrid screening and demonstrate 
that ABCA1 and β2-syntrophin are associated with each other in megakaryocytes. We 
further demonstrated that the ABCA1 antibody also precipitates β2-syntrophin in 4 d 
differentiated macrophages and in macrophages loaded with E-LDL for 24 h (Figure 27 
B). 
 
 
 
Figure 26: ABCA1 blot in various cell lysates. Immunoblot with 30µg cell lysates from 
human primary fibroblasts (donor 1 and 2), 5µg lysate from human platelets (3 donors), and 
5µg from the Meg-01 cell line using ABCA1antibody. 
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Another protein detected in the ABCA1 precipitate was utrophin and the amount of 
ABCA1 associated with β2-syntrophin and utrophin is similar in control and foam cells, 
indicating that cholesterol-induced ABCA1 expression is not associated with an altered 
formation of ABCA1/β2-syntrophin/utrophin complexes (Figure 28). 
 
 
Figure 27: ABCA1 interacts with β2-syntrophin. A. ABCA1 (IP, ABCA1) and a control (IP, 
control) antiserum covalently linked to beads were incubated with cell lysate from Meg-01cells 
and β2-syntrophin was detected in the precipitate by immunoblotting. β2-syntrophin antiserum 
(IP, β2-syntrophin) precipitates ABCA1 from Meg-01 cell lysates. ABCA1 was not detected in 
the control incubation (IP, control).  
B. β2-syntrophin is detected in ABCA1 precipitates from macrophages differentiated 4 d with 
M-CSF and subsequently incubated with E-LDL. 
 
A 
B 
Figure 28: ABCA1/β2-syntrophin complex interacts with utrophin. A. ABCA1 antiserum 
precipitates similar amounts of β2-syntrophin and utrophin in 4 d differentiated macrophages 
(M-CSF) and foam cells (E-LDL). B. Similar amounts of β2-syntrophin are precipitated with β2-
syntrophin antibody (IP, β2-syntrophin) in control (M-CSF) and E-LDL incubated 
macrophages. 
A B 
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The ABCA1/β2-syntrophin/utrophin complex is bound to the cytoskeleton by the 
interaction of utrophin to actin, a mechanism which could link ABCA1 and β2-syntrophin to 
the intracellular shuttling of ABCA1 (Figure 29) 
 
To further elucidate the distribution of ABCA1/β2-syntrophin complex throughout the cell, 
we isolated Lubrol rafts from whole cell lysates and blotted for both ABCA1 and β2-
syntrophin. E-LDL-loaded macrophages were solubilized in 1% Lubrol and fractionated by 
sucrose gradient centrifugation. Immunoblots using ABCA1 antiserum revealed a faint 
signal in the microdomain fractions; however, ABCA1 is found mainly in the soluble 
fraction (Figure 30, lanes 7, 8) not associated with rafts. Furthermore, β2-syntrophin is not 
associated with microdomains whereas utrophin is detectable in all Lubrol density 
fractions with the majority in the soluble fraction (Figure 30, lanes 7, 8), followed by a 
Figure 29: Interaction of ABCA1 C-terminus with β2-syntrophin and utrophin. The figure shows
the domains expressed on each protein. The last four amino acids in the ABCA1 sequence are a 
PDZ-binding domain, they interact with the PDZ-domain in β2-syntrophin. In addition, β2-syntrophin 
reveals a pleckstrin homology (PH) domain and a syntrophin unique domain (SUD) wich are 
capable of interacting with the two conserved tryptophans (WW) found in utrophin. Utrophin, in turn, 
interacts with actin and thus to the cytoskeleton. 
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similar abundance in the high density fractions (Figure 30, lanes 5, 6) and the 
microdomains represented by the low density fractions (Figure 30,  lanes 2–4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. PROTEIN-PROTEIN INTERACTIONS OF SYNTAXIN 13, ABCA1 AND FLOTILLIN-1 
PDZ proteins also bind to the C-terminus of the ABC-transporter CFTR. The N-terminal 
region of CFTR is associated with syntaxin 1a. We investigated whether ABCA1 also 
binds to members of the syntaxin family, which play a vital role in vesicular transport and 
membrane budding and fusion events. 
In order to identify ABCA1 interactive syntaxins we first examined the mRNA expression 
and protein levels of syntaxins in monocytes, macrophages, E-LDL loaded and 
subsequently HDL3-deloaded foam cells. Fifteen members of the syntaxin family are 
present in the human genome with different subcellular locations of the corresponding 
proteins 188. We focused on syntaxins with relevance for endocytosis, phagocytosis and 
secretion namely the syntaxins 2, 3 and 4 located at the plasma membrane, syntaxin 8 
and 13 associated with the early endosome, syntaxin 7 that plays a role in the biogenesis 
of lysosomes and syntaxin 6 that is involved in the release of vesicles from the Trans 
Golgi Network (TGN). Syntaxin 1 is not expressed in macrophages 73 and therefore was 
not analyzed.  
ABCA1 is induced during monocytic differentiation and further upregulated by sterol 
loading of these cells. Therefore, we investigated the expression of syntaxins in 
monocytes, in in-vitro differentiated macrophages, in macrophages incubated with 
Figure 30: Microdomain localization of ABCA1 and associated proteins. Immunoblots were 
performed with ABCA1, β2-syntrophin, and utrophin antiserum. LDF  indicates microdomains, 
whereas the high  density fraction (HDF) is not associated with rafts. Fraction 8 represents the 
soluble membrane proteins and P is the insoluble pellet. 
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enzymatically modified LDL (E-LDL) for 24 h and in E-LDL loaded cells subsequently 
treated with HDL3 for 24 h to allow cholesterol efflux. Syntaxin 4, 6 and 7 are down 
regulated during phagocytic differentiation whereas the expression of syntaxin 2, 3, 4, 8 
and 13 was unchanged. Incubation with E-LDL induced syntaxin 3, 6 and 13 and the 
subsequent addition of HDL3 reversed this upregulation for syntaxin 3 and 13. Syntaxin 2 
and 8 were found reduced in E-LDL loaded macrophages and HDL3 treatment again 
upregulated syntaxin 2 expression whereas syntaxin 8 levels were not altered (Figure 31). 
Figure 31: Analysis of syntaxin 
expression in primary human 
monocytes and macrophages.  
The expression of syntaxin 2, 3, 4, 6, 
7, 8, and 13 was investigated in 
monocytes, M-CSF differentiated 
macrophages, macrophages 
incubated for 24 h with 40 µg/ml 
ELDL, and E-LDL–loaded cells 
subsequently treated with 100 µg/ml 
HDL3 for additional 24 h using 
immunoblots. A. Syntaxin 3, 6, and 
13 were induced by E-LDL. B. 
Syntaxin 2 and 8 were down-
regulated by E-LDL. C. Syntaxin 4 
and 7 are not regulated by E-LDL. β-
actin was used as a loading control. 
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To determine whether these changes in protein expression are transcriptionally or post-
transcriptionally regulated we established TaqMan® assays for syntaxin 2, 3, 4, 6, 8 and 
13. The mRNA expression was determined in monocytes, macrophages, foam cells and 
E-LDL loaded cells treated with HDL3. The mRNA abundance of the syntaxins 
investigated was unchanged under the conditions described above (Figure 32) and 
therefore the differential expression of syntaxins is most likely related to altered protein 
stability and regulatory mechanism at the post-transcriptional level.  
 
 
The similar upregulation of ABCA1, syntaxin 3, 6 and 13 by sterols and the 
downregulation by HDL3 for ABCA1, syntaxins 3 and 13 may indicate a functional 
association of these syntaxin and ABCA1. 
Therefore, we further performed immunoprecipitation experiments using cell lysates from 
differentiated and E-LDL treated macrophages and were able to precipitate syntaxin 13 
with ABCA1 antibodies (Figure 33 A). to confirm for this result, we co-immunoprecipitated 
ABCA1 from the lysates using syntaxin 13 antibodies (Figure 33 B). Although syntaxin 3 
and 6 and ABCA1 were co-ordinately regulated, we could not identify an interaction in 
macrophages or foam cells (not shown). In E-LDL loaded cells, an increased amount of 
ABCA1 interactive syntaxin 13 was detected when compared to macrophages. This could 
be explained by the enhanced expression of ABCA1 and syntaxin 13 in E-LDL treated 
macrophages.  
Figure 32: mRNA expression of syntaxins. mRNA was analysed by TaqMan®, normalized 
to 18s RNA and related to macrophages as calibrator. Fold-changes below 2,5-fold were 
considered as non significant. 
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To confirm this interaction in living cells, immunofluorescence microscopy was performed 
with HL-60 cell line and monocyte-derived macrophages. The cells were differentiated and 
fixed with a mixture of paraformaldehyde and glutarylaldehyde in order to gain a better 
staining for the intracellular localized proteins. Prior to staining the cells with the primary 
antibodies, the cells were permeabilized with PBS containing Triton X-100 and SDS. The 
antibodies were diluted 1:100 for syntaxin 13 antibody and 1:300 for ABCA1 antibody and 
applied to the cells for 1 h. After washing the cells with PBS, the secondary antibody was 
added and incubated for 1 h. Texas Red-labeled anti-rabbit for ABCA1 and FITC-labeled 
anti-mouse for syntaxin 13. the slides were further processed for immunofluorescent 
microscopy and DAPI was used to stain the nuclei (Figure 34). 
Figure 34: Syntaxin 13 colocalizes with ABCA1. Human monocytes (A, B, C) and differentiated HL-
60 cells (D, E, F) were fixed and incubated with ABCA1 (A and D) or syntaxin 13 (B and E) antibodies. 
The merged images are shown in C and F. Yellow area resembles the overlap. Bars represent 10 µm. 
Figure 33: Interaction of ABCA1 with syntaxin 13 demonstrated by immunoprecipitation.
A. Immunoblot of syntaxin 13 precipitated with control (lanes 1 and 2) and ABCA1 antibody 
(lane 3 and 4) from cell lysates prepared from 4 d differentiated macrophages and E-LDL–
loaded cells. B. Immunoblot of ABCA1 precipitated with syntaxin 13 antibody from cell lysates 
prepared from 4 d differentiated macrophages and E-LDL–loaded cells.  
A 
B 
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To gain insight into the functionality of this interaction, we aimed to knock-out syntaxin 13 
and measure choline-phospholipid efflux to apoA-I and HDL3.  
In order to have a suitable model for transfection experiments, the myelomonocytic HL-60 
cell line which can be induced to differentiate to macrophages by PMA 38, was employed. 
The cells were transfected with siRNA targeting syntaxin 13 (NM_177424).  
Successful knock-out of syntaxin 13 was confirmed by western blotting. Cells treated with 
syntaxin 13 siRNA also revealed a reduced ABCA1 protein level, indicating a disturbed 
ABCA1 function (Figure 35 A).  
 
Figure 35: Knock-down of syntaxin 13 and [3H]choline-phospholipid efflux in HL-60 
cells.  
A. Lysates of PMA-differentiated HL-60 cells, differentiated HL-60 cells transfected with 
syntaxin 13 siRNA and HL-60 cells transfected with a non-silencing control siRNA were 
blotted and membranes were incubated with syntaxin 13, ABCA1 and actin antibody. 
B. The cells were loaded with  [3H]choline-phospholipid efflux and deloaded with apoA-I or 
HDL3. The lipid efflux relative to the unspecific efflux from three independent experiments is 
given in percent. The significance of the decrease in efflux between syntaxin 13-silenced 
cells and control cells was calculated using t test; *p< 0.05.  
A 
B 
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Choline-phospholipid efflux was determined in PMA differentiated HL-60 cells, in cells 
transfected with a control siRNA and cells where the expression of syntaxin 13 was 
silenced by a syntaxin 13 specific siRNA.  
The knockdown of syntaxin 13 RNA and protein in HL-60 cells led to a significant 
decrease in choline-phospholipid efflux to apoA-I and HDL3; whereas lipid efflux was not 
affected in the control transfected cells (Figure 35 B). 
Syntaxin 13 has been reported to mediate endosomal cycling of plasma membrane 
proteins and is required for the interaction of endosomes with the phagosome 42. ABCA1 
has been found on endosomes 138 but its association with phagosomes has never been 
investigated.  
Therefore, macrophages were fed with 0,8 µm blue-dyed latex phagobeads for 1 h, 
washed and the internalization of the phagobeads into phagosomes was allowed for 2, 4, 
6, 12 and 20 h. Immunoblots using purified phagosomal proteins were performed. Both 
ABCA1 and syntaxin 13 were similarly detectable in the 2 h and 4 h fraction, reaching 
their peak after 6 h and decreasing afterward (Figure 36).  
The phagosomal markers flotillin-1 and Rab-9 as well as the lysosomal marker LAMP1 
were also detected in order to gain insight into the maturation of phagosomes throughout 
time and the increasing merge of phagosomes with lysosomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Phagosomal localization of ABCA1 interactive proteins. Phagosomes were 
purified from 4 d differentiated macrophages incubated with latex beads for 2, 4, 6,12, and 20 h. 
Purified phagosomal proteins were used for immunoblotting. The expression of ABCA1, syntaxin 
13, flotillin-1, Rab 9, and LAMP1 was analyzed.  
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To investigate whether ABCA1 and syntaxin 13 interact in phagosomes, we performed 
additional co-immunoprecipitation assays with stringent RIPA buffer (Figure 37) and found 
that syntaxin 13 antibodies co-immunoprecipitated ABCA1 and, for confirmation, ABCA1 
antibodies co-immunoprecipitated syntaxin 13 from phagosomal lysates. For negative 
control a rabbit antibody was used. 
 
To further support the hypothesis that ABCA1 may regulate phagocytosis, the phagocytic 
activity of fibroblasts from control donors and fibroblasts isolated from the Tangier patients 
TD1 (yielding a mutation at K171X), TD3 II:4 and TD5 III:4 21 was measured by flow 
cytometry using fluorescent yellow green-labeled phagobeads. Fibroblasts from Tangier 
patients with ABCA1 mutations had a significantly higher internalization rate compared 
Figure 38: The phagocytic activity of fibroblasts was determined in human fibroblasts with 
functional, recombinant ABCA1 or lacZ as control after 4 h incubation with fluoresbrite yellow green 
microspheres by flow cytometry. Both, the increased phagocytosis of Tangier compared with 
normal fibroblasts as well as the reduced phagocytic activity of ABCA1-transfected cells when 
compared with lacZ-transfected  fibroblasts were statistically significant (p< 0.05). TD1, 3, and 5: 
fibroblasts from TD patients. Ctrl1, 2, and 3: fibroblasts from healthy individuals. 
Figure 37: ABCA1 interacts with syntaxin 13 in phagosomes. A. Immunoblot of 
ABCA1 precipitated with syntaxin13 antibody from phagosomal protein fraction (6 h). B. 
Syntaxin 13 precipitated with ABCA1. Control rabbit antibody was used as negative 
control. 
BA 
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with controls, further supporting a function of ABCA1 in the phagocytic uptake of particles 
(Figure 38). Recombinant expression of wild-type ABCA1 in Tangier fibroblasts led to a 
decreased phagocytosis rate as was seen in control fibroblasts. These findings indicate 
that ABCA1 is located at the plasma membrane and in the phagosome. Both 
compartments are involved in phagocytosis and may also be important in ABCA1-
dependent lipid efflux.  
Flotillin-1 49 and ABCA1 54 are raft-associated proteins. A wide variety of detergents have 
been used to isolate rafts and significant differences exist among the preparations. 
Flotillin-1 is enriched in Triton X-114–insoluble microdomains, and 5–10% of ABCA1 are 
located in Lubrol WX rafts, whereas it is absent from Triton X-100 rafts. Using whole cell 
lysates, we examined whether flotillin-1 and syntaxin 13 colocalize in Lubrol WX–insoluble 
microdomains in E-LDL–loaded macrophages solubilized in 1% Lubrol WX and 
fractionated by sucrose gradient centrifugation. Immunoblots using ABCA1 antibodies 
confirmed our previous data reported by Drobnik et al. 54 (Figure 39 A). 
Figure 39: Microdomain localization of ABCA1-associated proteins  and ABCA1 interaction 
with flotillin-1. A. E-LDL–loaded macrophages were solubilized in 1% Lubrol WX or Triton X-100 and 
fractionated by sucrose gradient centrifugation. Immunoblots were performed with  ABCA1, syntaxin 
13, syntaxin 4, syntaxin 7, and flotillin-1. The fractions 2–5 indicate rafts, whereas lanes 6–8 are not 
associated with rafts. Fraction 8 represents soluble membrane proteins and P is the insoluble pellet. 
B. Immunoblot of flotillin-1 precipitated with control and ABCA1 antibody from cell lysates prepared 
from 4 d differentiated macrophages. 
 
A 
B 
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Syntaxin 13 was highly abundant in Lubrol WX rafts but not detectable in Triton X-100 
rafts and flotillin-1 co-purifies with Triton X-100 and Lubrol WX rafts. Syntaxin 4, localized 
at the plasma membrane, was also identified in Lubrol WX microdomains, whereas 
syntaxin 7, a marker of late endosomes, was not detected. The abundance of ABCA1 and 
flotillin-1 at the plasma membrane and phagosomes together with their colocalization in 
Lubrol WX rafts may indicate a direct interaction of ABCA1 and flotillin-1. Subsequent 
immuno-precipitation confirmed that flotillin-1 is directly associated with ABCA1 (Figure 39 
B). 
5. LIPOPROTEIN ANALYSIS OF THE PALLIDIN KO MICE  
Since syntaxin 13 interacts in vivo with syntaxin 13-interacting protein (pallidin), sera from 
pallidin knock-out mice were analyzed for their lipoprotein profile in order to study the 
potential influence of syntaxin 13 on HDL metabolism. 
Sera from 4 pallidin knock-out mice and 4 wild-type mice were collected and pooled in 
each category.  The sera were separated by fast protein liquid chromatography (FPLC) 
and subsequently lipoproteins were analyzed by electrospray ionization - tandem-mass 
spectrometry (ESI-MS/MS). The results show that the syntaxin 13-interacting protein 
deficient pallidin mouse has less free cholesterol and sphingomyelin in the HDL fraction. 
HDL phosphatidylcholine is also slightly impaired while lysophosphatidylcholine is 
increased in the pallid mouse when compared to wild type, an observation possibly 
related to an enhanced esterification rate mediated by LCAT which catalyzes the 
formation of cholesterol esters on HDL particles. This is further supported by the 
increased CE/FC-ratio in the HDL fraction. VLDL-triglycerides were also found decreased 
which may indicate that syntaxin 13-interacting protein is also operative in the VLDL 
secretory pathway and thus a reduced SPM leads to increased LCAT activity in the pallid 
mouse (Figure 40). 
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Figure 40: Lipoprotein analysis of pallidin ko mice (yellow) in comparison 
to wild type mice (Blue) the pallidin mouse has increased lysophosphatydil 
choline and reduced triglycerides, free cholesterol and sphingomyelin. 
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6. IDENTIFICATION OF MACROPHAGE-SPECIFIC GENES INVOLVED IN LIPID 
TRAFFICKING USING GENE-CHIPS 
The second aim of this thesis was to identify cholesterol and phospholipid traffic genes 
differentially expressed during loading of macrophages with different atherogenic lipids, 
namely: E-LDL and Ox-LDL. For this approach, oligonucleotide gene arrays were used. 
Monocytes were incubated in-vitro and RNA samples were taken as is shown in figure 39. 
 
Total RNA from monocytes of 6 healthy donors bearing the Apo E3/E3 phenotype were 
pooled, reverse transcribed, fluorescently labeled with streptavidin-phycoerytrin and 
hybridized to Affymetrix Gene chips U133A, the results were analyzed with the Affymetrix 
Microarray Suite 5.0™. Genes with significant up- and down-regulation by loading, 
deloading or differentiation were sorted accordingly. This led to fourteen gene lists which 
rendered a percentage distribution for the E3/E3 phenotype as shown in table 6. 
Figure 41: Incubation protocol. Differentiation, loading and deloading of 
monocytes/macrophages to isolate RNA and protein for subsequent experiments. 
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To verify whether our obtained array data are reliable, we compared our results with 
results from literature on well characterized genes like ABCA1, LDL-R, CD36 and 
adipophilin. The expression patterns were concordant. 
 
The expression profile obtained for ABCA1, adipophilin and CD36 with DNA chip 
experiments went along well with the pattern expected, since it has been published 
previously that all of these genes are being upregulated by lipid loading with either E-LDL 
or Ox-LDL 76,115,197. The LDL-R was significantly downregulated by lipid loading and 
upregulated by deload also a result previously published by Hussein et. al. 91 (Table 7). 
This comparison shows that the incubation of the cells with lipoproteins, the modification 
of lipoproteins, the isolated RNA, the hybridization of arrays and the analysis of the data 
resulted in reliable results reflecting the processes occurring in-vivo. 
To evaluate mRNA expression profiles in macrophages loaded with two different modified 
lipoproteins, on the basis of biologically coherent functional and/or structural units, we 
established defined categories that rely on systematic literature surveys, data base 
Table 7: The regulation of four described genes in ApoE3/E3 phenotype, which correlated 
well with the expected regulation published. 
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Hs.147259 ATP-binding cassette, sub-family A (ABC1), member 1 ABCA1 130 ++ 9,2 I 2,0 I -1,4 D 2,0 I -1,2 D
Hs.3416 Adipose differentiation-related protein ADFP 1966 ++ 1,5 I 2,3 I 1,0 D 3,5 I -1,1 D
Hs.443120 CD36 antigen (collagen type I receptor, thrombospondin receptor) CD36 2978 ++ -2,6 D 2,8 I 1,1 NC 2,5 I 1,7 NC
Hs.213289 Low density lipoprotein receptor (familial hypercholesterolemia) LDLR 990 ++ -2,0 D -8,6 D 3,2 I -4,0 D 1,4 I
Unigene
Load Deload
ShortGene title
Mono Diff Load Deload
  E3     E3     E3     E3     E3     E3     E3     E3     E3   
Mono MF E-LDL Ox-LDL
Table 6: Number of genes regulated by incubation with lipoproteins an ApoE3/E3 
macrophages. 
Category
E-LDL Ox-LDL E-LDL Ox-LDL
Load Specific Up 20 178 0,5% 4,2%
Load Specific Down 497 105 11,7% 2,5%
Deload Specific Up 625 166 14,7% 3,9%
Deload Specific Down 54 38 1,3% 0,9%
Genes regulated during differentiation
Total significantly reglated genes
Category
Load Deload Load Deload
Common Up 29 31 0,7% 0,7%
Common Down 129 1 3,0% 0,0%
Inversly regulated 16 113 0,4% 2,7%
Genes regulated during differentiation
Total significantly reglated genes
1443 34,0%
4240
4240
Number of genes Percentage
Number of genes Percentage
1443 34,0%
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analyses and unpublished data sets from our laboratory. Using this approach, a total of 73 
categories of interest were defined. These are listed in table 8. 
 
 
 
The number of 31.941 genes resembles the total number of genes that were listed in all 
categories. This “search list” contained redundancies due to the fact that numerous genes 
could be assigned to more than one category. A total of 4240 genes from the search list 
displayed significant regulation in apoE3/E3 macrophages under conditions of E-LDL or 
Ox-LDL mediated cholesterol uptake followed by cholesterol efflux.  
Table 8: Pathways assembled according to literature survey, data base analysis and 
unpublished data sets in our institute.
Nr. Name of pathway Nr. Name of pathway 
1 Wnt/Frizzled 38 Proteoglycans / Mucins / Defensins / Trefoils / IgA
2 Notch/Hedgehog/Stem cell genes 39 Hyaluronan
3 CD genes / Receptors / Tetraspans / Pentaspans / Ligands 40 Elastin/Fibrillin/Keratin/Fibulin
4 Vesicular trafficking / lipid droplet 41 Connective tissue disease
5 ABC Transporter/ATPases/Walker motif family 42 EGF family
6 Ion Chanels/Porins/solute carriers 43 Junctional control
7 Phagosome/Annexines/Connexins/Copins 44 other ECM proteins
8 Rab/Ras pathway 45 G protein receptors and G proteins
9 Rac/Cdc42 regulatory pathways 46 Kinases + Phosphatases
10 Lamellar body/GPI-anchored/Golgi 47 NFkB signaling/NFkB target genes
11 Adapter proteins/PDZ family/Domain proteins/coiled coil 48 ZNF202 target genes and coregulators
12 Cytoskeleton/Actin/Tubulin/Myosin/Spectrin/Migration/polarization POLII/TAFs/CDK/Cyclins/CDCs
13 ABCA1/ABCA7/NPC/Cav  associated /CDT-kinases in transcriptional control
14 Purin & Pyrimidin metabolism/FAD/NAD/Nucleotide/Nucleoside 50 Nucleosome/Nuclear matrix
15 TNF receptor signaling 51 Nuclear receptors
16 TNF/PI3 kinase coupling 52 PPAR/LxR/PxR/RxR/FxR nuclear receptor target genes
17 Apoptosis/Proteasome 53 ZNF TCFs
18 Mitochondrion/Peroxisome 54 Homeobox
19 Insulin/Glukose/Glutathione/Glucuronides/Energy/b-Oxidation 55 RNA-Polymerases I and III
20 Thrombosis/Haemostasis 56 Other specific transcription factors
21 Detoxifikation: Phase I / Cytochromes 57 Splicing
22 Detoxifikation: Phase II 58 Translation machinery
23 Heat shock 59 IL-1b/Cytokines/Chemokines/Poetins
24 NO/Thioredoxin/Metallothionins/Selenoproteins 60 IFNg regulated genes
25 Cholesterol metabolism / SREBP1/2 / bile acid 61 Homocysteine
26 Fatty acid metabolism / Retinoids / S100 62 Lipid sensitive genes in C. elegans
27 Glycerophospholipids 63 complement, defensins, Granzymes
28 Phosphatidylinositol and Ca++ metabolism / GPI biosynthesis 64 IBD candidate loci
29 Sphingolipids 65 Colon expressed genes
30 Gangliosides 66 not yet classified to pathways
31 Sulfatides/Cholesterol sulfate 67 unknowns
32 Glykosylation/Sialation/CTP/UTP/GTP/ITP 68 Replikation
33 Proteinases/Serpins/MMPs/ADAMS/Kallikreins/Calpains/Cytostatins 69 Apos/Lipid binding proteins
34 Integrins 70 Lysosome/CLNsSTART
35 TGFb-family/BMP/TGFb/Activins/Inhibins and signaling 71 CD13 / Ezetrol pathway
36 Collagens 72 HNF1a / CDX2 / GATA4 
37 Laminins 73 Placenta/Prostate/Sperm/Testes
49
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The percentage distribution of genes in the 73 pre-defined pathways is shown in table 9. 
 
It is noticeable that differentiation of monocytes to macrophages has a great influence on 
the gene expression, leading to severe upregulation in many pathways. Moreover, it is 
Table 9: percentage of genes regulated by differentiation, E-LDL or Ox-LDL loading and 
subsequent HDL3 deloading were the different regulations are given different colors (red 
for up- and blue for down-regulation). 
PW Pathway
Apo E3/E3 Sum Up % Dwn % Up % Dwn % Up % Dwn % Up % Dwn %
1 Wnt/Frizzled 214 4,2 15,9 10,7 7,5 2,8 9,3 6,5 6,1
2 Notch/Hedgehog/Stem cell genes 402 2,7 15,4 9,2 7,0 2,5 9,2 6,2 5,5
3 CD genes / Receptors / Tetraspans / Pentaspans / Ligands 216 6,0 19,4 12,5 9,7 7,9 20,4 11,1 8,8
4 Vesicular trafficking / lipid droplet 743 4,0 14,3 7,9 6,1 3,5 13,7 8,2 5,2
5 ABC Transporter/ATPases/Walker motif family 82 13,4 12,2 15,9 8,5 9,8 6,1 4,9 7,3
6 Ion Chanels/Porins/solute carriers 405 2,5 9,9 6,2 3,5 3,5 4,9 3,5 5,4
7 Phagosome/Annexines/Connexins/Copins 523 10,5 11,5 12,8 11,3 8,6 11,7 14,5 10,3
8 Rab/Ras pathway 192 8,3 7,8 8,9 11,5 6,8 8,3 9,9 6,3
9 Rac/Cdc42 regulatory pathways 37 10,8 21,6 0,0 10,8 5,4 13,5 10,8 8,1
10 Lamellar body/GPI-anchored/Golgi 473 6,6 12,3 12,1 8,7 6,8 7,4 8,0 8,9
11 Adapter proteins/PDZ family/Domain proteins/coiled coil 461 6,1 12,1 10,2 5,9 6,5 8,0 7,4 8,9
12 Cytoskeleton/Actin/Tubulin/Myosin/Spectrin/Migration/polarization 217 3,7 9,2 10,6 5,5 3,7 7,4 6,0 5,1
13 ABCA1/ABCA7/NPC/Cav  associated 371 5,7 15,6 14,6 5,7 8,9 11,1 8,1 8,6
14 Purin & Pyrimidin metabolism/FAD/NAD/Nucleotide/Nucleoside 60 8,3 13,3 15,0 16,7 6,7 16,7 15,0 10,0
15 TNF receptor signaling 158 5,1 17,1 10,8 8,9 7,0 10,1 5,7 9,5
16 TNF/PI3 kinase coupling 38 15,8 21,1 7,9 10,5 18,4 5,3 5,3 5,3
17 Apoptosis/Proteasome 591 4,2 9,8 10,0 4,9 9,5 6,8 5,4 10,0
18 Mitochondrion/Peroxisome 329 9,1 10,0 21,3 8,2 14,9 2,4 8,5 10,3
19 Insulin/Glukose/Glutathione/Glucuronides/Energy/b-Oxidation/Fucose 381 5,5 11,5 12,6 5,8 10,0 5,8 6,8 6,8
20 Thrombosis/Haemostasis 39 0,0 23,1 12,8 10,3 2,6 15,4 2,6 5,1
21 Detoxifikation: Phase I / Cytochromes 125 3,2 12,8 8,0 4,0 8,8 7,2 4,0 7,2
22 Detoxification: Phase II 74 5,4 13,5 14,9 8,1 5,4 12,2 6,8 6,8
23 Heat shock 58 8,6 5,2 12,1 8,6 8,6 5,2 6,9 8,6
24 NO/Thioredoxin/Metallothionins/Selenoproteins 242 5,0 14,9 16,1 6,2 7,9 10,3 7,4 6,2
25 Cholesterol metabolism / SREBP1/2 / bile acid 34 14,7 41,2 29,4 11,8 20,6 32,4 29,4 8,8
26 Fatty acid metabolism / Retinoids / S100 206 8,3 12,6 13,6 5,3 13,6 7,8 8,3 7,8
27 Glycerophospholipids 14 0,0 7,1 7,1 14,3 21,4 0,0 14,3 14,3
28 Phosphatidylinositol and Ca++ metabolism / GPI biosynthesis 229 2,2 14,4 7,9 5,2 5,2 6,1 5,7 7,4
29 Sphingolipids 14 7,1 0,0 7,1 14,3 21,4 7,1 7,1 14,3
30 Gangliosides 49 10,2 12,2 6,1 10,2 6,1 10,2 8,2 4,1
31 Sulfatides/Cholesterol sulfate 13 0,0 0,0 23,1 0,0 7,7 7,7 7,7 0,0
32 Glykosylation/Sialation/CTP/UTP/GTP/ITP 203 4,4 15,3 9,4 3,9 6,9 8,4 9,4 7,4
33 Proteinases/Serpins/MMPs/ADAMS/Kallikreins/Calpains/Cytostatins 193 3,6 14,0 11,4 6,2 4,7 11,4 5,2 5,2
34 Integrins 31 6,5 3,2 16,1 9,7 12,9 6,5 6,5 9,7
35 TGFb-family/BMP/TGFb/Activins/Inhibins and signaling 173 1,7 12,7 8,7 4,0 1,2 8,1 4,6 3,5
36 Collagens 84 4,8 8,3 7,1 6,0 6,0 9,5 7,1 6,0
37 Laminins 31 0,0 6,5 9,7 6,5 0,0 9,7 6,5 6,5
38 Proteoglycans / Mucins / Defensins / Trefoils / IgA 60 1,7 15,0 11,7 5,0 1,7 3,3 0,0 6,7
39 Hyaluronan 96 4,2 8,3 8,3 9,4 6,3 7,3 7,3 5,2
40 Elastin/Fibrillin/Keratin/Fibulin 103 2,9 13,6 9,7 8,7 2,9 8,7 3,9 2,9
41 Connective tissue disease 202 4,5 14,4 15,3 8,4 6,4 10,9 5,4 7,4
42 EGF family 112 2,7 19,6 7,1 8,0 1,8 15,2 8,9 2,7
43 Junctional control 113 1,8 10,6 3,5 2,7 1,8 5,3 3,5 3,5
44 other ECM proteins 96 3,1 18,8 11,5 5,2 5,2 12,5 3,1 5,2
45 G protein receptors and G proteins 412 2,2 12,6 7,3 2,4 1,7 7,3 2,4 2,4
46 Kinases + Phosphatases 592 3,0 11,0 10,3 7,3 4,9 6,3 6,8 7,8
47 NFkB signaling/NFkB target genes 84 6,0 13,1 9,5 13,1 7,1 14,3 14,3 7,1
48 ZNF202 target genes and coregulators 26 7,7 11,5 19,2 3,8 11,5 19,2 11,5 15,4
49 POLII/TAFs/CDK/Cyclins/CDCs/CDT-kinases in transcriptional control 250 4,0 14,0 16,4 5,6 9,2 5,6 4,0 9,2
50 Nucleosome/Nuclear matrix 114 1,8 9,6 6,1 1,8 0,9 1,8 0,9 8,8
51 Nuclear receptors 54 1,9 14,8 9,3 5,6 3,7 3,7 3,7 3,7
52 PPAR/LxR/PxR/RxR/FxR nuclear receptor target genes 721 7,4 16,2 12,1 8,0 8,2 15,0 10,0 7,6
53 ZNF TCFs 228 0,9 6,1 5,3 4,8 1,8 2,6 3,1 6,1
54 Homeobox 63 0,0 7,9 1,6 1,6 0,0 1,6 1,6 3,2
55 RNA-Polymerases I and III 18 5,6 0,0 16,7 0,0 5,6 0,0 0,0 5,6
56 Other specific transcription factors 334 1,2 12,9 7,8 6,0 1,5 9,0 4,5 4,8
57 Splicing 61 3,3 8,2 14,8 3,3 4,9 3,3 4,9 3,3
58 Translation machinery 237 6,8 19,4 33,3 6,8 15,2 4,6 5,1 29,5
59 IL-1b/Cytokines/Chemokines/Poetins 72 2,8 13,9 9,7 4,2 4,2 12,5 5,6 4,2
60 IFNg regulated genes 201 7,5 14,9 9,0 10,4 9,0 16,4 8,5 12,9
61 Homocysteine 30 3,3 6,7 10,0 10,0 10,0 3,3 0,0 13,3
62 Lipid sensitive genes in C. elegans 229 4,4 10,9 11,8 6,6 6,1 5,7 6,1 9,2
63 Complement, defensins, Granzymes 110 4,5 17,3 11,8 2,7 5,5 18,2 7,3 4,5
64 IBD candidate loci 810 4,0 13,0 10,6 4,8 6,2 7,9 5,4 7,0
65 Colon expressed genes 1484 7,7 14,9 12,9 9,6 8,8 10,5 8,9 10,8
66 not yet classified to pathways 1452 3,2 9,2 8,1 5,2 4,7 5,6 5,2 6,2
67 unknowns 3038 2,1 9,6 8,4 3,8 3,9 4,1 3,3 6,5
68 Replikation 109 1,8 10,1 11,0 3,7 4,6 3,7 2,8 3,7
69 Apolipoproteins / Lipid binding proteins 23 4,3 13,0 13,0 4,3 4,3 0,0 13,0 4,3
70 Lysosome/CLNsSTART 42 7,1 16,7 11,9 7,1 9,5 11,9 4,8 9,5
71 CD13 / Ezetrol pathway 771 6,2 10,5 12,2 7,0 9,7 7,9 7,5 6,7
72 HNF1a / CDX2 / GATA4 66 1,5 13,6 3,0 3,0 1,5 1,5 4,5 1,5
73 Placenta/Prostate/Sperm/Testes 32 0,0 0,0 18,8 0,0 15,6 6,3 6,3 15,6
74 HNF1a / CDX2 / GATA4 target genes 623 6,3 11,6 8,7 8,3 7,4 8,8 9,6 7,2
Sum 20773 958 2538 2209 1313 1300 1669 1343 1553
Ox-LDL DeloadE-LDL Load E-LDL Deload Ox-LDL Load
V.Results                                                                                                                                         93 
noticed that loading the cells with E-LDL leads to downregulation, subsequent deload to 
upregulation of many genes. 
6.1. E-LDL MEDIATED CHOLESTEROL FLUX 
Our statistical analysis of apoE3/E3 macrophages revealed that n=167 (1.3%) of the 
genes are upregulated during E-LDL mediated cholesterol uptake whereas the number of 
downregulated genes during E-LDL loading was n=1,640 (13.2%). 
As for the consequent deload of macrophages with HDL3, the E-LDL-loaden macrophages 
displayed an increase for n=2074 (17%). The genes downregulated by HDL3-deload after 
E-LDL loading were: n=311 (2.5%). The genes that showed most pronounced regulation 
in apoE3/E3 individuals in E-LDL loading include various members of the cholesterol 
metabolism pathway including PPARs, vesicular transport genes, the wingless-frizzled 
pathway and genes from the detoxification machinery.  
In contrast, deloading led to a significant regulation in the ABCA1-related genes, -
oxidation, mitochondrial genes and the laminins, also striking was the upregulation of the 
RNA polymerase II complex (RNA polymerase II peptides A, E, F, H, I, and L) as well as 
various members of the cyclin and cyclin-dependent kinase (cdk) families (cyclins D1, D2, 
D3, E1, F, cdk10, cdk inhibitor 2A, cdk inhibitor 2C, cdk inhibitor 1C) and multiple 
components of the translation machinery (figure 42A).  
Cholesterol efflux in apoE3/E3 macrophages following E-LDL mediated cholesterol uptake 
induced the upregulation of a strikingly large portion among the regulated translation 
machinery associated genes (n=84). The vast majority of these genes included structural 
elements of the 40S and 60S ribosomal subunits suggesting that cholesterol efflux from 
macrophages has a profound effect on the expression of integral components of the 
ribosome complex (figure 42B). The genes that showed strongest upregulation include the 
members of the large subunit of ribosomal proteins (RP) RPL36, RPL28, RPLP2 and 
RPL14 respectively. Beside structural ribosomal proteins members of the translation 
initiation complex were upregulated during cholesterol export. These included the majority 
of the subunits of the eukaryotic translation initiation factor (EIF)-3 (EIF3S4, EIF3S5, 
EIF3S9, EIF3S6IP, EIF3S3, EIF3S7, EIF3S8) and members of the EIF-2 and EIF-4 
complexes (EIF2B5, EIF2C1, EIF4EL3) (Table 10 and Figure 42C). 
V.Results                                                                                                                                         94 
Table 10: Expression analysis of genes relevant for the translation machinery. 
(blue:downregulation, red:upregulation, (marked only when fold change >=2)). 
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Hs.334798 Eukaryotic translation elongation factor 1 delta EEF1D 652 ++ ++ -1,7 ++ 3,7 + 1,7 ++ -1,7
Hs.283551 Eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa EIF2B5 211 ++ + -1,2 ++ 3,0 ++ 2,0 + -1,1
Hs.309452 Eukaryotic translation initiation factor 2C, 1 EIF2C1 206 ++ + -1,5 ++ 2,3 + 1,2 + 1,1
Hs.127149 Eukaryotic translation initiation factor 3, subunit 3 gamma, 40kDa EIF3S3 1084 ++ + -1,6 ++ 2,5 + 1,2 + -1,1
Hs.28081 Eukaryotic translation initiation factor 3, subunit 4 delta, 44kDa EIF3S4 373 ++ ++ -1,9 ++ 3,2 + 1,6 + -1,1
Hs.381255 Eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa EIF3S5 786 ++ ++ -1,9 ++ 2,6 + 1,4 + -1,2
Hs.119503 Eukaryotic translation initiation factor 3, subunit 6 interacting protein EIF3S6IP 1470 ++ + -1,6 ++ 3,2 + 1,5 + -1,3
Hs.55682 Eukaryotic translation initiation factor 3, subunit 7 zeta, 66/67kDa EIF3S7 1179 ++ ++ -1,9 ++ 2,5 + 1,3 + -1,2
Hs.371001 Eukaryotic translation initiation factor 3, subunit 9 eta, 116kDa EIF3S9 877 ++ + -1,6 ++ 3,5 + 1,7 + -1,5
Hs.211823 Eukaryotic translation initiation factor 4E-like 3 EIF4EL3 376 ++ + 1,2 ++ 2,5 ++ 1,9 + -1,2
Hs.310621 Eukaryotic translation initiation factor 5A EIF5A 304 ++ ++ -2,0 ++ 3,7 + 1,0 + 1,1
Hs.448396 Ribosomal protein L10a RPL10A 1430 ++ + -1,7 ++ 2,5 + 1,2 + 1,1
Hs.388664 Ribosomal protein L11 RPL11 1667 ++ + -1,5 ++ 2,1 + 1,4 + -1,1
Hs.408054 Ribosomal protein L12 RPL12 2267 ++ + -1,4 ++ 2,5 + 1,2 + -1,1
Hs.410817 Ribosomal protein L13 RPL13 2225 ++ + -1,5 ++ 2,8 + 1,6 + -1,6
Hs.449070 Ribosomal protein L13a RPL13A 5210 ++ + -1,5 ++ 2,8 + 1,2 + -1,2
Hs.446522 Ribosomal protein L14 RPL14 1245 ++ + -1,4 ++ 3,2 + 1,7 + -1,4
Hs.409634 Ribosomal protein L18 RPL18 2370 ++ ++ -2,3 ++ 3,0 + 1,2 + -1,3
Hs.381123 Ribosomal protein L21 RPL21 2908 ++ + -1,3 ++ 2,1 + 1,3 + -1,3
Hs.406300 Ribosomal protein L23 RPL23 2069 ++ ++ -1,9 ++ 3,0 + 1,4 + 1,0
Hs.419463 Ribosomal protein L23a RPL23A 6816 ++ + -1,2 ++ 2,3 + 1,4 + -1,1
Hs.184582 Ribosomal protein L24 RPL24 2134 ++ + -1,2 ++ 3,2 + 1,5 + -1,3
Hs.405528 Ribosomal protein L27 RPL27 3415 ++ + -1,1 ++ 2,3 + 1,5 + -1,2
Hs.356342 Ribosomal protein L27a RPL27A 5175 ++ + -1,5 ++ 2,8 + 1,4 ++ -1,2
Hs.356371 Ribosomal protein L28 RPL28 2490 ++ ++ -2,0 ++ 3,5 + 1,3 + -1,2
Hs.430207 Ribosomal protein L29 RPL29 1623 ++ ++ -2,1 ++ 2,6 + 1,1 + -1,1
Hs.119598 Ribosomal protein L3 RPL3 3778 ++ + -1,5 ++ 2,1 + 1,2 + -1,1
Hs.400295 Ribosomal protein L30 RPL30 3642 ++ + -1,3 ++ 2,1 + 1,3 + -1,1
Hs.265174 Ribosomal protein L32 RPL32 3443 ++ + -1,2 ++ 2,3 + 1,4 + -1,1
Hs.250895 Ribosomal protein L34 RPL34 1566 ++ + -1,5 ++ 3,0 + 1,4 + -1,3
Hs.182825 Ribosomal protein L35 RPL35 2023 ++ + -1,5 ++ 2,5 + 1,3 + 1,1
Hs.408018 Ribosomal protein L36 RPL36 835 ++ ++ -2,1 ++ 3,7 + 1,1 + -1,5
Hs.454495 Ribosomal protein L36a RPL36A 2577 ++ ++ -2,1 ++ 2,8 + 1,1 + -1,1
Hs.444749 Ribosomal protein L36a-like RPL36AL 1325 ++ + -1,3 ++ 2,5 + 1,5 + -1,3
Hs.80545 Ribosomal protein L37 RPL37 1757 ++ + -1,4 ++ 2,5 + 1,4 + -1,2
Hs.433701 Ribosomal protein L37a RPL37A 7167 ++ + -1,2 ++ 2,1 + 1,4 - -1,1
Hs.380953 Ribosomal protein L38 RPL38 3084 ++ + -1,5 ++ 3,0 + 1,2 + -1,2
Hs.300141 Ribosomal protein L39 RPL39 4550 ++ + -1,1 ++ 2,3 + 1,3 + -1,2
Hs.381172 Ribosomal protein L41 RPL41 6742 ++ + -1,1 ++ 2,1 + 1,3 + -1,1
Hs.469653 Ribosomal protein L5 RPL5 2222 ++ + -1,1 ++ 2,5 + 1,4 + -1,3
Hs.421257 Ribosomal protein L7 RPL7 6157 ++ + -1,2 ++ 2,1 + 1,4 - -1,1
Hs.416801 Ribosomal protein L7a RPL7A 4661 ++ + -1,6 ++ 2,3 + 1,3 + -1,1
Hs.178551 Ribosomal protein L8 RPL8 2281 ++ ++ -1,9 ++ 2,8 + 1,0 + 1,1
Hs.412370 Ribosomal protein L9 RPL9 4474 ++ + -1,2 ++ 2,0 + 1,6 + -1,1
Hs.406620 Ribosomal protein S10 RPS10 5835 ++ + -1,6 ++ 2,5 + 1,2 - -1,2
Hs.433529 Ribosomal protein S11 RPS11 3094 ++ ++ -1,9 ++ 3,0 + 1,1 + -1,1
Hs.380956 Ribosomal protein S12 RPS12 2741 ++ + -1,2 ++ 2,5 + 1,5 + -1,1
Hs.446588 Ribosomal protein S13 RPS13 3722 ++ + -1,1 ++ 2,0 + 1,2 + -1,1
Hs.381126 Ribosomal protein S14 RPS14 3849 ++ + -1,7 ++ 2,3 + 1,1 + 1,0
Hs.406683 Ribosomal protein S15 RPS15 4183 ++ + -1,5 ++ 2,6 + 1,2 + -1,1
Hs.370504 Ribosomal protein S15a RPS15A 3485 ++ + -1,4 ++ 2,3 + 1,3 + -1,1
Hs.397609 Ribosomal protein S16 RPS16 2770 ++ + -1,4 ++ 2,8 + 1,4 + -1,1
Hs.433427 Ribosomal protein S17 RPS17 4328 ++ + -1,1 ++ 2,1 + 1,5 + -1,1
Hs.275865 Ribosomal protein S18 RPS18 4336 ++ + -1,7 ++ 2,6 - 1,2 + -1,1
Hs.381184 Ribosomal protein S19 RPS19 3129 ++ + -1,6 ++ 2,6 + 1,2 + -1,1
Hs.498569 Ribosomal protein S2 RPS2 6637 ++ + -1,7 ++ 2,3 + 1,1 + 1,1
Hs.8102 Ribosomal protein S20 RPS20 3624 ++ + 1,1 ++ 2,0 + 1,5 + -1,2
Hs.372960 Ribosomal protein S21 RPS21 2174 ++ + -1,7 ++ 3,2 + 1,2 + -1,2
Hs.534369 Ribosomal protein S23 RPS23 5152 ++ + -1,2 ++ 2,1 + 1,3 + -1,1
Hs.356794 Ribosomal protein S24 RPS24 4359 ++ + -1,4 ++ 2,3 + 1,2 + -1,1
Hs.512676 Ribosomal protein S25 RPS25 1646 ++ + -1,7 ++ 3,0 + 1,4 + -1,2
Hs.355957 Ribosomal protein S26 RPS26 1346 ++ ++ -2,0 ++ 2,5 + 1,1 + -1,1
Hs.337307 Ribosomal protein S27 RPS27 3710 ++ + -1,5 ++ 2,8 + 1,3 + -1,1
Hs.311640 Ribosomal protein S27a RPS27A 2736 ++ + -1,1 ++ 2,6 + 1,6 ++ -1,4
Hs.108957 Ribosomal protein S27-like RPS27L 1160 ++ + -1,1 ++ 2,1 ++ 2,3 + -1,1
Hs.153177 Ribosomal protein S28 RPS28 3836 ++ + -1,6 ++ 3,0 + 1,4 + -1,3
Hs.539 Ribosomal protein S29 RPS29 3557 ++ + -1,4 ++ 3,0 + 1,2 + -1,1
Hs.387576 Ribosomal protein S3 RPS3 2820 ++ ++ -1,7 ++ 2,8 + 1,3 + -1,2
Hs.446628 Ribosomal protein S4, X-linked RPS4X 3003 ++ + -1,5 ++ 2,6 + 1,4 + -1,1
Hs.149957 Ribosomal protein S6 kinase, 90kDa, polypeptide 1 RPS6KA1 1811 ++ ++ -2,0 ++ 2,5 + -1,1 + 1,1
Hs.444012 Ribosomal protein S7 RPS7 2473 ++ + -1,1 ++ 2,1 + 1,4 + -1,2
Hs.139876 Ribosomal protein S9 RPS9 1484 ++ ++ -2,3 ++ 3,0 + 1,1 + -1,1
Hs.437594 Ribosomal protein, large P2 RPLP2 2814 ++ ++ -2,3 ++ 3,5 + 1,1 + -1,1
Hs.443796 Ribosomal protein, large, P0 RPLP0 5451 ++ + -1,5 ++ 2,8 + 1,5 + -1,1
Hs.356502 Ribosomal protein, large, P1 RPLP1 4300 ++ + -1,2 ++ 2,3 + 1,4 + -1,2
Hs.461178 Eukaryotic translation initiation factor 1A, Y-linked EIF1AY 92 ++ ++ 1,7 ++ -3,5 ++ -3,5 + 1,4
Hs.151777 Eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa EIF2S1 689 ++ ++ 2,1 + 1,0 ++ 2,5 + 1,5
Hs.102506 Eukaryotic translation initiation factor 2-alpha kinase 3 EIF2AK3 143 ++ ++ 2,0 ++ -2,8 + 1,6 + -1,2
Hs.173987 Eukaryotic translation initiation factor 3, subunit 1 alpha, 35kDa EIF3S1 613 ++ + 1,6 + 1,2 ++ 2,0 + 1,5
Hs.79306 Eukaryotic translation initiation factor 4E EIF4E 622 ++ ++ 2,1 ++ -2,5 + 1,3 ++ 2,1
Hs.433702 Eukaryotic translation initiation factor 5 EIF5 1454 ++ + -1,1 ++ -2,0 + -1,3 ++ 2,0
Hs.158688 Eukaryotic translation initiation factor 5B EIF5B 370 ++ ++ 3,2 ++ -3,7 + -1,1 + 1,5
Hs.180911 Ribosomal protein S4, Y-linked 1 RPS4Y1 1126 ++ + -1,1 - -1,2 ++ -8,6 + -1,4
E-LDL Ox-LDL
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Interestingly, only one gene from the upregulated ribosomal genes during E-LDL 
deload (n=84) was significantly regulated during Ox-LDL deload and the majority 
of these genes (n=83) did not exhibit any regulation. These findings indicate 
dramatic differences in the regulation of ribosomal genes in response to 
cholesterol export when cholesterol efflux from E-LDL and Ox-LDL loaded 
macrophages is being compared. 
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Figure 42: A. Regulation of multiple components of the RNA polymerase II 
complex in apoE3/E3 macrophages during cholesterol deloading following E-
LDL mediated cholesterol influx. B. Regulation of translation initiation and 
elongation factors of the ribosome complex in apoE3/E3 macrophages in 
response to cholesterol deloading  
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6.2. OX-LDL MEDIATED CHOLESTEROL FLUX 
Loading the macrophages with Ox-LDL resulted in the upregulation of n=757 (6.1%) and a 
downregulation of n=671 (5.4%) genes. Export of cholesterol following Ox-LDL loading 
increased n=1022 (8.2%) genes and only n=133 (1.1%) were downregulated. The genes 
regulated during Ox-LDL load are more distributed and show only pronounced regulation 
in the cholesterol metabolism pathway and the extracellular matrix pathway. 
Genes related to the apolipoproteins and their binding proteins were regulated similarly 
both in E-LDL and Ox-LDL deloading, as well as genes from the ZNF202 pathway and the 
PPARs. In controversy to E-LDL deloading, cholesterol efflux following loading with Ox-
LDL did not result in statistically significant regulation of translation machinery associated 
genes in apoE3/E3 macrophages. 
Figure 42: C. Regulation of integral components of the ribosome complex in 
apoE3/E3 macrophages in response to choleaterol deload with HDL3. D. Regulation 
of ATPase and non-ATPase factors of the ATP-synthase during E-LDL deload. 
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In conclusion, numerous genes of the nuclear machinery are involved in the macrophage 
response to E-LDL cholesterol loading, whereas Ox-LDL loading of macrophages had 
only a moderate effect on this pool of genes. This reflects the existence of two different 
regulatory pathways that control the trafficking of E-LDL and Ox-LDL in apoE3/E3 
macrophages.  
6.3. BIOCHEMICAL PATHWAYS AND CANDIDATE GENES WITH RELEVANCE TO 
LIPID TRAFFIC IN MACROPHAGES  
To further decipher the genes obtained in the previous list, we focused on more defined 
pathways which describe endocytosis, intracellular processing and exocytosis of lipids. In 
addition, certain intracellular machineries have been exploited i.e. phagosomes, vesicular 
trafficking genes and ABCA1-related genes. The percentage of genes regulated is 
displayed in table 11. 
 
The four categories: endocytosis, coated vesicles, phagosome and budding / fusion show 
a similar regulation pattern with E-LDL and Ox-LDL concerning the number of regulated 
genes. However, the genes in the three pathways: vesicular transport, calcium transport 
and exocytosis were primarily regulated by E-LDL and only to a small extent by Ox-LDL. 
Both calcium transport and exocytosis-related genes were down-regulated by E-LDL load 
and up-regulated by E-LDL deload. These results are significant but still have to be 
verified by independent experiments. 
Table 11: Percentage distribution of genes in the defined pathways 
Up Dwn Up Dwn Up Dwn Up Dwn
1 Endocytosis 19 21,1 21,1 26,3 10,5 15,8 31,6 36,8 0,0
2 Coated vesicle 94 1,1 4,3 14,9 4,3 3,2 3,2 12,8 1,1
3 Vesicle transport 53 1,9 15,1 11,3 1,9 5,7 1,9 7,5 0,0
4 Phagosome 211 1,4 6,6 13,3 4,7 8,1 6,6 14,2 0,5
5 Budding / Fusion 62 1,6 6,5 12,9 0,0 3,2 0,0 9,7 0,0
6 Ca+2 transport 100 0,0 17,0 21,0 1,0 6,0 6,0 10,0 0,0
7 Exocytosis ABCA1-related 196 1,5 18,4 17,3 1,5 6,1 6,1 9,7 1,0
Pathway # genes
ApoE3/E3
E-LDL Ox-LDL
Load Deload Load Deload
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A pool of 20 non redundant genes was compiled that have been associated with cell 
endocytosis in general, those genes are mainly scavenger receptors and LDL related 
genes. Among those, 3 genes were up-, 8 genes were downregulated in apoE3/E3 
macrophages during E-LDL or Ox-LDL mediated cholesterol flux respectively, whereas 
only CD163 (a member of the scavenger receptor cysteine-rich (SRCR) superfamily, 
which is exclusively expressed by monocytes and macrophages) was up-regulated by 
HDL3 deloading both in E- and Ox-LDL-loaded macrophages, another 3 genes (SCARB2, 
PPARG and LDL receptor adaptor protein) were regulated inversely by HDL3 deloading 
(Table 12). 
 
A total number of n=211 genes were compiled in the phagosomal list, from which 85 were 
significantly regulated during load and/or deload. These genes were assembled according 
6.3.1. REGULATION OF GENES IN THE ENDOCYTIC AND PHAGOCYTIC PATHWAY 
IN MACROPHAGES 
Table 12: Genes related to  the endocytosis pathway that are regulated by E-LDL 
and Ox-LDL loading and successive HDL3-mediated deloading. 
0 Endocytosis receptors
Hs.213289 Low density lipoprotein receptor (familial hypercholesterolemia) LDLR 990 ++ ++ -8,6 ++ 3,2 ++ -4,0 ++ 1,4
Hs.184482 LDL receptor adaptor protein ARH 219 ++ ++ -1,9 ++ 2,8 ++ 1,2 ++ -2,2
Hs.162757 Low density lipoprotein-related protein 1 LRP1 177 ++ ++ -1,5 ++ 2,6 ++ -1,2 ++ 1,3
Hs.210343 Low density lipoprotein receptor-related protein 6 LRP6 53 + + -3,0 + 2,6 + -1,1 + -1,2
Hs.410784 Low density lipoprotein receptor-related protein 8, Apo-E receptor LRP8 277 ++ + -2,0 + 1,7 ++ -1,2 ++ -2,0
Hs.534325 Fc fragment of IgG, high affinity Ia, receptor for (CD64) FCGR1A 208 ++ ++ -1,3 ++ 1,0 ++ -3,7 ++ 4,0
Hs.352642 Fc fragment of IgG, low affinity IIa, receptor for (CD32) FCGR2A 285 ++ ++ -1,5 ++ 1,5 ++ -2,1 ++ 1,4
Hs.372679 Fc fragment of IgG, low affinity IIIb, receptor for (CD 16) FCGR3B 158 ++ ++ -2,5 + 1,1 ++ -10,6 + 13,9
Hs.443120 CD36 Thrombospondin receptor CD36 2978 ++ ++ 2,8 ++ 1,1 ++ 2,5 ++ 1,7
Hs.349656 Scavenger receptor class B, member 2 SCARB2 512 ++ ++ 2,0 ++ -2,8 ++ -2,3 ++ -6,1
Hs.436887 Macrophage scavenger receptor 1 CD204 147 ++ ++ 2,6 ++ -1,1 ++ 1,9 ++ 1,6
Hs.74076 CD163 antigen CD163 1354 ++ ++ -1,7 ++ 2,1 ++ -2,8 ++ 2,1
Hs.519624 CD14 antigen CD14 1174 ++ ++ -3,5 ++ 3,5 ++ -2,8 ++ 1,1
Hs.444310 CD83 antigen (activated B lymphocytes superfamily) CD83 996 ++ ++ 2,0 ++ 1,0 ++ 2,3 ++ 1,1
0 RAB - Traffic genes
Hs.227327 RAB1A, member RAS oncogene family RAB1A 352 ++ ++ 1,1 + -3,0 ++ 1,1 ++ 4,0
Hs.78305 RAB2, member RAS oncogene family RAB2 453 ++ ++ 1,0 ++ -2,3 ++ -1,3 ++ 2,6
Hs.27744 RAB3A, member RAS oncogene family RAB3A 12 - - -2,0 + 4,9 - -1,1 - 1,1
Hs.296169 RAB4A, member RAS oncogene family RAB4A 172 ++ ++ -1,2 ++ -1,1 ++ 1,1 ++ 2,0
Hs.73957 RAB5A, member RAS oncogene family RAB5A 180 ++ ++ -1,6 + 1,1 + -1,7 ++ 2,3
Hs.479 RAB5C, member RAS oncogene family RAB5C 505 ++ ++ -2,5 ++ 1,7 ++ -2,8 ++ 2,1
Hs.75618 RAB11A, member RAS oncogene family RAB11A 94 ++ ++ 1,0 ++ 1,4 ++ -1,1 ++ 2,0
Hs.151536 RAB13, member RAS oncogene family RAB13 946 ++ ++ -1,4 ++ 2,5 ++ 1,4 ++ -1,4
Hs.5807 RAB14, member RAS oncogene family RAB14 611 ++ ++ 1,3 ++ -2,0 ++ 1,1 ++ 2,8
Hs.281117 RAB22A, member RAS oncogene family RAB22A 216 ++ ++ 1,2 ++ -1,6 ++ 1,1 ++ 2,0
Hs.298530 RAB27A, member RAS oncogene family RAB27A 186 ++ ++ -1,1 ++ -2,0 ++ 1,0 ++ 1,2
Hs.108923 RAB38, member RAS oncogene family RAB38 31 - + 1,1 ++ 2,5 ++ 2,5 ++ 1,5
Hs.302498 RAB40B, member RAS oncogene family RAB40B 28 - - 1,5 + 13,9 + 3,7 - -3,0
0 Lipid droplet genes
Hs.496383   Acyl-Coenzyme A: cholesterol acyltransferase) 1 SOAT1 188 ++ ++ 2,0 ++ -1,7 ++ 2,1 ++ 1,5
Hs.406678 Acyl-CoA synthetase long-chain family member 1 ACSL1 883 ++ ++ 2,0 ++ -1,1 ++ 1,9 ++ 1,1
Hs.3416 Adipose differentiation-related protein (Adipophilin) ADFP 1966 ++ ++ 2,3 ++ 1,0 ++ 3,5 ++ -1,1
Hs.376046 Butyrophilin, subfamily 3, member A2 BTN3A2 173 ++ ++ -2,1 ++ 2,3 ++ -1,1 ++ 1,6
Hs.83190 Fatty acid synthase FASN 153 ++ ++ -2,8 ++ 2,0 ++ -1,1 ++ -1,1
Hs.187579 Hydroxysteroid (17-beta) dehydrogenase 7 HSD17B7 391 ++ ++ -2,3 + 2,5 ++ -1,2 + 1,0
Hs.180878 Lipoprotein lipase LPL 1377 ++ ++ 2,0 ++ 1,9 ++ -2,1 ++ 3,0
Hs.439776 Stomatin STOM 660 ++ ++ 2,3 ++ -2,0 ++ 2,5 ++ -1,2
Hs.179986 Flotillin 1 FLOT1 564 ++ ++ -2,0 ++ 1,7 ++ 1,0 ++ 1,0
Hs.18799 Flotillin 2 FLOT2 528 ++ ++ -2,0 ++ 2,1 ++ -1,2 ++ 1,4
ShortGene nameUnigene
E-LDL
Mono
Ox-LDL
Load Del. Load Del.
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to the phagosomal identity gene list, nicely reviewed by the group of Desjardins 26. It was 
noticeable that a significant number of genes were upregulated by deload after E-LDL 
loading n=28 (13.3%) and Ox-LDL loading n=30 (14.2%). Nevertheless, only one gene 
(major histocompatibility complex, class II, DQ beta 1) was regulated in an identical 
manner in E-LDL and Ox-LDL deloaded macrophages. The genes, upregulated during 
deload of E-LDL-loaded macrophages, include solute carrier family members (SLC12A9, 
SLC25A5 and SLC25A6) and major histocompatibility members (HLA-A and HLA-B) but 
were not regulated in Ox-LDL deloaded cells. On the other hand, deloading Ox-LDL-
loaded macrophages mainly induced ATPases (ATP6V1G1, ATP6V1D and ATP6V1C1), 
cathepsins (C, S, and Z) and RABs (2, 3A, 5A, 5C, 11A, 14 and 22A). Rab4, 5 A, 5C and 
11 are involved in the early endosome fusion and regulate ER-Golgi transport, their 
exclusive upregulation upon Ox-LDL deload whereas E-LDL deload does not lead to such 
a massive increase, only 2 genes from 13 are upregulated. This shows the involvement of 
different pathways when the cells is being loaded by different particles. Thus, the transport 
of Ox-LDL is more reliant on the coated-pit pathway. 
As an additional difference between E- and Ox-LDL deloading, we mention the ATPases 
(ATP6V1G1, ATP6V1C and ATP6V1D1) which are inversely regulated. 
LDL-receptor mediated cholesterol uptake downregulates intracellular cholesterol 
synthesis by inhibition of HMGCoA reductase and inhibition of LDL-receptor by feedback 
mechanism. This cholesterol sensitive regulatory system leads to subsequent deloading 
of E-LDL whereas Ox-LDL is trapped inside. 
From a total number of n=94 genes, 43 were significantly regulated. During loading no 
significant changes could be observed, but again during deloading n=14 genes (14.9%) 
from the E-LDL loaded macrophages are upregulated and only n=4 (4.3%) 
downregulated. The Ox-LDL deloading shows a similar picture: n=12 (12.8%) are 
upregulated, only one gene (1.1%) is downregulated (Table 13). 
Interestingly, about half of these genes n=6 (6.4%) are regulated inversely by E-LDL and 
Ox-LDL deloading, those genes are: adaptor-related protein complex 1, adaptor-related 
protein complex 3, cathepsin S, LDL receptor adaptor protein and RAB14. All these genes 
mediate vesicle coating through the adapter protein pathway. Cathepsin S has been 
shown to block HDL3-induced cholesterol efflux and cathepsin secreting cells seem to 
promote foam cell formation 120. Moreover, the AP-2 pathway is exclusively regulated by 
6.3.2. REGULATION OF GENES IN THE COATED VESICLE PATHWAY IN 
MACROPHAGES 
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E-LDL since it includes the LDL-related protein, in contrast to the AP-4 pathway which 
genes are upregulated only during Ox-LDL deload. 
The AP-3 pathway which is linked to syntaxin 13 is more E-LDL sensitive, since this 
pathway is involved in vesicle fusion, a more downstream event of vesicle-trafficking. 
 
 
A pool of 53 non redundant genes has been associated with cellular vesicular trafficking, 
n=24 (45.3%) of them were significantly regulated. Those genes were clustered in t-
SNAREs and v-SNAREs. During E-LDL load, a downregulation could be observed in n=10 
(18.9%) genes, E-LDL deload led to upregulation of n=6 (11.3%) (Table14). The Ox-LDL 
load and successive deload did not show such an amount of regulation. 
 
 
 
 
6.3.3. REGULATION OF GENES IN THE VESICULAR TRANSPORT PATHWAY IN 
MACROPHAGES 
Table 13: Genes related to  the adapter protein1-4 pathway that are regulated by E-
LDL and Ox-LDL loading and successive HDL3-mediated deloading. 
0 AP-1 pathway
Hs.418710 adaptor-related protein complex 1, sigma 1 subunit AP1S1 164 ++ + -1,7 ++ 3,5 + 1,7 ++ -1,1
Hs.40368 adaptor-related protein complex 1, sigma 2 subunit AP1S2 707 ++ + 1,0 ++ -2,8 ++ -2,5 ++ 4,9
Hs.355832 Cell division cycle 42 (GTP binding protein, 25kDa) CDC42 436 ++ ++ 1,7 ++ -1,1 ++ 1,0 ++ 2,5
Hs.380749 clathrin, light polypeptide (Lcb) CLTB 315 ++ ++ -1,1 ++ 3,2 + 1,6 + 1,1
Hs.14376 actin, gamma 1 ACTG1 8753 ++ + 1,1 + 1,5 ++ -1,5 ++ 2,3
Hs.119000 actinin, alpha 1 ACTN1 1826 ++ + 1,2 + 2,1 + 1,7 ++ 1,0
Hs.150101 lysosomal-associated membrane protein 1 LAMP1 2845 ++ ++ 1,3 ++ 2,0 + 1,7 ++ -1,1
Hs.85226 lipase A, lysosomal acid, cholesterol esterase (Wolman disease) LIPA 5657 ++ + 1,5 ++ 1,3 ++ -1,2 ++ 2,3
Hs.121575 cathepsin D CTSD 270 ++ + 1,4 ++ 1,7 ++ 2,0 + -1,1
Hs.11590 cathepsin F CTSF 59 + ++ -2,1 ++ 3,0 + 1,1 + -1,4
Hs.181301 cathepsin S CTSS 1885 ++ + 1,0 ++ -2,1 + 1,3 ++ 2,3
Hs.255230 glucuronidase, beta GUSB 261 ++ ++ 1,5 ++ 1,9 ++ 2,1 ++ -1,1
Hs.522169 Iduronate 2-sulfatase (Hunter syndrome) IDS 547 ++ ++ -1,1 + 2,0 ++ 2,1 + -1,1
0 AP-2 pathway
Hs.19121 adaptor-related protein complex 2, alpha 2 subunit AP2A2 441 ++ ++ -1,6 ++ 2,6 + 1,0 ++ 1,0
Hs.119591 adaptor-related protein complex 2, sigma 1 subunit AP2S1 605 ++ + -1,3 ++ 2,1 ++ 1,1 + 1,4
Hs.184482 LDL receptor adaptor protein ARH 219 ++ + -1,9 ++ 2,8 ++ 1,2 ++ -1,2
0 AP-3 pathway
Hs.446648 adaptor-related protein complex 3, beta 1 subunit AP3B1 522 ++ ++ -1,1 + -1,1 + -1,1 ++ 2,6
Hs.19720 adaptor-related protein complex 3, sigma 2 subunit AP3S2 323 ++ + -2,0 ++ 2,8 + -1,1 ++ 1,2
Hs.20021 vesicle-associated membrane protein 1 (synaptobrevin 1) VAMP1 118 + ++ -2,1 ++ 2,6 + -1,4 + 1,0
Hs.371366 adaptor protein with pleckstrin homology and src homology 2 domains APS 343 ++ ++ -2,0 ++ 2,3 ++ -1,2 + 1,0
Hs.479 RAB5C, member RAS oncogene family RAB5C 505 ++ ++ -2,5 + 1,7 ++ -2,8 ++ 2,1
Hs.151536 RAB13, member RAS oncogene family RAB13 946 ++ + -1,4 + 2,5 + 1,4 ++ -1,4
Hs.5807 RAB14, member RAS oncogene family RAB14 611 ++ ++ 1,3 + -2,0 + 1,1 ++ 2,8
Hs.6906 v-ral simian leukemia viral oncogene homolog A (ras related) RALA 177 ++ ++ 1,3 ++ -1,1 ++ 2,5 ++ -2,1
0 AP-4 pathway
Hs.355832 cell division cycle 42 (GTP binding protein, 25kDa) CDC42 436 ++ + 1,7 + -1,1 + 1,0 ++ 2,5
Hs.179735 ras homolog gene family, member C RHOC 350 ++ ++ -1,1 + 1,6 + -1,4 ++ 2,1
Hs.6838 ras homolog gene family, member E ARHE 62 + ++ 2,3 ++ -1,7 + 1,2 + 1,7
Hs.301175 ras-related C3 botulinum toxin substrate 2 (rho family) RAC2 3863 ++ + 1,0 ++ 1,7 + -1,9 + 2,0
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The COP-I machinery is involved in trafficking from GOLGI to ER compartment, COP-II 
controls trafficking from ER to GOLGI. The genes involved in this pathway significantly 
regulated by E-LDL and Ox-LDL loading and HDL3 deloading are listed in table 15. From 
n=62 genes, only 19 were significantly regulated, mostly during deload of E-LDL and ox-
LDL loaded macrophages (Table 15). Nevertheless, the different loading status seems to 
affect completely different proteins in the COP-I / COP-II machinery, indicating different 
uptake and transport processes involved in E-LDL and Ox-LDL loading (Table 15). 
ARL7 seems to play a key role in Ox-LDL shuttling and deloading, due to its involvement 
in vesicular trafficking via coated pit proteins, a fact which again underlines the fact that 
Ox-LDL is transported by coated pits more that E-LDL is. 
 
 
 
 
6.3.4. REGULATION OF GENES IN THE COP MACHINERY IN MACROPHAGES
Table 14: Genes related to  the SNARE complex pathway that are regulated by  
E-LDL and Ox-LDL loading and successive HDL3-mediated deloading. 
0 Vescular / vesicle-related proteins
Hs.173878 Nipsnap homolog 1 (C. elegans) NIPSNAP1 86 + ++ -2,5 ++ 2,6 ++ -1,6 ++ -1,2
Hs.431279 N-ethylmaleimide-sensitive factor NSF 471 ++ ++ -1,2 + 2,1 ++ 2,0 ++ 1,1
Hs.75932 N-ethylmaleimide-sensitive factor attachment protein, alpha NAPA 195 ++ ++ -2,0 ++ 1,3 ++ -1,4 ++ 1,6
Hs.202308 Synaptosomal-associated protein, 23kDa SNAP23 211 ++ ++ -1,3 + -1,1 + -1,3 ++ 3,0
Hs.82240 Syntaxin 3A STX3A 50 + - 2,3 - 1,6 + 4,0 ++ 2,5
Hs.421457 Syntaxin 5A STX5A 116 ++ ++ -2,8 ++ 3,5 ++ 1,0 ++ -1,1
Hs.434916 Syntaxin 7 STX7 116 ++ ++ -1,1 ++ 1,0 ++ 1,1 ++ 2,0
Hs.43812 Syntaxin 10 STX10 195 ++ ++ -2,1 ++ 2,3 ++ -1,1 ++ 1,1
Hs.325862 Syntaxin binding protein 1 STXBP1 239 ++ ++ -2,3 ++ 2,6 ++ 1,4 + -1,1
Hs.379204 Syntaxin binding protein 2 STXBP2 305 ++ ++ -2,0 ++ 2,1 ++ 1,0 ++ 1,1
Hs.20021 Vesicle-associated membrane protein 1 (synaptobrevin 1) VAMP1 118 + ++ -2,1 ++ 2,6 ++ -1,4 + 1,0
Hs.25348 Vesicle-associated membrane protein 2 (synaptobrevin 2) VAMP2 99 ++ ++ -2,8 + 1,5 + -1,5 + 1,1
Hs.66708 Vesicle-associated membrane protein 3 (cellubrevin) VAMP3 1204 ++ ++ 1,1 - -1,4 - -1,4 ++ 4,6
Hs.6651 Vesicle-associated membrane protein 4 VAMP4 193 ++ ++ -2,0 ++ 1,5 ++ 1,1 ++ 1,0
Hs.534425 Vesicle-associated membrane protein 5 (myobrevin) VAMP5 18 - - -4,6 ++ 4,9 ++ -2,6 + -3,5
Hs.165195 VAMP-associated protein A, 33kDa VAPA 2178 ++ ++ 1,3 + 1,4 + 2,0 ++ 1,0
Hs.24167 Synaptobrevin-like 1 SYBL1 649 ++ ++ 1,1 ++ -1,7 + 1,1 ++ 2,8
Hs.414343 Synaptogyrin 1 SYNGR1 52 + ++ -1,7 + 5,3 ++ 1,5 + 1,1
Hs.401730 Synaptojanin 1 SYNJ1 183 ++ + 1,1 ++ -1,3 + -1,5 ++ 2,3
Hs.434494 Synaptojanin 2 SYNJ2 66 + ++ -1,4 - -2,6 ++ 2,8 + -1,1
Hs.443661 Synaptojanin 2 binding protein SYNJ2BP 58 ++ ++ -1,1 ++ -2,5 - -1,4 ++ 1,7
Hs.154679 Synaptotagmin I SYT1 134 ++ ++ -2,0 ++ 1,9 ++ -1,1 + 1,3
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In apoE3/E3 macrophages, microarray analysis revealed the expression of n=100 genes 
which, based on their biological context, could stringently be assigned to the calcium 
transport pathway. Among these, n=44 (44%) genes were regulated by cholesterol flux 
and n=17 (17%) genes displayed a significant downregulation response to E-LDL load 
and even n=21 (21%) genes were upregulated during deload of E-LDL loaded 
macrophages.  
As for Ox-LDL, only n=6 (6%) were downregulated upon loading and three were 
coordinately regulated, those are S100 calcium binding proteins (A8, A9, A12). Moreover, 
the calcium binding protein A8 (calgranulin A) was the strongest regulated gene in this 
pathway, with a 45.3- and 90.5- fold downregulation upon E-LDL and Ox-LDL load, 
respectively (Table 16). 
 
6.3.5. REGULATION OF GENES IN THE CALCIUM SIGNALLING PATHWAY IN 
MACROPHAGES  
Table 15: Genes related to  the budding and fusion pathway that are regulated by  
E-LDL and Ox-LDL loading and successive HDL3-mediated deloading. 
0 COP-machinery
Hs.25277 ARF-GAP, RHO-GAP, ankyrin repeat and plekstrin homology ARAP3 314 ++ ++ -2,0 + 2,3 + -1,3 + 1,2
Hs.25584 ADP-ribosylation factor GTPase activating protein 1 ARFGAP1 216 ++ ++ -2,0 + 2,6 ++ 1,0 + -1,1
Hs.310323 ADP-ribosylation factor guanine nucleotide-exchange factor 2 ARFGEF2 502 ++ ++ 1,5 ++ -2,0 ++ 1,2 ++ 1,7
Hs.6838 Ras homolog gene family, member E ARHE 62 + + 2,3 ++ -1,7 ++ 1,2 ++ 1,7
Hs.127602 Rho GTPase activating protein 10 ARHGAP10 188 + + -1,6 + 3,7 + 1,2 + 1,0
Hs.435063 Rho GTPase activating protein 22 ARHGAP22 35 + + -1,4 ++ 2,3 + 1,1 + -1,2
Hs.444036 Rho GTPase activating protein 4 ARHGAP4 70 ++ + -2,0 ++ 2,6 ++ -1,6 ++ 1,1
Hs.6066 Rho guanine nucleotide exchange factor (GEF) 4 ARHGEF4 39 + + -2,0 + 1,5 ++ 1,1 + -1,3
Hs.355832 Cell division cycle 42 (GTP binding protein, 25kDa) CDC42 436 ++ ++ 1,7 ++ -1,1 ++ 1,0 ++ 2,5
Hs.510533 CDC42 binding protein kinase beta (DMPK-like) CDC42BPB 68 ++ ++ -2,8 ++ 2,5 ++ -1,1 + -1,1
Hs.372800 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 ARHGEF6 206 ++ ++ -2,0 ++ 2,6 ++ -1,4 ++ 1,1
Hs.162121 Coatomer protein complex, subunit alpha COPA 767 ++ ++ -1,2 ++ -1,3 ++ -1,2 ++ 2,0
Hs.10326 Coatomer protein complex, subunit epsilon COPE 433 ++ + -1,6 + 1,3 + -1,1 + 2,0
Hs.6671 COP9 constitutive photomorphogenic homolog subunit 4 (Arabidopsis) COPS4 467 ++ ++ 1,1 ++ 1,3 ++ 2,0 ++ 1,2
Hs.15591 COP9 constitutive photomorphogenic homolog subunit 6 (Arabidopsis) COPS6 336 ++ ++ -1,3 ++ 2,8 ++ 2,0 ++ 1,2
Hs.286221 ADP-ribosylation factor 1 ARF1 557 ++ ++ 1,1 + -2,3 ++ -1,1 ++ 2,8
Hs.119177 ADP-ribosylation factor 3 ARF3 689 ++ ++ -1,5 ++ 2,6 ++ 1,0 ++ 1,1
Hs.89474 ADP-ribosylation factor 6 ARF6 215 ++ + 1,0 + -4,0 + -1,1 ++ 3,2
Hs.372616 ADP-ribosylation factor-like 1 ARL1 328 ++ ++ 1,2 ++ -1,1 ++ 1,2 ++ 2,0
Hs.182215 ADP-ribosylation factor-like 3 ARL3 191 ++ ++ -1,1 ++ 2,0 ++ 1,4 ++ 1,1
Hs.245540 ADP-ribosylation factor-like 4 ARL4 110 + + 1,5 + -1,1 + 2,3 ++ 1,4
Hs.111554 ADP-ribosylation factor-like 7 ARL7 30 + ++ -1,3 ++ 1,0 ++ 2,0 ++ -2,8
Hs.277255 ADP-ribosylation factor-like 10C ARL10C 1417 ++ ++ 1,3 ++ 1,0 ++ 2,0 ++ 1,1
Hs.9552 ADP-ribosylation factor-like 2 binding protein ARL2BP 426 ++ ++ -1,2 + 1,1 ++ -1,2 + 2,1
Hs.405689 ARF binding protein 1, golgi associated, gamma adaptin ear containing GGA1 1742 ++ ++ -1,6 ++ 2,6 ++ 1,5 ++ -1,3
Hs.133340 ARF binding protein 2, golgi associated, gamma adaptin ear containing GGA2 138 ++ ++ 1,0 ++ 1,1 ++ 1,1 ++ 2,6
Hs.87726 ARF binding protein 3, golgi associated, gamma adaptin ear containing GGA3 226 ++ ++ -2,0 ++ 1,1 ++ -1,1 + 1,1
Hs.107614 Sec 6 (S. cerevisiae) homolog SEC6 99 + ++ -1,7 ++ 4,3 ++ 1,7 ++ -2,3
Hs.272927 Sec23 homolog A (S. cerevisiae) SEC23A 180 ++ ++ 1,3 ++ 1,1 ++ 2,0 ++ 1,2
Hs.173497 Sec23 homolog B (S. cerevisiae) SEC23B 413 ++ ++ -1,3 ++ 1,2 ++ -1,4 ++ 2,6
Hs.300208 Sec23 interacting protein SEC23IP 273 ++ + 1,5 - -1,6 + 1,6 ++ 2,8
Hs.365863 Sec10-like 1 (S. cerevisiae) SEC10L1 215 ++ - 3,5 - -5,7 - -1,1 + 18,4
Hs.75232 Sec14-like 1 (S. cerevisiae) SEC14L1 109 ++ ++ -1,4 + -1,7 + -2,1 ++ 2,3
Hs.430576 Sec14-like 2 (S. cerevisiae) SEC14L2 32 + + -1,1 + 3,0 + 1,4 + -1,9
Hs.330767 Sec63-like (S. cerevisiae) SEC63 201 ++ ++ -1,3 + -1,4 + -2,1 ++ 2,0
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S100 calcium binding proteins are members of a multigenic family that comprises 
19 members and are differentially expressed in a large number of cell types. 
Members of this protein family have been implicated in the Ca2+-dependent 
regulation of a variety of intracellular activities such as protein phosphorylation, 
enzyme activities, cell proliferation and differentiation, the dynamics of 
cytoskeleton constituents, the structural organization of membranes, intracellular 
Ca2+-homeostasis, inflammation, and in protection from oxidative cell damage. 
S100 proteins probably are an example of calcium-modulated, regulatory proteins 
that intervene in the fine tuning of a relatively large number of specific intracellular 
and extracellular activities.  
 
 
 
Table 16: Genes related to  the calcium signalling and metabolism pathway that are 
regulated by E-LDL and Ox-LDL loading and successive HDL3-mediated deloading. 
0 Ca++
Hs.75527 adenylosuccinate lyase ADSL 486 ++ ++ -1,1 ++ 2,0 ++ 2,0 ++ 1,0
Hs.65425 calbindin 1, 28kDa CALB1 24 + + -4,6 + 6,5 - -1,3 + -1,1
Hs.406234 calcium binding protein P22 CHP 473 ++ ++ -1,4 ++ 2,1 ++ 1,5 ++ -1,1
Hs.425808 calmodulin 2 (phosphorylase kinase, delta) CALM2 6032 ++ ++ 1,2 ++ 1,5 ++ -1,1 ++ 2,0
Hs.334330 calmodulin 3 (phosphorylase kinase, delta) CALM3 288 ++ ++ -1,1 ++ 2,5 ++ -1,3 ++ 1,6
Hs.155560 calnexin CANX 2740 ++ ++ 1,1 ++ 1,3 ++ 1,6 ++ 1,3
Hs.388469 calpain, small subunit 1 /// calpain, small subunit 1 CAPNS1 828 ++ ++ -1,1 ++ 1,0 ++ -1,2 ++ 2,0
Hs.350899 calpain 2, (m/II) large subunit CAPN2 2478 ++ ++ 2,0 ++ -1,1 ++ 2,8 ++ 1,6
Hs.433673 calreticulin CALR 859 ++ ++ -4,6 ++ 9,2 ++ 1,1 ++ -1,5
Hs.355832 Cell division cycle 42 (GTP binding protein, 25kDa) CDC42 436 ++ ++ 1,7 ++ -1,1 ++ 1,0 ++ 2,5
Hs.172674 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 NFATC3 240 ++ ++ -1,1 ++ -1,5 ++ 1,2 ++ 2,3
Hs.85701 phosphoinositide-3-kinase, catalytic, alpha polypeptide PIK3CA 122 ++ ++ -1,1 ++ -1,7 ++ -1,2 ++ 2,6
Hs.239818 phosphoinositide-3-kinase, catalytic, beta polypeptide PIK3CB 233 ++ ++ -1,1 ++ 2,0 ++ 2,0 ++ -1,5
Hs.355888 phospholipase C, beta 2 PLCB2 75 + + -1,6 + 2,8 + -1,2 + 1,5
Hs.437137 phospholipase C, beta 3 (phosphatidylinositol-specific) PLCB3 107 + + -2,0 + 3,7 + 1,0 + 1,1
Hs.349611 protein kinase C, alpha PRKCA 349 ++ ++ 1,0 ++ 1,5 ++ -1,6 ++ 2,0
Hs.155342 protein kinase C, delta PRKCD 661 ++ ++ -1,2 ++ -1,1 ++ -2,0 ++ 2,6
Hs.315366 protein kinase C, eta PRKCH 239 ++ ++ -1,4 ++ 1,3 ++ 2,0 ++ -1,1
Hs.280604 protein phosphatase 3 (calcineurin B, type I) PPP3R1 121 ++ ++ -2,0 ++ 2,6 ++ 1,2 ++ 1,0
Hs.81256 S100 calcium binding protein A4 (calvasculin, metastasin) S100A4 2209 ++ ++ -1,1 ++ 2,8 ++ 1,5 ++ -1,1
Hs.416073 S100 calcium binding protein A8 (calgranulin A) S100A8 4289 ++ ++ -45,3 ++ 6,5 ++ -90,5 ++ 6,5
Hs.112405 S100 calcium binding protein A9 (calgranulin B) S100A9 861 ++ ++ -4,3 ++ 4,0 ++ -16,0 ++ 6,1
Hs.19413 S100 calcium binding protein A12 (calgranulin C) S100A12 145 ++ ++ -2,3 ++ 1,6 + -2,1 + 1,2
Hs.446592 S100 calcium binding protein A13 S100A13 315 ++ ++ -2,3 + 2,5 ++ -1,1 ++ -1,3
Hs.288998 S100 calcium binding protein A14 S100A14 88 ++ + -2,3 + 1,6 + -1,4 + 1,5
Hs.2962 S100 calcium binding protein P S100P 58 ++ ++ -7,5 + 10,6 + 2,8 + -1,6
Hs.83760 troponin I, skeletal, fast TNNI2 5 - - 1,5 ++ 3,2 ++ 2,6 + 1,1
Hs.436186 type 1 tumor necrosis factor receptor shedding aminopeptidase regulator ARTS-1 143 ++ ++ 1,0 ++ 2,8 ++ 2,1 ++ 1,0
0 Channels
Hs.149900 inositol 1,4,5-triphosphate receptor, type 1 ITPR1 165 ++ ++ 1,2 ++ 1,0 ++ 2,6 ++ -1,2
Hs.427717 ryanodine receptor 3 RYR3 66 ++ ++ -2,1 ++ 1,7 ++ -1,1 ++ 1,3
Hs.406751 inositol 1,4,5-triphosphate receptor, type 2 ITPR2 57 ++ ++ -1,6 ++ 1,7 ++ -2,1 ++ 1,4
Hs.154210 endothelial differentiation, sphingolipid G-protein-coupled receptor, 1 EDG1 31 + + -3,5 ++ 4,0 ++ -1,5 + -1,1
Hs.125116 Calcium channel, voltage-dependent, alpha 1I subunit CACNA1I 90 + + -2,5 + 3,0 + -1,1 + 1,1
Hs.400460 Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit CACNA1A 63 ++ ++ -2,0 + 2,1 ++ -1,4 ++ 1,4
Hs.371458 Chloride channel 6 CLCN6 160 + + -2,3 + 1,6 + -2,0 + 2,0
Hs.408883 Sodium channel, voltage-gated, type I, beta SCN1B 51 + + -1,6 + 2,3 + -1,5 + 1,4
Hs.186877 Sodium channel, voltage-gated, type XI, alpha SCN11A 48 ++ ++ -2,1 ++ 2,3 ++ 1,3 ++ -1,2
Hs.121495 Potassium voltage-gated channel, Isk-related family, member 1 KCNE1 63 + + -2,3 ++ 2,3 + -1,1 + 1,0
Hs.354740 Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 KCNMA1 53 - - -1,7 ++ 4,3 ++ 1,1 ++ 1,0
Hs.463 Potassium inwardly-rectifying channel, subfamily J, member 1 KCNJ1 8 - - -4,0 - 4,9 - -8,0 - 1,4
Hs.1547 Potassium inwardly-rectifying channel, subfamily J, member 2 KCNJ2 367 ++ ++ -1,1 ++ 1,4 ++ -2,5 ++ 2,1
Hs.10082 Potassium intermediate/calcium-activated channel, subfamily N, member 4 KCNN4 1001 ++ ++ -1,1 ++ 2,0 ++ -1,7 ++ 2,0
Load
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This category contains ABCA1-related genes, their interaction partners and genes 
involved in lipid metabolism in addition to genes which are, at least on the transcriptional 
level, similarly regulated as ABCA1. It is noticeable that from n=196 genes, n=36 (18.4%) 
are being downregulated upon E-LDL load, whereas n=34 (17.3%) are being upregulated 
by further deloading with HDL3 (Table 17).  
 
Among those genes was the sterol regulatory element binding transcription factor 
(SREBF1) which was downregulated by E-LDL load, 3-hydroxy-3-methylglutaryl-
Coenzyme A reductase which was only Ox-LDL sensitive and was downregulated by load 
and upregulated by deload. In addition, genes involved in proteasomal degradation like 
(HSPA8; HSPD1; PSMA1; PSMC2; PSMD1; SLC’s; Ubiquitination proteins) and genes 
functional in phagosomal maturation and degradation (RAB; RAS) were regulated, raising 
6.3.6. REGULATION OF ABCA1-RELATED GENES IN THE EXOCYTOSIS PATHWAY
IN MACROPHAGES 
Table 17: Genes related to  the exocytosis pathway and regulated by E-LDL and 
Ox-LDL loading and further HDL3-mediated deloading. 
0 Exocytosis
Hs.147259 ATP-binding cassette, sub-family A (ABC1), member 1 ABCA1 130 ++ ++ 2,0 ++ -1,4 ++ 2,0 ++ -1,2
Hs.21330 ATP-binding cassette, sub-family B (MDR/TAP), member 1 ABCB1 95 ++ ++ -3,2 + 3,0 + -1,1 + -1,1
Hs.496383   Acyl-Coenzyme A: cholesterol acyltransferase) 1 SOAT1 188 ++ ++ 2,0 ++ -1,7 ++ 2,1 ++ 1,5
Hs.25584 ADP-ribosylation factor GTPase activating protein 1 ARFGAP1 216 ++ ++ -1,9 + 2,6 ++ 1,0 + -1,1
Hs.436683 AFG3 ATPase family gene 3-like 2 (yeast) AFG3L2 263 ++ ++ -1,1 ++ 2,1 ++ 2,3 ++ -1,4
Hs.355832 Cell division cycle 42 (GTP binding protein, 25kDa) CDC42 436 ++ ++ 1,7 ++ -1,1 ++ 1,0 ++ 2,5
Hs.162121 Coatomer protein complex, subunit alpha COPA 767 ++ ++ -1,2 ++ -1,3 ++ -1,2 ++ 2,0
Hs.9641 Complement component 1, q subcomponent, alpha polypeptide C1QA 35 + + -3,7 ++ 4,6 ++ -4,6 ++ 1,1
Hs.272813 Dual oxidase 1 DUOX1 38 ++ ++ -2,8 + 1,5 + 1,0 + 1,0
Hs.82002 Endothelin receptor type B EDNRB 55 ++ + -2,1 ++ 2,1 + -1,2 + 1,1
Hs.77432 Epidermal growth factor receptor EGFR 46 ++ ++ -2,3 ++ 2,5 ++ -1,1 ++ 1,2
Hs.179986 Flotillin 1 FLOT1 564 ++ ++ -2,0 ++ 1,7 ++ 1,0 ++ 1,0
Hs.18799 Flotillin 2 FLOT2 528 ++ ++ -2,0 ++ 2,1 ++ -1,2 ++ 1,4
Hs.446309 Glutathione S-transferase A1 GSTA1 107 ++ ++ -2,5 ++ 2,1 ++ -1,1 ++ 1,1
Hs.279837 Glutathione S-transferase M2 (muscle) GSTM2 132 ++ ++ -3,2 + 6,1 + -1,5 ++ 1,6
Hs.2006 Glutathione S-transferase M3 (brain) GSTM3 107 ++ ++ -3,2 ++ 3,0 ++ 1,2 ++ 1,2
Hs.405689 Golgi associated, gamma adaptin ear containing, ARF binding protein 1 GGA1 1742 ++ ++ -1,6 ++ 2,6 ++ 1,5 ++ -1,3
Hs.406751 Inositol 1,4,5-triphosphate receptor, type 2 ITPR2 57 ++ ++ -1,6 ++ 1,7 ++ -2,1 ++ 1,4
Hs.212296 Integrin, alpha 6 ITGA6 68 ++ ++ 1,7 + 1,0 ++ 2,1 ++ 1,1
Hs.76038 Isopentenyl-diphosphate delta isomerase IDI1 1063 ++ ++ -4,0 ++ 3,7 ++ -2,0 ++ 1,7
Hs.213289 Low density lipoprotein receptor (familial hypercholesterolemia) LDLR 990 ++ ++ -8,6 ++ 3,2 ++ -4,0 ++ 1,4
Hs.433391 Metallothionein 1G MT1G 523 ++ ++ -4,0 ++ 3,7 ++ 4,9 ++ -4,3
Hs.438462 Metallothionein 1H MT1H 493 ++ ++ -5,3 ++ 5,3 + 4,6 ++ -4,3
Hs.101474 Microtubule associated serine/threonine kinase 2 MAST2 149 ++ ++ -1,3 ++ 2,6 ++ 1,4 ++ -1,2
Hs.196914 Minor histocompatibility antigen HA-1 HA-1 239 ++ ++ -2,0 ++ 3,7 ++ 1,1 + -1,7
Hs.173878 Nipsnap homolog 1 (C. elegans) NIPSNAP1 86 + + -2,5 ++ 2,6 ++ -1,6 ++ -1,2
Hs.439312 Phospholipid transfer protein PLTP 4 - + -1,4 ++ 1,1 ++ -3,0 ++ 1,5
Hs.24557 RAB11 family interacting protein 5 (class I) RAB11FIP5 115 ++ ++ -2,5 ++ 2,5 ++ -1,1 ++ -1,1
Hs.190284 sterol regulatory element binding transcription factor 1 SREBF1 77 + + -3,2 ++ 1,7 + 1,1 + -1,6
Hs.372800 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 ARHGEF6 206 ++ ++ -2,0 ++ 2,6 ++ -1,4 ++ 1,1
Hs.349656 Scavenger receptor class B, member 2 SCARB2 512 ++ ++ 2,0 ++ -2,8 ++ -2,3 ++ 6,1
Hs.437096 SREBP CLEAVAGE-ACTIVATING PROTEIN SCAP 182 ++ ++ -1,9 ++ 2,6 ++ 1,4 + -1,3
Hs.439776 Stomatin STOM 660 ++ ++ -2,0 ++ 2,5 ++ -1,2 ++ -1,1
Hs.414343 Synaptogyrin 1 SYNGR1 52 + - -1,7 + 5,3 ++ 1,5 + 1,1
Hs.434494 Synaptojanin 2 SYNJ2 66 + + -1,4 - -2,6 + 2,8 + -1,1
Hs.443661 Synaptojanin 2 binding protein SYNJ2BP 58 ++ ++ -1,1 ++ -2,5 ++ -1,4 ++ 1,7
Hs.1501 Syndecan 2 (heparan sulfate proteoglycan 1) SDC2 4756 ++ ++ 1,4 ++ -1,1 ++ 2,1 ++ -1,1
Hs.397729 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) HMGCS1 291 ++ ++ -2,1 ++ 3,0 ++ -2,1 ++ 1,9
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the assumption that the proteasome might be involved in degradation of apolipoprotein 
components. 
The ATPase, H+ transporting, lysosomal 34 kDa, V1 subunit D was identically regulated 
as ABCA1, as was acetyl-Coenzyme A acetyl-transferase 1 (SOAT1),  implicating the 
theory that ATP-synthases may be involved in cholesterol uptake or depletion. In order to 
further strengthen this hypothesis, all significantly ATP-synthases were listed to see their 
expression at loading and further deloading. From n=18 ATP-synthase encoding genes, 
n=8 (44%) were upregulated by E-LDL deload but did not respond to Ox-LDL deloading 
(Table 18).  
This indicates a more close relationship of the E-LDL uptake route, which enters the cell 
outside coated pits, with the membrane ATP-synthase complex than Ox-LDL which enters 
the cell via coated-pit dependent receptors. 
Table 18: ATP-synthases and their regulation by E-LDL and Ox-LDL loading and 
successive HDL3-mediated deloading. 
0 ATP synthases
Hs.80986 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1 ATP5G1 329 ++ ++ -1,1 ++ 2,8 ++ 1,7 + 1,2
Hs.85539 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit e ATP5I 683 ++ + 1,0 ++ 3,5 ++ 1,7 ++ -1,5
Hs.235557 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit f, isoform 2 ATP5J2 1456 ++ + -1,2 ++ 2,5 + 1,4 + 1,2
Hs.107476 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit g ATP5L 2553 ++ - -1,5 ++ 2,6 + 1,2 + 1,1
Hs.298280 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1 ATP5A1 2223 ++ + 1,1 + 2,3 ++ 1,6 - 1,2
Hs.406510 ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide ATP5B 2246 ++ ++ 1,0 ++ 2,0 ++ 1,6 ++ 1,4
Hs.501304 ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit ATP5D 339 ++ ++ -1,7 ++ 2,8 - -1,1 - 1,0
Hs.177530 ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit ATP5E 2085 ++ ++ 1,1 ++ 2,1 ++ 1,6 ++ -1,4
Hs.409140 ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit ATP5O 1444 ++ ++ -1,1 + 2,3 + 1,5 + 1,1
Hs.386678 solute carrier family 16 (monocarboxylic acid transporters), member 3 SLC16A3 1216 ++ ++ -2,0 ++ 2,6 ++ -1,6 ++ 1,1
Hs.79172 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5 SLC25A5 2961 ++ ++ -1,2 ++ 2,0 ++ 1,4 ++ 1,1
Hs.350927 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6 SLC25A6 1768 ++ ++ -2,1 ++ 3,5 ++ 1,4 ++ -1,2
Hs.32951 solute carrier family 29 (nucleoside transporters), member 2 SLC29A2 36 + + -11,3 + 12,1 + -1,4 + 1,1
Hs.407135 adenosine deaminase ADA 59 + ++ -2,5 ++ 2,0 ++ -1,5 + -1,1
Hs.148822 adenosine deaminase, RNA-specific, B1 (RED1 homolog rat) ADARB1 109 + + -1,9 + 2,5 + -1,1 + 1,1
Hs.82927 adenosine monophosphate deaminase 2 (isoform L) AMPD2 558 ++ ++ -3,7 ++ 4,9 ++ -1,3 ++ -1,4
Hs.205353 ectonucleoside triphosphate diphosphohydrolase 1 ENTPD1 241 ++ ++ -1,4 ++ 4,9 ++ -2,0 ++ 1,7
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ABC transporters have various functions in the human body and several ABC proteins 
(MDRs, MRPs, ABCG2) are responsible for drug export in treated tumor cells, providing 
cellular mechanisms for the development of multi drug resistance. Also, ABC transporters 
have greatly gained attention because mutations in these proteins are the cause of human 
inherited diseases. Among these are familial HDL deficiency also referred to as Tangier 
disease caused by mutations in ABCA1 21,24,159 cystic fibrosis caused by mutations in the 
ABCC7/CFTR gene 41, and sulfonylurea receptor ABCC8/SUR mutations associated with 
familial persistent hyperinsulinemic hypoglycemia of infancy (PHHI) which is characterized 
by dysregulated insulin secretion from pancreatic beta cells. 
Since the identification of ABCA1 as a major component of the reverse cholesterol and 
phospholipid transport pathway, it is important to elucidate its functions and to identify its 
interaction partners. In addition, ABCA1 expressed in the liver, is the major player in the 
determination of plasma HDL-cholesterol and also exerts HDL-independent anti-
atherogenic properties by reducing monocyte filopodia formation and subsequent 
subendothelial migration.  
Several factors control the expression and activity of ABCA1. Lipid uptake by macrophage 
cells has been shown to be a potent inducer of ABCA1 expression 115. Several 
transcriptional control elements acting via alternative promoters have been characterized. 
The ABCA1 upstream region contains a macrophage specific promoter preceding exon 1. 
This sequence binds the repressors ZNF202 and USF1/2, as well as the activating factors 
Sp1/Sp3 and the oxysterol-induced RXR/LXR heterodimer 166. The LXR/RXR responsive 
elements in promoter 1 triggers retinoic acid and oxysterol dependent activation of the 
ABCA1 promoter and thereby confer the observed induction of ABCA1 during lipid loading 
of macrophages. 
The identification and molecular understanding of ABCA1-associated proteins will provide 
important insights into ABCA1 function. ApoA-I, as a primary acceptor of phospholipids, 
associates with ABCA1 195 as does Cdc42 52.  
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In this thesis we were able to show that ABCA1 interacts with several other proteins, 
namely: FADD, β2-syntrophin, syntaxin 13 and flotillin-1, figure 42 shows the domains of 
ABCA1 and the interacting partners. 
Fas-associated death domain protein (FADD) is an adaptor molecule that bridges the 
interactions between membrane death receptors (FAS) and initiator caspases, namely 
caspase-8 and caspase-10, in the cytoplasmic death-inducing signaling complex (DISC). 
Recent evidence indicates that FADD primarily resides in the nucleus and appears to 
shuttle between nucleus and cytoplasm. FADD plays a well-established role in 
transduction of apoptotic signals and other cellular processes. 
We provided evidence that FADD directly interacts with ABCA1 in the hepatoma cell line 
HepG2, in the megakaryoblastic leukemia cell line Meg-01, and in primary human 
fibroblasts indicating that the association of ABCA1 with FADD is not cell-type specific. 
The FADD-ABCA1 interaction is a surprising finding that links HDL metabolism and 
reverse lipid efflux with a protein mainly described in the context of death receptor-
induced apoptosis. Recombinant expression of the ABCA1 C-terminus and FADD-DN 
significantly reduced cellular efflux of choline phospholipid to apoA-I. This underlines the 
importance of proteins associated with the C-terminus of ABCA1 for ABCA1 function and 
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Figure 42: The domains of ABCA1 and interacting partners. 
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indicates that full-length FADD is one of these accessory proteins. The death effector 
domain of FADD is known to interact with the death effector domain of caspase 8 87. 
However, caspase 8 was not found in ABCA1/FADD complexes, and activation of 
caspases was not necessary for apoA-I- dependent phospholipid efflux. The expression of 
FADD was found to be reduced in primary fibroblasts from five TD patients compared with 
fibroblast from four controls. FADD expression was not altered in cholesterol-loaded or 
serum-starved cells nor influenced by stimulating reverse lipid efflux, and therefore the 
reduced expression of FADD in TD fibroblasts is not a secondary response to disturbed 
cholesterol homeostasis. FADD expression was reduced in fibroblasts from patients with 
mutated ABCA1 but was not down-regulated in HepG2 cells stably expressing ABCA1 C 
terminus or FADD-DN with reduced apolipoprotein A-I-dependent phospholipid efflux. 
Therefore the reduced expression of FADD may be a consequence of absent or defective 
ABCA1 protein. ABCA1 was suggested to be a phosphatidylserine translocase that 
facilitates phosphatidylserine exofacial flipping. The transient local exposure of anionic 
phospholipids in the outer membrane leaflet enhances the engulfment of apoptotic cells 75, 
endocytosis 207, and binding of apoA-I. The association of ABCA1 with FADD shown here 
and the high expression of ABCA1 on platelets may reflect an ABCA1-related 
phosphatidylserine translocase effect. Alternatively the FADD/ABCA1 interaction may 
indicate an anti-apoptotic ABCA1 function independent from phosphatidylserine 
translocase activity.  
Members of the ABC transporter superfamily are highly homologous. The alignment of the 
C-terminal region of ABCA1 and ABCR, the knowledge of causal mutations or 
polymorphisms, in addition to the recent finding that ABCA1 is not an active pump but 
may rather function as a regulator similar to ABCC7 (CFTR) or ABCC8 (SUR1) may be a 
useful approach to identify amino acids or peptides with important functions in these 
proteins. Besides the high conservation within the ABCA proteins, the C-terminal peptide 
sequence of ABCA1 is unique within this protein family representing a PDZ site. CFTR 
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was already shown to associate with PDZ domains 14. The syntrophins α, β1, β2, γ1, γ2 are 
intracellular membrane proteins with multiple protein interaction domains. These include 
two functional pleckstrin homology domains (PH), a PDZ domain, and a C-terminal 
syntrophin-unique (SU) region. PH domains bind to proteins or phosphatidylinositol lipids 
and may mediate signal dependent membrane association. PDZ domains are molecular 
adaptors and position their targets in the appropriate position or cell compartments. PDZ 
domains either bind to carboxyterminal peptides or interact with a second PDZ domain. 
The second PH domain and the highly conserved SU domain of syntrophins are required 
for interaction with dystrophin/utrophin, and β2-syntrophin was found to be mainly 
associated with utrophin in skeletal muscle. In utrophin and dystrophin a central helical 
coiled-coil domain separates the actin binding N-terminal domain from the cysteine-rich C-
terminal region. The WW domain in the cysteine-rich C-terminal region interacts with β-
dystroglycan whereas the final C-terminal region of utrophin may associate with 
dystrobrevins and syntrophin. β2-Syntrophin was shown here to be expressed in 
monocytes, macrophages, fibroblasts, and megakaryocytic cells and therefore may be a 
general adaptor of membrane proteins to the actin cytoskeleton via utrophin, a protein 
highly homologous to dystrophin, which is abundant in various cells and tissues.  
In this work we also identified β2-syntrophin as an ABCA1-interacting protein and further 
confirmed that utrophin also contributes to this complex. The function of this complex may 
be analogous to the ICA512 (islet cell autoantigen)-β2-syntrophin/utrophin complex in 
pancreatic β-cells where the exocytosis of secretory granules is hindered by the 
association of ICA512 enriched in the membrane of secretory vesicles with β2-
syntrophin/utrophin/actin complexes. Stimulation of insulin secretion results in the 
dephosphorylation of β2-syntrophin by an ocadaic acid-sensitive phosphatase that 
promotes the dissociation of ICA512 from β2-syntrophin and the subsequent release of 
these vesicles.  
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ABCA1 was found to reside on intracellular vesicles and the trafficking of these vesicles 
may be hindered by an association of ABCA1 to the cytoskeleton via β2-
syntrophin/utrophin. ABCA1 protein is induced during foam cell formation whereas similar 
amounts of ABCA1 were found to be associated with β2-syntrophin/ utrophin in E-LDL-
loaded macrophages and controls. This indicates that in cholesterol loaded macrophage 
induction of ABCA1 synthesis enlarges the pool of ABCA1 not linked to the cytoskeleton 
further supporting an inhibitory role of its β2-syntrophin association.  The C-terminal 
sequence (KESYV) of ABCA1 has already been described as a binding target for the PDZ 
domains syntrophin 65. ABC-transporters have different functions and can be classified 
according to their ATPase activity and Mg++-dependent ATP binding capacity, either as 
active transporters (transport pumps) revealing a high intrinsic ATPase activity like MDR1, 
or as transport regulators, having only a low ATPase activity like SUR1 and CFTR. The C-
terminus of CFTR has been shown to bind PSD95-Discs large-ZO1 (PDZ) domain 
proteins. Whereas, CFTR N-terminus interacts with syntaxin 1A and SNAP-23 44 known to 
form the N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex 
with synaptosomal-associated protein 25 (SNAP-25) and vesicle-associated membrane 
protein (VAMP). The SNARE protein syntaxin 1A is well described to directly bind to 
CFTR and to modulate its activity. Homologies in mechanism and structure between 
ABCA1 and CFTR led us to the assumption that ABCA1 may interact with syntaxins which 
we aimed to identify. The regulation of syntaxins 2, 3, 4, 6, 7, 8 and 13 was investigated in 
macrophages loaded with E-LDL and syntaxins 3, 6 and 13 were found induced in lipid-
loaded cells. Since ABCA1 is similarly regulated by atherogenic lipoproteins the direct 
interaction of ABCA1 with syntaxin 3, 6 and 13 was analyzed. Syntaxin 13 turned out to 
directly associate with ABCA1 whereas syntaxin 3 and 6 failed to bind to ABCA1. 
To gain further insights into the functionality, we silenced syntaxin 13 in PMA 
differentiated HL-60 using specific siRNA probes. This led to a decrease of both syntaxin 
13 and ABCA1 protein expression and reduced apoA-I mediated choline-phospholipid 
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efflux, indicating that syntaxin 13 stabilizes ABCA1 expression and thereby regulates 
ABCA1 mediated lipid release. ABCA1 co-purifies with Lubrol WX rafts and apoA-I 
preferentially depletes lipids from these microdomains 54. Both flotillin-1, recently 
described to copurify with Triton X-114 rafts, and syntaxin 13 were demonstrated in this 
thesis to be also associated with Lubrol WX rafts. Although flotillin-1 expression is not 
regulated during macrophage differentiation or incubation with atherogenic lipoproteins, 
flotillin-1 was found to directly interact with ABCA1 and therefore, ABCA1 forms a complex 
with either syntaxin 13, or flotillin-1 or both.  Besides being localized at the plasma 
membrane, detergent insoluble microdomains have been detected in phagosomes and 
endosomes and may control internalization pathways. ABCA1 was detected in 
endosomes 138 and may also associate with phagosomes. The phagosome proteome was 
recently described and flotillin-1 is highly abundant in this cellular compartment 64. 
Purification of phagosomal proteins using the method described by Desjardin et al. 50 and 
subsequent immunoblot analysis confirmed this finding and, in addition, identified ABCA1 
as a phagosomal protein. Syntaxin 13 was also co-purified and co-immunoprecipitation 
revealed a direct association of phagosomal ABCA1 and syntaxin 13.  
Endocytosis is increased in Tangier fibroblasts as a consequence of enhanced membrane 
inward bending related to the phosphatidylserine translocase function of ABCA1 207.  Type 
II phagocytosis occurs through sinking of the particles into the cell and inward bending of 
the membrane and therefore is also enhanced in cells with ABCA1 deficiency as was 
shown in this work. Recombinant expression of ABCA1 in Tangier fibroblasts normalized 
the uptake of phagobeads by Tangier cells providing additional evidence that ABCA1 is 
involved in phagocytosis. Furthermore the effect of type II phagocytosis includes the 
reorganization of the cytoskeleton and Rho A, and Rho A was found accumulated in 
Tangier fibroblasts. These findings are not contradictory to the observation that ABCA1 
promotes the engulfment of apoptotic cells, a phagocytic process involving Fcγ-receptors 
and pseudopodia extension initiated by outward bending of the membrane (type I 
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phagocytosis). Syntaxin 13 is a soluble NEM-sensitive factor-attachment protein receptor 
(SNARE) protein, a family of proteins which mediates the coordinated fusion of 
membranes through the formation of four-helical bundle structure protein complexes 188. 
Overexpression of syntaxin 13 blocks CFTR trafficking through the non-conventional 
pathway from the ER to the Golgi indicating a role of syntaxin 13 in CFTR maturation 204.  
Furthermore, syntaxin 13 functions in membrane fusion events during the recycling of 
plasma membrane proteins as well as in lysosome and endosome fusion with the 
phagosome 42. These findings raise the possibility that syntaxin 13 plays a role in phago-
lysosomal release of lipids in macrophages. 
HDL is mainly internalized by a receptor-mediated pathway not associated with clathrin-
coated pits 162 and apoA-I was identified in phagosomes isolated with latex beads, further 
supporting an internalization pathway different from classical coated pit endocytosis. The 
identification of ABCA1 as a regulator of phagocytosis may indicate a crosstalk of 
phagocytic and endocytic pathways involved in ABCA1-mediated efflux with cholesterol 
deposited in late endosomes and lysosomes as the preferred source. The enhanced 
uptake of apoA-I by endocytic and phagocytic ingestion may also explain the increased 
catabolism of apoA-I in Tangier patients.  
In conclusion, our results indicate that ABCA1 forms a heteromeric complex with 
syntaxin 13 and flotillin-1. This complex is already formed in differentiated monocyte-
derived macrophages and does not require induction by E-LDL loading. Syntaxin 13 
deficiency causes ABCA1 protein degradation and therefore syntaxin 13 may be important 
in ABCA1 maturation and vesicular transport. These findings indicate that besides 
retroendocytosis of apoA-I and HDL, the phagosomal and lysosomal compartment may be 
involved in ABCA1 dependent choline-phospholipid efflux.  
The latter findings related to vesicular transport and fusion prompted us to search for the 
link between syntaxin 13 and intracellular lipid trafficking. This link was the syntaxin 13 
interacting protein (pallidin). Huang et al 86 showed that mutations in pallidin in mice lead 
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to „pallid“ and „gunmetal“ phenotypes. The latter mutants are defective in a more 
downstream event of vesicle-trafficking: namely, vesicle-docking and fusion. These mice 
suffer from hypo pigmentation, lung fibrosis, kidney lysosomal enzyme elevation and 
prolonged bleeding. Other described mutations in mice like the „mocha” and „pearl” mice 
have platelet storage pool deficiency (SPD), these mutants have defects in the Ap-3 
complex 86,199.  In drosophila, mutations in the adapter related protein complex 3 (AP-3) as 
well as mutations in ABCG5 and ABCG8 (both half-size ABC transporters which interact 
to form the functional full-size) lead to changes in the eye color, due to trafficking 
disturbances in lysosomes and related organelles 88.  
In humans these phenotypes refer to diseases called Hermansky-Pudlak syndrome (HPS) 
and Chediak-Higachi syndrome (CHS), autosomal recessive disorders which lead to 
storage defects resulting, among others, from defects in secretory lysosomes. This leads 
to pulmonary fibrosis and prolonged bleeding. 
Biochemical and genetic evidence indicates that the HPS-associated genes encode 
components of at least 3 distinct protein complexes: the adapter complex AP-3; the 
HPS1/HPS4 complex; and BLOC-1 (biogenesis of lysosome-related organelles complex-
1), consisting of the proteins encoded at 2 mouse HPS loci, pallid  and muted, and at least 
3 other unidentified proteins. 
The AP-3 pathway has many constituents as shown in literature: ARL7 57, Syntaxin 13 
and ABCA1 10, Syntaxin 13-interacting protein (pallidin), Cdc42 83,163 ABCG1/G2/G4 
(which leads to mutations: white, brown and scarlet), HPS1-7:Hermansky-Pudlak-
Syndrome complex, P2-Purinergic receptors and GIRKs (G-protein coupled inward 
rectifying K-channels). 
ABCA1 interacts with syntaxin 13 which in turn is linked to pallidin the syntaxin 13 
interacting protein, the latter is linked to bleeding disorders in mice. This suggested 
pattern would create a direct link between ABCA1 and congenital bleeding disorders. 
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Recent publications show evidence that HDL-deficiency in Tangier patients is related to 
impaired platelet activation, which in turn results from genetic defects in the AP-3 gene 141. 
Lipoprotein analysis of sera from pallidin knock-out and pallidin wild type mice performed 
at our institute indicated that pallidin knock-out mice had less free cholesterol and less 
triglyceride compared to wild type mice. In addition, the composition of HDL revealed that 
pallidin knock-out mice had less sphingomyelin (SPM) and less phosphatidylcholine (PC). 
In the cellular membrane, phosphatidylserine (PS) and phosphatidylethanolamine (PE) 
are mainly located in the inner monolayer whereas the outer layer consists dominantly of 
the choline-containing phospholipids, phosphatidylcholine (PC) and sphingomyelin (SPM) 
170. 
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An initial process in coagulation is the loss of membrane asymmetry and the redistribution 
of PS from the inner to the outer leaflet of the platelet plasma membrane 113. At least in 
monocytic cells, ABCA1 facilitates PS exofacial flipping 74 and the high abundance of 
ABCA1 in platelets would suggest a similar action in thrombocytes. 
Besides residing at the plasma membrane, ABCA1 is located in phagosomes and 
additional lysosome-related cellular compartments. A defect in lysosome-related 
compartments may impair the transport of ABCA1 to the cell membrane leading to loss of 
ABCA1-dependent PS flipping. This could eventually lead to impaired coagulation and 
prolonged bleeding in the pallidin mouse. Furthermore, cholesterol may be trapped in 
lysosomes due to defects in BLOC-1 and AP-3 pathway. This might explain reduced free 
cholesterol in the HDL fraction. 
The gene expression profiling data presented in this study reveal that in human 
macrophages cholesterol influx and efflux is associated with the regulation of three major 
functional pathways of the cell: the nuclear compartment, the ribosomal complex and the 
ubiquitin proteasome pathway. Importantly, our results demonstrate differential regulation 
during E-LDL and Ox-LDL loading and further HDL3 dependent deloading of these 
pathways in cells carrying the Apo E3/E3 genotype. 
In Apo E3/E3 macrophages cholesterol efflux following E-LDL loading resulted in the 
synchronous upregulation of significant numbers of nuclear and ribosomal genes, while in 
HDL3-dependent deloading of Ox-LDL loaded macrophages the genes were not 
regulated. These findings provide evidence for differential regulation of nuclear and 
ribosomal genes in macrophage cholesterol export according to the type of modified LDL 
used to mimic atherogenic cholesterol loading. 
Nuclear and transcriptional genes were induced in HDL treated E-LDL foam cells but only 
minor regulatory response was detected in Ox-LDL loaded cells incubated with HDL3.  
Thus our data indicate that the export of E-LDL and Ox-LDL derived cholesterol involves 
clusters of inversely regulated nuclear, ribosomal and proteasomal networks suggesting 
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the involvement of distinct regulatory complexes in the cellular processing of either 
modified lipoprotein class. This is in agreement with our recent observation that E-LDL 
and Ox-LDL have a different impact on the cellular cholesterol and sphingolipid 
metabolism in macrophages (Paper accepted in Cytometry). 
Cholesterol uptake by macrophages mediated by E-LDL and Ox-LDL resulted in the 
suppression of components of the nuclear, ribosomal and proteasomal networks. This 
effect occurred largely independent of whether E-LDL or Ox-LDL was used as a 
cholesterol source; this is in contrasts to the inverse responses found during cholesterol 
export.  
Together, our results (i) identify the nuclear compartment, the ribosome and the ubiquitin 
proteasome system as transcriptional regulatory complexes involved in the control of 
cholesterol trafficking in the cell and (ii) demonstrate a differential regulation of gene 
clusters by two different modified LDL types. 
Among the nuclear genes that showed significant implication in cholesterol flux are the 
cyclins D1, D2, D3, E1, F and multiple components of the RNA polymerase II complex 
including the RNA polymerase II peptides A, E, F, H, I, and L, respectively. To date, little 
is known about the role of cholesterol within the nucleus. A recent report demonstrated 
that inhibition of cholesterol esterification in vascular smooth muscle cells, which induces 
their arrest in G1, is accompanied by down-regulation of cyclin D1 mRNA thus 
establishing a link between cholesterol metabolism and the control of cell cycle G1/S 
transition 11. Our finding that cholesterol export induces the concerted upregulation of the 
mRNAs of multiple cyclins strongly supports the existence of an interlink between the cell 
cycle and cholesterol trafficking. Recently, the presence of cholesterol has been 
demonstrated in chromatin and two fractions were identified, one soluble and another 
which is only extractable after SMase or proteinase K digestion 3. Although initial data 
point to a role of intranuclear cholesterol in the control of DNA synthesis, no information is 
currently available whether there is a link between cholesterol and the RNA polymerase II 
VI. Discussion                                                                                                                                118 
complex. The coordinate upregulation of the RNA polymerase II constituents A, E, F, H, I, 
and L in response to sustained cholesterol export establish for the first time such a 
functional interlink. It will be challenging to elucidate the molecular mechanisms that are 
implicated in this novel regulatory network. 
The second intriguing finding of our study comes from the realization that cholesterol 
export influences the gene expression of a substantial portion of structural elements of the 
large and small ribosomal subunits. Coordinated expression of the ribosomal protein (RP) 
genes at the transcriptional level is a prerequisite for ensuring a roughly equimolar 
accumulation of ribosomal proteins. Transcriptional studies in rapidly proliferating cells 
indicated equivalent expression of RNA polymerases on three unlinked murine RP genes, 
consistent with the equal abundance of the corresponding mRNAs 130 suggesting that 
similar promoter strength and mRNA processing efficiency might provide a basis for the 
coordinated expression of RP genes. However, whether this concept applies to all RP 
genes or to distinctive subsets of genes is presently unclear. We found that a fraction of 
65 out of the 85 known eukaryotic ribosomal proteins 150 were upregulated under 
conditions of cholesterol efflux. The regulation of the majority of the RPS and RPL genes 
(70%) during cholesterol flux provides initial evidence for the synchronization of the 
assembly of the ribosome complex on the gene regulatory level. It supports the 
assumption that the maintenance of the ribosome complex requires coordinate regulation 
of its structural components. Moreover, our data demonstrate a large scale regulatory 
impact on RP mRNA levels suggesting that cholesterol flux affects the availability of 
functional ribosomal complexes. Based on such a mechanism, cholesterol may thus 
indirectly control the cellular translation machinery. 
The processing of lipids in macrophages occurs within the lysosome, and subsequent 
storage in cytoplasmic lipid droplets. Ox-LDL induces less cytoplasmic cholesteryl ester 
accumulation than E-LDL, a result of the chemical alterations during oxidation, leading to 
(i) conversion of a large proportion of cholesterol to oxysterols, and (ii) oxidation of the 
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fatty acyl group of LDL cholesteryl esters, rendering them resistant to lysosomal 
hydrolysis and trapping them within these organelles 94. But this is only the fact if mildly 
oxidized LDL is used and most of the lipoprotein cholesterol is intact, nevertheless, E-LDL 
yields higher amounts of cholesterol that does Ox-LDL this is due to cholesterol esterase 
treatment of E-LDL leading to higher amount of free cholesterol entering the cell when 
loaded with E-LDL, which is subsequently esterified by ACAT after leaving the lysosome. 
Human scavenger receptor class B type II (SCARB2), which is a splice variant of SR-BI, is 
a  lysosomal integral membrane glycoprotein which promotes cholesterol efflux 134, was 
found inversely regulated by E- and Ox-LDL. E-LDL load led to an increase but Ox-LDL 
load led to a decrease of expression, further deloading had inverse effects. This could 
indicate that SCARB2 may play a role in depletion of Ox-LDL but not E-LDL from the cell. 
In fact, further processing of Ox-LDL is different from processing of E-LDL and Ox-LDL is 
trapped in the lysosome, an assumption which may rely on the different regulation of the 
COP-I and COP-II machinery during loading of macrophages with different lipids.  
E-LDL seemed to address fewer COP-I (responsible for trafficking from GOLGI to ER) and 
COP-II (responsible for ER to GOLGI trafficking) machinery genes, whereas Ox-LDL 
mainly regulated COP-II machinery genes. 
On the other hand, ATP synthases were mainly upregulated during E-LDL but not Ox-LDL 
deload, this could be due to the increased amount of cholesterol in E-LDL loaded 
macrophages compared to Ox-LDL loaded macrophages, since HDL3 functions as a 
cholesterol acceptor resulting in ATP-dependent cholesterol efflux through ABCA1. 
Taken together, the previously presented data suggest that the endocytic and exocytic 
pathway seems to be closely controlled by the concert of the following genes: ABCA1, 
ApoAI, ATP-synthase and SR-BI. ApoAI interacts with and regulates the hydrolysis activity 
of α−β chains of the ATP-synthase which is a receptor for ApoE-rich HDL. Thus, the ATP-
synthase either promotes the conversion of ADP to ATP or contrariwise. The presence of 
ATP either increases the influx by raising the pace of phagocytosis which is ATP-
VI. Discussion                                                                                                                                120 
dependent, or increases the activity of ABCA1 leading to increases efflux. The internal 
regulator of cholesterol homeostasis is NPC1 which controls the cholesterol transport 
intracellularly. 
In conclusion, all the data raised by gene array technology hold a great scientific potential. 
Gene arrays can provide a broad overview on gene expression; also the transcriptional 
profiling can reveal patterns of gene expression which can be used to predict functional 
changes of the cell. Nevertheless, this data can not be adapted without verification since 
the technology still bears an amount of uncertainty derived from several factors including 
cross-interactions, inaccurate oligonucleotide sequences or SNPs, which can lead to an 
improper annealing and a false result. The chip-technology is, however, a very powerful 
tool in predicting regulations of pathways and establishing links between various cellular 
pathways and foreseeing tendencies in the expression of genes, which can help to relate 
gene expression to certain diseases. 
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VIII. SUMMARY 
  
The ATP-binding cassette transporter 1 (ABCA1) has recently been identified as a major   
regulator of systemic HDL. The main focus of this work was to identify and further 
characterize ABCA1-interactive proteins. A Yeast-Two-Hybrid screening with the last 144 
amino acids of the ABCA1 C-terminus as bait was performed. Our results indicate that 
ABCA1 forms a heteromeric complex with each of: Fas-associated death domain (FADD), 
β2-syntrophin, syntaxin 13 and flotillin-1, indicating a role for ABCA1 beyond mere reverse 
cholesterol transport. The interactions of the identified putative ABCA1-associated 
proteins were confirmed by independent approaches. In addition, functional studies were 
performed to elucidate the physiological consequences of these protein complexes.  
The finding that FADD directly interacts with ABCA1 is surprising and links cellular HDL 
metabolism with a protein mainly described in the context of death receptor-induced 
apoptosis, since FADD plays a well-established role in transduction of apoptotic signals 
and other cellular processes. The FADD/ABCA1 interaction may indicate an anti-apoptotic 
ABCA1 function independent from a suggested phosphatidylserine translocase activity. 
The C-terminal sequence of ABCA1 has been described previously as a binding motif for 
the PDZ domains of syntrophin. We showed that ABCA1 binds β2-syntrophin, a PDZ 
protein that acts as a general adaptor of membrane proteins to the actin cytoskeleton via 
utrophin, a protein highly homologous to dystrophin. 
The cystic fibrosis transmembrane conductance regulator (CFTR), a member of the ABC 
transporter family, has been reported to interact with syntaxin 1A. Thereupon, we 
investigated the interaction of ABCA1 with syntaxins and identified syntaxin 13 as a direct 
ABCA1-interactor in this family. Syntaxin 13, through its interacting protein pallidin 
(syntaxin 13 interacting protein), is linked to Hermansky-Pudlak syndrome (HPS) and 
Chediak-Higachi syndrome (CHS). These lysosomal storage diseases are associated with 
pulmonary fibrosis and prolonged bleeding caused by defects in the Adapter protein-3 
complex (AP-3). Recent publications show that ABCA1 mutations in Tangier patients are 
related to impaired platelet activation due to the presence of ABCA1, syntaxin 13 and 
syntaxin 13-interacting protein in the AP-3 pathway. 
Moreover, ABCA1 deficiency leads to enhanced phagocytosis in Tangier macrophages 
and fibroblasts, related to disturbances of the AP-3 pathway. The enhanced uptake of 
apoA-I by endocytic and phagocytic ingestion may also explain the increased catabolism 
of apoA-I in Tangier patients. Syntaxin 13 deficiency causes ABCA1 protein degradation 
and therefore syntaxin 13 may be important in ABCA1 maturation and vesicular transport. 
This finding links ABCA1 to a potential regulator of phagocytosis indicating that both the 
phagosomal and lysosomal compartment may be involved in ABCA1-dependent choline-
phospholipid efflux.  
  
The integral membrane protein flotillin-1 was also found to interact with ABCA1. 
Overexpression of flotillin-1 enhances filipodia formation, linking ABCA1 to migration and 
cytoskeletal changes.  
In the second part of the work human monocyte-derived macrophages were loaded with 
differently modified atherogenic LDLs, namely enzymatically degraded LDL (E-LDL) and 
oxidized LDL (Ox-LDL), and subsequently deloaded by HDL3 in order to ascertain 
differential gene regulation within lipid-related pathways. This characterization was 
performed by Affymetrix U133a gene chips. The processing of lipids in macrophages 
occurs within the lysosome combined with subsequent storage in cytoplasmic lipid 
droplets. Our results indicate that Ox-LDL induces less cytoplasmic cholesteryl ester 
accumulation than E-LDL, a result of the chemical alterations during oxidation. We further 
showed that cholesterol efflux influences the gene expression of a substantial portion of 
structural elements of the large and small ribosomal subunits. Deloading of E-LDL, but not 
Ox-LDL, loaded macrophages led to a distinguished upregulation of genes in the 
polymerase-II complex, indicating a close relationship between E-LDL, taken up outside 
clathrin coated pits by phagocytosis, and the control mechanisms at the transcriptional 
level. This E-LDL specific effect continues more downstream in the translation machinery 
represented by the 40S and 60S ribosomal genes as well as in the proteasomal 
degradation machinery where unneeded proteins are promptly degraded. 
In addition, ATP synthases were also upregulated during HDL3-induced deloading of E-
LDL, but not Ox-LDL, loaded macrophages, possibly due to the increased amount of 
cholesterol in E-LDL compared to Ox-LDL-loaded macrophages, since HDL3 functions as 
a cholesterol acceptor resulting in ATP-dependent cholesterol efflux through ABCA1. In 
addition, LDL-receptor mediated cholesterol uptake downregulates intracellular 
cholesterol synthesis by inhibition of HMGCoA reductase and inhibition of LDL-receptor by 
feedback mechanism. This cholesterol sensitive regulatory system leads to subsequent 
deloading of E-LDL whereas Ox-LDL is trapped inside the cell. Thus, certain modification 
types of lipoproteins may indirectly control cellular translation machinery. 
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